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Abstract
Intracellular inclusions containing the protein α-synuclein (α-syn), known as Lewy pathology (LP),
characterize the age-related neurodegenerative disorders termed synucleinopathies, the most prevalent
being Parkinson’s disease (PD). The motor and non-motor symptoms that define PD correlate closely with
neuronal dysfunction and/or loss in select brain regions such as the hippocampus and the dopaminergic
neurons of the substantia nigra pars compacta (SNpc). Genetic evidence indicates that perturbations in
α-syn are causative for PD, and data from histopathology, cellular, and animal models suggest that LP
transmits between brain regions. How LP affects stereotypical neuronal populations and is associated
with selective neuronal toxicity has been difficult to study because the majority of disease models do not
recapitulate both features. I therefore used a novel mouse model where recombinant α-syn is misfolded
in vitro into pre-formed fibrils (PFFs) and used to initiate the formation of Lewy-like pathology and
neuronal loss. In this thesis, I first reviewed the evidence relating to α-syn pathological spreading,
neuronal vulnerability, and neurotoxicity. One mechanism of vulnerability that emerged from my research
is that hippocampal CA2-3 neurons are selectively vulnerable to PFF-induced toxicity relative to
neighboring neurons due to their higher α-syn protein levels. Neuronal viability could be rescued by
reducing α-syn expression but only within a short window after pathology formation, suggesting a toxic
threshold in these neurons. However, toxicity could still be attenuated at later time points with
antioxidants acting through a glutathione-dependent mechanism. Another key finding is that mice lacking
a functional adaptive immune system (AIS) show no detectable alterations in α-syn accumulation, SNpc
neuron loss, or motor phenotype after intracerebral PFF-injection. In the process of demonstrating that
the AIS is not necessary for these processes, I identified a mouse strain with known innate immune
system dysfunction that exhibited a potentiated phenotype. Taken together, these results suggest that
both cell-autonomous and non-autonomous factors help determine neuronal vulnerability and contribute
to neurodegeneration in synucleinopathies.
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IDENTIFYING FACTORS THAT MODULATE NEURONAL SUBTYPE VULNERABILITY
TO LEWY PATHOLOGY
Esteban Luna
Dr. Kelvin C. Luk
Intracellular inclusions containing the protein α-synuclein (α-syn), known as Lewy
pathology (LP), characterize the age-related neurodegenerative disorders termed
synucleinopathies, the most prevalent being Parkinson’s disease (PD). The motor and
non-motor symptoms that define PD correlate closely with neuronal dysfunction and/or
loss in select brain regions such as the hippocampus and the dopaminergic neurons of
the substantia nigra pars compacta (SNpc). Genetic evidence indicates that
perturbations in α-syn are causative for PD, and data from histopathology, cellular, and
animal models suggest that LP transmits between brain regions. How LP affects
stereotypical neuronal populations and is associated with selective neuronal toxicity has
been difficult to study because the majority of disease models do not recapitulate both
features. I therefore used a novel mouse model where recombinant α-syn is misfolded in
vitro into pre-formed fibrils (PFFs) and used to initiate the formation of Lewy-like
pathology and neuronal loss. In this thesis, I first reviewed the evidence relating to α-syn
pathological spreading, neuronal vulnerability, and neurotoxicity. One mechanism of
vulnerability that emerged from my research is that hippocampal CA2-3 neurons are
selectively vulnerable to PFF-induced toxicity relative to neighboring neurons due to their
higher α-syn protein levels. Neuronal viability could be rescued by reducing α-syn
expression but only within a short window after pathology formation, suggesting a toxic
threshold in these neurons. However, toxicity could still be attenuated at later time points
with antioxidants acting through a glutathione-dependent mechanism. Another key
finding is that mice lacking a functional adaptive immune system (AIS) show no
vi

detectable alterations in α-syn accumulation, SNpc neuron loss, or motor phenotype
after intracerebral PFF-injection. In the process of demonstrating that the AIS is not
necessary for these processes, I identified a mouse strain with known innate immune
system dysfunction that exhibited a potentiated phenotype. Taken together, these results
suggest that both cell-autonomous and non-autonomous factors help determine
neuronal vulnerability and contribute to neurodegeneration in synucleinopathies.
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PREFACE
The research in this thesis was done under the supervision of Dr. Kelvin C. Luk. I
began my thesis work reviewing the literature regarding α-synuclein, its role in disease,
and its prion-like properties. This culminated in a review, presented in Chapter 2, and
provided a solid foundation on which to develop my hypotheses and a deeper
understanding of the Parkinson’s disease model that I would come to use. I set out
initially to determine the cell-death pathway(s) occurring in an α-synuclein based model
of Parkinson’s disease pathology. I quickly learned that I had to optimize the toxicity
assay I planned to use in this project because I initially had difficulty achieving sufficient
neuronal toxicity to study cell death. This initial set back was actually a blessing in
disguise because through trial and error in trying to optimize the assay I found what I first
perceived to be a problem was actually an interesting finding. My initial observation that
there was limited neuronal death in this model was actually because there were neurons
of varying subtypes within the primary culture with different levels of susceptibility to
pathology and toxicity. This led to our initial research paper in Chapter 3 examining
neuronal subtype vulnerability.
During the time of the investigations described in Chapter 3, I became involved in
another interesting project our lab had been collaborating with another group on, which
focused on the role of the immune system in Parkinson’s disease. This project piqued
my interest because it brought together two areas of biology that I wished to explore and
has led to some fascinating initial discoveries. The research in Chapter 4 tries to answer
a critical question in the field of Parkinson’s disease regarding how the adaptive immune
system interacts with the intracerebral α-syn pathology that characterizes the disease,
but interestingly, it has also raised many more fundamental questions. This work should
serve as a jumping off point to explore the role of the innate immune system in
xiii

Parkinson’s disease. I sincerely hope that this exciting project will be picked up by
another enterprising student or post-doc in the future.
My research career began at Penn State University when I was obtaining my
Bachelors in Biochemistry and Molecular Biology. There, I worked under the tutelage of
Dr. Melissa Rolls determining the mechanism of the diffusion barrier at the axon initial
segment in Drosophila neurons. It was here that my interest in neurobiology began. In
coming to the University of Pennsylvania MD/PHD program, I wanted to take the
research skills I had learned and apply them to medically relevant problems. I initially
chose to work in this lab due to the combination of interesting basic biology discoveries,
translational research, and the collaborative nature between bench scientists and
clinicians. Working with Kelvin at the Center for Neurodegenerative Disease Research
has been an eye-opening experience. I set out to try and make a small contribution to
the medical and scientific world, but I believe I have made a larger contribution than I
originally intended. Now that I am completing my graduate training, I actually feel that my
training has only begun. I am now more capable at identifying gaps in knowledge and
developing testable hypotheses to address those areas. These skills will serve me well
not only scientifically, but also when I work with patients. I plan on entering a neurology
residency program after completing medical school and staying in academia, although I
am still undecided as to whether I want to stay in neurodegenerative diseases. I plan to
keep my eyes open in the clinic for interesting unmet needs that I can pursue in my own
laboratory.
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Chapter 1: Introduction
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1.1 Introduction and thesis overview
Several age-related neurodegenerative disorders such as Parkinson’s disease
(PD) share the common property of being characterized by the pathologic accumulation
of proteins within the central nervous system (CNS) (Aguzzi 2009; Forman et al., 2004).
PD is the most prevalent of a group of disorders known as synucleinopathies, so named
because in these diseases the protein α-synuclein (α-syn) pathologically aggregates and
accumulates intracellularly (Spillantini et al., 1997). Intraneuronal aggregates of α-syn
within the cell body are termed Lewy Bodies while aggregates in the cell processes are
termed Lewy neurites (Goedert et al., 2013). Lewy Bodies and Lewy neurites are
collectively referred to as Lewy Pathology. Lewy Pathology is also present in Dementia
with Lewy Bodies (DLB), and another member of the synucleinopathy family, Multiple
System Atrophy (MSA), also features intracellular α-syn inclusions that occur mainly in
oligodendrocytes. PD affects over 500,000 people in the United States and is the focus
in the majority of studies regarding synucleinopathies due to its higher prevalence
(Kowal et al., 2013). Although PD is the most highly studied of the synucleinopathies,
observations regarding PD may help us glean information about DLB and MSA because
they share the characteristic pathologic α-syn accumulation.
Current treatments for synucleinopathies are limited. None are curative, and
disease-modifying (i.e., disease-course altering) therapies that prolong life or prevent
symptoms from worsening are lacking (Francardo et al., 2017). Thus, there is an urgent
need to develop novel therapeutics as well as biomarkers for these disorders, which in
turn requires better knowledge of the causes and natural history of these conditions.
As described below in greater detail, Lewy Pathology and neurodegeneration in
synucleinopathies affect certain CNS areas while sparing other, often neighboring,
regions. A key gap in our understanding of synucleinopathies is determining what
2

features actually predispose specific neuronal populations to Lewy Pathology formation
and toxicity and, on the other hand, what might protect non-vulnerable neurons. Several
brain regions are well characterized for their propensity to develop Lewy Pathology and
degenerate, such as the substantia nigra pars compacta (SNpc) where nigrostriatal
dopamine (DA) neurons reside and the noradrenergic neurons of the locus coeruleus
(Armstrong et al., 2014; Hall et al., 2014; Surmeier et al., 2017; Espay et al., 2014). One
emerging hypothesis is the unique metabolic, electrophysiological, and anatomical
characteristics of DA producing neurons found in the SNpc like autonomous pacemaking calcium currents, increased production of free radicals generated by cytosolic
DA, and extensive arborization, together contribute to the selective vulnerability of SNpc
DA neurons (Surmeier and Schumaker, 2013). However, other regions that lack many of
these traits and do not produce catecholamines, for example the Cornu Ammonis (CA)
2-3 neurons of the hippocampus, also develop Lewy Pathology, suggesting other factors
are also responsible for neuronal vulnerability (Armstrong et al., 2014; Hall et al., 2014).
Although these cellular characteristics exist at the cell-autonomous level, noncell-autonomous mechanisms like neuroinflammation may also further influence
neuronal vulnerability and toxicity (Wong and Krainc, 2017; Gelders et al., 2018).
Exploring these cell autonomous and non-cell-autonomous modes of neuronal
vulnerability could provide insights into novel therapeutic options for the
synucleinopathies.
To begin addressing what cell-autonomous or non-cell-autonomous factors might
affect neuronal vulnerability and toxicity in the face of intraneuronal α-syn inclusion
formation, I first reviewed recent knowledge regarding α-syn accumulation, spread of
pathological α-syn, neuronal vulnerability factors, and neurotoxicity mechanisms, which
is presented in Chapter 2 (Luna and Luk, 2015). This provided the foundational
3

knowledge for me to continue with my original work which is presented in Chapters 3
and 4 where both cell-autonomous and non-cell-autonomous mechanisms of neuronal
vulnerability are studied in more depth.
In Chapter 3, I found that hippocampal CA2-3 neurons are more vulnerable to αsyn pathology induced toxicity due to their higher α-syn expression compared to
adjacent neuronal populations. I also found that decreasing α-syn expression could
rescue these neurons, although rescue required a strong knock-down early in the
pathology-formation process. Furthermore, the data presented in Chapter 3 suggest that
α-syn toxicity is mediated through a glutathione dependent mechanism and can occur in
a cell-autonomous manner.
Chapter 4 explores of the role the immune system may have in modulating
neuronal vulnerability to α-syn aggregation. I found that the adaptive immune system is
not necessary for α-syn aggregation, neuronal loss, nor motor behaviors after pathology
formation in the SNpc in our synucleinopathy model. However, the innate immune
system may actually be playing a significant role in influencing these phenotypes. A
mouse strain with several identified variations in the innate immune system developed
increased α-syn aggregation, more neuronal loss, and a worse motor phenotype in an
age dependent manner. This finding implicates the innate immune system in modifying
Lewy Pathology aggregation and its associated effects. The final conclusions of these
studies and several potential future directions that have been made possible by this
research are then presented in Chapter 5.
The rest of this introduction serves to complement these studies by providing an
overview of PD, the development of PD models, and previous key findings that inform us
about PD pathobiology especially relating to the spread of Lewy Pathology from
neuronal regions and neurotoxicity mechanisms.
4

1.2 Clinical phenotype and treatment
This section provides a history of the identification of PD and the clinical
presentation of PD patients at varying stages of disease along with the affected
neuroanatomical regions that correlate with the phenotype. Also, a description of
symptomatic treatments that are commonly used and their mechanisms of action is
included.

1.2.1 Motor symptoms and neuroanatomical correlates
PD was first formally described by James Parkinson in 1817 who coined the term
Paralysis Agitans based on the characteristic tremor patients presented with (Parkinson,
1817). Parkinson first examined this disease by studying six case studies from London,
most of whom he observed in the street. Even though Parkinson is credited with the
discovery of the disease, this syndrome seems to have been known to earlier
civilizations as well. Ancient Indian and Chinese sources describe disorders similar to
PD (Manyam, 1990; Zhang et al., 2006). It was not until about 50 years later that JeanMartin Charcot refined the condition’s medical description and first suggested naming
the disease “Parkinson’s disease” as Paralysis Agitans did not fully describe how
patients with this disorder presented (Charcot, 1872).
The primary symptoms that denote PD are motor symptoms. These include
bradykinesia, rigidity, resting tremor, as well as postural instability in late stages of the
disorder. Some of the first pathological studies into PD showed a relationship between
SNpc loss and PD (Tretiakoff, 1921; Brissaud, 1925). It was also noted in 1957 that the
parkinsonian state induced in rabbits by reserpine was reversed by treatment with Ldopa, the precursor to DA (Carlsson et al., 1957). DA was quickly discovered in the
5

human brain, and its distribution was mapped out (Carlsson et al., 1958; Ohara et al.,
1959). After these discoveries, DA levels were measured in the PD brain and found to
be lower, implying that the cause of the PD symptoms was the loss of DA producing
neurons in the SNpc that express tyrosine hydroxylase, a key enzyme in the production
of DA (Ehringer and Hornykiewicz, 1960).
Patients typically present with varying degrees of severity in the motor symptoms
and can be classified into 3 categories based on their symptomatology. These include
tremor-predominant, akinetic-rigid, and postural instability/gait rigidity (Marras and Lang,
2013). These categories are derived from the predominant symptoms that affect patients
such as the resting tremor, bradykinesia, or the postural instability, respectively. Some
evidence suggests that patients classified as tremor-predominant have better outcomes,
but others find that patient presentation can be heterogeneous. Patients can also switch
subtypes through the course of disease making this classification difficult to interpret
(Hershey et al., 1991; Alves et al., 2006; Burn et al., 2006).
There are several other motor symptoms associated with PD that most likely
stem from the primary impairments in movement that define the disease. These include
hypomimia (masked facial expression), speech impairment, dysphagia, blurred vision,
micrographia, dystonia, shuffling gait, and festination. All of these symptoms are thought
to share impaired movement as a cause. These features can help differentiate PD from
similar disorders such as Essential Tremor, Progressive Supranuclear Palsy, Dementia
with Lewy Bodies (DLB), and Multiple System Atrophy (MSA) (Tolosa et al., 2006).
The Movement Disorders Society (MDS) has established absolute criteria with
which to diagnose PD (Table 1.1) (Postuma et al., 2015). The criteria are predominantly
clinical in nature where patients must at least have bradykinesia with either a resting
tremor or rigidity to be considered to have PD or “probable” PD. Although these criteria
6
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Table 1.1 Table of diagnostic criteria from the MDS (From Postuma et al., 2015). The main
criteria to diagnose PD are bradykinesia with either rigidity or a rest tremor. This is supplemented
with support criteria, such as response to DA replacement therapy or the presence of dyskinesia.
Patients must have at least two support criteria to establish clinical PD. The criteria also state
absolute exclusion criteria like cerebellar symptoms, which include ataxia or oculomotor
symptoms as these are not associated with PD. There are also certain red flag symptoms that
can be counter balanced with support criteria. These include rapid progression or no progression
as these could suggest other disorders but are rarely found in PD.

are necessary for PD diagnosis, other diagnostic tests may be done to help identify PD if
the patient does not present with classical symptoms, has a similar disorder, or has
confounding co-morbidities. Among these is the DaTscan which measures DA
transporter binding in the striatum of patients. Because PD patients lose DA neurons
that project from the SNpc to the striatum, there is a concordant loss of DA transporter
density in this region. This can help in differentiating between different forms of
parkinsonism (Stoessl, 2011). Many patients develop symptoms asymmetrically at first
before the disease establishes itself bilaterally. This finding is supported by DaTscan
data showing that DA transporters are lost asymmetrically if patients are tested early
enough in the disease course. Patients can also receive a radiographic tracer that
resembles a dopamine precursor, [18F]-fluorodopa, which also shows decreased uptake
in the striatum in PD. Again this results from the loss of DA innervation into the striatum
(Pavese et al., 2012). Although this testing can be used to differentiate PD from similar
disorders, they are not used to monitor the clinical progression of patients and their
response to treatment. Rather, this is done through the use of the Unified Parkinson’s
Disease Rating Scale (UPDRS) (Postuma et al., 2015). The UPDRS consists of 6
8

sections that tests various aspects of cognition, motor ability, and daily activities. It is
primarily used in research to monitor treatment benefits in an objective manner.

1.2.2 Non-motor symptoms
PD has classically been considered a movement disorder stemming from neuron
loss in the SNpc leading to insufficient striatal DA. Recent years have yielded a surge of
new evidence that shows that PD has several non-motor clinical phenotypes. One of the
most common non-motor symptoms that PD patients can present with is constipation
and gastrointestinal dysfunction (Martinez-Martin et al., 2007). Up to 50% of PD patients
develop constipation, and constipation has been suggested to precede the motor
symptoms by up to twenty years (Kaye et al., 2006; Savica et al., 2009). The α-syn
inclusions that pathologically define PD have been found in several areas in the colon
along with Meissner’s and Auerbach’s plexus that innervate the colon (Braak et al.,
2006; Shannon et al., 2012; Hilton et al., 2014; Chandra et al., 2017). Interestingly, Lewy
Pathology is also found in the vagus nerve that innervates much of the colon and is also
present early in the disease course in the CNS nuclei from which the vagus nerve
emanates, the dorsal motor nucleus of the vagus (DMV) (Braak et al., 2004).
Furthermore, individuals that underwent vagotomies developed PD at a significantly
lower rate compared to controls and those who received partial vagotomies, suggesting
that the pathological process is transmitted from the gut to the CNS via the vagus nerve
(Svensson et al., 2015).
Sleep disturbances like REM-sleep behavior disorder and restless leg syndrome
are also associated with PD and can precede the onset of the motor symptoms
(Schenck et al., 1996; Wong et al., 2014). Anywhere from 50%-80% of PD patients
develop these disorders while up to 95% of REM-sleep behavior disorder patients
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convert into PD (Tandberg et al., 1998; Oerlemans and de Weerd, 2002; Hogl et al.,
2018). Neuropathological studies have found that REM-sleep behavior disorder patients
have Lewy Pathology located in the brainstem (Boeve et al., 2013). Brainstem regions
that develop Lewy Pathology and likely contribute to REM-sleep behavior disorder are
the pedunculopontine nucleus, gigantocellular reticular nucleus, lateral dorsal tegmental
nuclei, dorsal raphe nucleus, the coeuleus-subcoeruleus complex, and the reticular
activating system (Peever et al., 2014; Seidel et al., 2015). These regions develop
pathology early on in the PD disease course before motor symptoms develop (Braak et
al., 2004).
Patients with advanced PD often develop cognitive impairment, dementia, and
hallucinations (Forsaa et al., 2010; Aarsland et al., 2017). The prevalence of dementia
can be as high as 40% of patients and as many as 20% of patients also develop
hallucinations (Forsaa et al., 2010; Lee and Weintraub, 2012). Pathology in cortical and
subcortical regions appear to correlate with the onset of these symptoms, but this
pathological picture is made more complicated by the fact that PD patients frequently
develop concurrent Amyloid-β and tau pathology which are implicated in Alzheimer’s
disease dementia (Mattila et al., 2000; Jellinger, 2008b; Toledo et al., 2016).

1.2.3 Current clinically available therapeutic strategies
Because PD’s most notable symptoms are motor in nature and are due largely to
the loss of DA, most of the pharmacological treatment strategies focus on maintaining or
increasing DA levels within the CNS. Treatment strategies that increase DA include the
administration of Levodopa, DA receptor agonists, and monoamine oxidase type B
(MAO-B) inhibitors. Two treatments that function by DA independent mechanisms are
anticholinergic agents and amantadine. Levodopa treatment is the oldest of these
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therapies and still remains the most widely used (Cotzias et al., 1969). As a precursor to
DA, Levodopa increases the supply of DA available at CNS nerve terminals
(Hornykiewicz, 2017). DA receptor agonists function via a similar mechanism by
increasing the activity of DA receptors thus mimicking DA, and MAO-B inhibitors prevent
the degradation of DA within nerve terminals to increase the supply of DA (Elmer and
Bertoni, 2008). Anticholinergic agents function by inhibiting the action of the
neurotransmitter acetylcholine in the CNS. Acetylcholine is in balance with DA and with
the loss of DA there can be excess cholinergic activity, which is prevented with the use
of anticholinergics (Duvoisin, 1967; Katzenschlager et al., 2003). Amantadine is an
antiviral agent that has been found to be mildly effective in treating parkinsonian
symptoms through an as of yet unknown mechanism (Schwab et al., 1972)
Lastly, surgical techniques exist to help reduce parkinsonian symptoms. The
most popular of these techniques being deep brain stimulation (DBS) in which rhythmic
electrical stimulation is applied to either the subthalamic nucleus or the globus pallidus
internus. The exact mechanism by which DBS works to alleviate symptoms, mainly
tremor, is still unknown, but it is believed that the device actually inhibits these neuronal
regions from functioning, thus allowing patients a greater range of movement (Fasano et
al., 2012). The above treatment modalities treat motor symptoms associated with PD,
but they do not affect the non-motor symptoms nor do they modify disease progression.
Further research, of which this thesis is a part of, needs to be done in order to discover
novel treatment regimens.

1.3 Histopathology and α-synuclein spreading
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This section provides an overview of the discovery and role of α-syn in PD. The
following section will also delve into the genetics of PD and the pathological features that
define the disease.

1.3.1 Discovery of α-synuclein and its role in Parkinson's disease
α-Syn is a 14kDa protein that was first identified by co-purifying with cholinergic
vesicles from the electric organ of torpedo californica (Maroteaux et al., 1988). This
provided the first evidence that α-syn is localized to the presynapse and may be involved
in vesicle regulation. The authors also noted that α-syn was present in the nucleus
leading them to coin the name synuclein where “syn” denotes its localization with
synaptic vesicles and “nucl” denotes its localization to the nucleus. α-Syn has since been
shown to interact with nuclear proteins, and it can also translocate to the nucleus after a
toxic insult in SNpc neurons (Goers et al., 2003; Kontopoulos et al., 2006; Specht et al.,
2005). α-Syn’s function in the nucleus remains unclear. Further confounding conclusions
regarding the role of α-syn in the nucleus is the fact that α-syn’s molecular weight falls
below the nuclear cut off of ~40kDa, thus allowing α-syn to freely diffuse into the
nucleus.
Independent of its identification in cholinergic vesicles, α-syn had also been
originally described in other contexts. For example, a portion of α-syn was discovered as
a component of Amyloid-β (Aβ) plaques present in Alzheimer’s disease brains and was
assigned the name “non-Aβ-amyloid component” (NAC). This fragment consists of
amino acid residues 61-95 of the protein (Ueda et al., 1993). This NAC domain was later
shown to form the β-sheet rich core found in the α-syn fibrils present in Lewy Pathology
and is also sufficient, when assembled into a fibrillar conformation, to induce aggregation
of endogenous α-syn (Giasson et al., 2001; Tuttle et al., 2016; Guerrero-Ferreira et al.,
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2018). Lastly, mRNA transcripts corresponding to α-syn were also shown to change
during song acquisition in zebra finches and was initially named synelfin due to its
potential for affecting plasticity (George et al., 1995). It is now known that α-syn is
expressed in other non-neuronal cell types like erythrocytes and belongs to a larger
family of synuclein proteins that also contains β-synuclein and γ-synuclein (Fauvet et al.,
2012; Bendor et al., 2013).
α-Syn is the most studied member of the synuclein family and the primary focus
of the research in this thesis because it was the first gene associated with autosomal
dominant PD (Polymeropoulos et al., 1996). Since that initial discovery, several other
lines of genetic evidence have shown that α-syn is causative in PD. Missense mutations
in α-syn (A30P, E46K, H50Q, G51D, A53E, A53T), duplications, and triplications of the
gene all cause PD, and polymorphisms in the α-syn promoter have been reported to
alter the risk of developing PD (Polymeropoulos et al., 1996; Kruger et al., 1998;
Singleton et al., 2003; Chartier-Harlin et al., 2004; Ibanez et al., 2004; Zarranz et al.,
2004; Maraganore et al., 2006; Kiely et al., 2013; Pasanen et al., 2014; Ferese et al.,
2015).
The most prominent histopathological feature of PD brain tissue are intracellular
protein inclusions that were first reported in 1912 by Fritz Jakob Heinrich Lewy (Lewy
1912; Goedert et al., 2013). In 1919, these eosinophilic inclusions were dubbed “Lewy
Bodies” by Konstantin Nikolaevich Tretiakoff, who also observed a link between them
and the degeneration of the substantia nigra in PD patient brains (Tretiakoff, 1919).
Their importance in disease was further highlighted when it was discovered that Lewy
Pathology is primarily composed of α-syn (Spillantini et al., 1997). This discovery
coincided with the genetic evidence which suggested that Lewy Pathology is a key driver
of pathogenesis.
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Mutations in several other genes (Parkin, PINK1, DJ-1, GBA, VPS35, ATP13A2,
and LRRK2) have been found to cause genetic forms of PD. Interestingly, patients with
DJ-1, PINK1, and GBA mutations have Lewy Pathology, but this has not been
established for the other mutations (Bandopadhyay et al., 2004; Ramirez et al., 2006;
Neumann et al., 2009; Samaranch et al., 2010; Doherty et al., 2013; Kalia et al., 2015).
Exploring how α-syn aggregation is modulated by these mutations or vice versa is a vital
area of PD research that requires further work. It remains unclear if the effects these
mutations exert are downstream or upstream of Lewy Pathology or perhaps causing
parkinsonian degeneration via a pathogenic pathway separate from sporadic PD. Owing
to the relatively low incidence of inherited PD cases, these post-mortem studies are
confounded by small sample sizes and the possibility that Lewy pathology could be lost
along with neuronal degeneration prior to histological examination (Schneider and
Alcalay, 2017).

1.3.2 Staging of Lewy Pathology: Braak Staging and spread of pathological αsynuclein
PD patients develop a wide distribution of Lewy Pathology within the CNS, but
how this is related to the disease course is only starting to be elucidated. Understanding
how Lewy Pathology is related to PD has been complicated by the observation that
Lewy Pathology is not specific to the synucleinopathies and occurs in individuals without
clinical symptoms. This finding is termed Incidental Lewy Body Disease and is found in
5-10% of people over the age of 60 when examined on autopsy (Dickson et al., 2008).
Furthermore, rare disorders like Pure Autonomic Failure or MSA can present with Lewy
Pathology in the peripheral nervous system (Kaufmann et al., 2001; Nishie et al., 2004).
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Nonetheless, an emerging finding is that Lewy Pathology in PD accumulates in a
stereotypical pattern in up to 67% of PD patients that coincides with the onset of
symptoms (Dickson et al., 2010). This pattern, also known as Braak staging, can be
broken down into six stages where Lewy Pathology appears in stage 1 in the brain stem
and olfactory bulb and continues to be distributed more rostrally from the brain stem to
higher cortical regions over the course of the disease (Summarized in Figure 1.1) (Braak
et al., 2003b; Braak et al., 2005; Lee and Koh, 2015).

Figure 1.1. Braak Staging of PD pathology. (From Goedert et al., 2013) (a, b) In stages 1 and
2, pathology begins in the brain stem and in the olfactory bulb. One of the main brain stem nuclei
known to be affected is the DMV. This corresponds to the presymptomatic phase when patients
do not exhibit any tremor or rigidity although they may have other non-motor symptoms. (c) By
stage 3-4, patients start to develop pathology in the midbrain and SNpc and begin to show the
motor symptoms that characterize PD. (d) Lastly, in stages 5 and 6, pathology is found in the
neocortex and other associated structures. As pathology progresses, those areas that were
affected at earlier stages develop more robust pathology which is indicated by the intensity of the
red shading. Arrows indicate the direction throughout the brain pathology is hypothesized to
spread in the Braak staging system.
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Although this spatiotemporal pattern suggests that the disease process travels or
spreads from one affected brain region to another, this has been the source of much
controversy because Lewy Pathology could alternatively develop in different brain
regions independently. The discovery of the prion protein (PrP) which converts naïve
protein into a pathological conformation has brought about a revolution regarding the
spreading hypothesis in regards to several neurodegenerative diseases including PD
(Prusiner 1982). Because diseases like Alzheimer’s disease, PD, and Huntington’s
disease all share the feature of pathological protein aggregations like PrP, there has
been considerable work to examine if the processes of prion-like template misfolding
and spreading also apply to these neurodegenerative disorders (Aguzzi 2009; Forman et
al., 2004). Specifically relating to PD, there is now orthogonal evidence to support the
hypothesis that the distribution of Lewy Pathology in the CNS is due to the prion-like
transmission of pathological α-syn seeds from one neuron to another. For example,
transplanted fetal mesencephalic grafts into PD patients actually develop Lewy
Pathology after several years suggesting that the disease process can transfer from
affected neurons to neurons that were presumably initially healthy and normal at the
time of transplantation (Kordower et al., 2008; Li et al., 2008). Also, recent structural and
functional MRI data suggests that the disease process in PD spreads along a pattern
dictated by network connectivity which further supports the transneuronal spreading of
PD pathology (Yau et al., 2018).
Until the past decade, the majority of research into PD and PD treatments has
focused on DA loss from the SNpc. Because of this, the majority of PD models aim to
achieve the loss of DA producing neurons that express tyrosine hydroxylase in the
SNpc. The first established model of PD utilized the neurotoxin 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP). MPTP was first identified as a by-product and
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contaminant in the synthesis of heroin. Patients who injected the contaminated heroin
developed parkinsonian features (Langston et al., 1983). Similar effects were later found
in non-human primates that were injected with MPTP (Langston et al., 1984b). This
model, together with other neurotoxin based models such as 6-OHDA, paraquat, and
rotenone, have massively expanded our knowledge of PD. DA neurons in the SNpc are
lost with the use of each of these compounds causing a parkinsonian-like motor
phenotype. These models are what first allowed us to gain a mechanistic understanding
of PD pathogenesis (Blandini et al., 2008; Berry et al., 2010; Greenamyre et al., 2010;
Panneton et al., 2010).
MPTP is converted to 1-methyl-4-phenylpyridinium by astrocytes which inhibits
mitochondrial complex 1 (Langston et al., 1984a; Markey et al., 1984; Nicklas et al.,
1985). MPTP treatment causes an increase in reactive oxygen species (ROS) and the
loss of ATP which eventually leads to neurodegeneration specific to tyrosine
hydroxylase positive neurons (Hasegawa et al., 1990; Chan et al., 1991). Adding to the
evidence that the MPTP model mimics aspects of PD, mice chronically treated with
MPTP experience gut motility dysfunction and cognitive impairments reminiscent of PD
patients (Tanila et al., 1998; Anderson et al., 2007). In fact, MPTP induced neurotoxicity
has also been found to be modulated by α-syn levels whereby α-syn knock-out mice are
resistant to MPTP (Dauer et al., 2002).
The dopaminergic neuronal toxin 6-OHDA provides a similar model to MPTP
where DA neuron loss occurs, but this molecule can be injected into the striatum of rats
which allows for the study of axonal degeneration of dopaminergic fibers (Lee et al.,
1996). Paraquat and rotenone are both pesticides that also affect mitochondrial function
and induce ROS (Heikkila et al., 1985; Fukushima et al., 1994).
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Although these toxins have helped us study the pathogenesis of PD and its
mechanism, none of these models reliably develop α-syn pathology that precedes
toxicity and that spreads in a stereotypical pattern resembling what is observed in the
disease state. Rotenone is capable of causing the formation of α-syn inclusions in the
SNpc, but these are infrequent and do not appear to spread to other PD relevant brain
regions (Betarbet et al., 2000). Similarly, it has also been reported that α-syn inclusions
can form with chronic low dose MPTP treatment, but this has been controversial (Fornai
et al., 2005; Shimoji et al., 2005).
To try and fill this gap in our knowledge base, genetic models have been
developed by knocking-down, knocking-out, or overexpressing the various genetic risk
factors for PD (Jiang and Dickson, 2017). The results from these models have also
aided us in our understanding of PD pathogenesis. The most used genetic model of PD
is the overexpression of either human wild-type or mutant α-syn using either viral vectors
or transgenic methods. The expression of α-syn mutants known to cause autosomal
dominant PD like A53T α-syn or A30P α-syn in transgenic mice results in Lewy-like
inclusions but have differential effects on motor phenotype and DA neuronal loss
(Giasson et al., 2002; Neumann et al., 2002). Furthermore, the expression of human WT
α-syn can cause aberrant α-syn accumulation with relatively modest DA neuronal loss
even though duplication and triplication of the α-syn gene is sufficient to cause early
onset autosomal dominant PD (Masliah et al., 2000; Chartier-Harlin et al., 2004;
Singleton et al., 2003). A potential confounder in these studies is the use of various
genetic promoters that can drive expression in neuronal populations not typically
affected in PD. An example is the development of α-syn aggregation in the spinal cord
with the expression of A53T α-syn on the mouse PrP promoter which can also drive
expression in non-neuronal cells (Giasson et al., 2002). Thus, these transgenic models
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also do not exhibit pathology spreading in a manner consistent with Braak staging
similar to the neurotoxin models. Furthermore, the genetic models continue to express
native mouse α-syn alongside the transgene. Given that mouse α-syn is also capable of
developing into a pathological fibrillar conformation similar to what is observed in Lewy
Pathology, this has also confounded interpretations of the findings (Luk et al., 2016).
Transgene expression also brings up the question of physiological significance regarding
these models because the co-expression and interaction of mouse and transgenic α-syn
could be in part responsible for the discrepancy in the observed phenotypes.
Interestingly, α-syn knock-out mice are viable and fertile. These mice exhibit DA release
abnormalities and a reduced vesicle recycling pool but are otherwise healthy suggesting
that α-syn loss of function alone is not a major contributor to PD pathogenesis
(Abeliovich et al., 2000; Cabin et al., 2002).
Knock-out, knock-down, and expression of other PD related genes has also been
attempted with varying results in terms of recapitulating various disease symptoms. Mild
mitochondrial impairment and motor phenotypes have been observed in knock-out and
loss-of function models of PINK1, Parkin, and DJ-1 mice, but this is not accompanied by
α-syn pathology nor SNpc neurodegeneration (Goldberg et al., 2003; Itier et al., 2003;
Chandran et al., 2008; Gispert et al., 2009). Mutations in LRRK2, a multidomain protein
with kinase and GTPase functions, is also known to cause PD in an autosomal dominant
manner (Funayama et al., 2002). Overexpression of either WT LRRK2 or LRRK2
mutants implicated in PD pathogenesis have been shown to impair DA release (Tong et
al., 2009; Yue et al., 2015), and the expression of either the R1441G or G2019S LRRK2
mutants via the bacterial artificial chromosome (BAC) transgenic method can also cause
impaired DA release without α-syn pathology (Melrose et al., 2010; Li et al., 2009). Only
recently has the conditional expression of the G2019S LRRK2 mutant with a
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tetracycline-inducible promoter been shown to induce DA cell loss along with α-syn
inclusion formation (Xiong et al., 2018). The difference in transgenic expression methods
or compensatory mechanisms within the transgenic mice likely account for the varying
phenotypes. Consistent with the possibility of compensation occurring in transgenic
animals, a recent study has shown that the double knock-out of LRRK1 and LRRK2 can
cause mild DA degeneration in an age dependent manner. This suggests that there is
compensation between LRRK homologs that had not been previously appreciated
(Giaime et al., 2017). Other genetic models such as the expression of VPS35, ATP13A2,
or GBA mutants are proving to be interesting by either causing DA cell loss, a motor
phenotype, or ameliorating α-syn toxicity, but these also lack the α-syn spreading and
subsequent toxicity that is hypothesized to occur in PD (Mazzulli et al., 2011; Schultheis
et al., 2013; Kett et al., 2015; Tang et al., 2015).
To address these pitfalls of the neurotoxin and genetic based models, a model
was developed that was derived from histopathological evidence that α-syn is
transmissible between neuronal populations. Both rodents and non-human primates
form α-syn aggregates after the intracerebral injection of brain extracts from either
transgenic mice that develop accumulations of α-syn or preparations derived from MSA
or PD patient brains that contain Lewy Pathology (Mougenot et al., 2011; Luk et al.,
2012a; Watts et al., 2013; Recasens et al., 2014). Even recombinant α-syn prepared into
pre-formed fibrils (PFFs) can initiate α-syn aggregation in cultured immortalized cells that
express α-syn, primary neuronal cultures, and in vivo in both dopaminergic and nondopaminergic cell populations distant from the injection site (Luk et al., 2009; VolpicelliDaley et al., 2011; Luk et al., 2012b; Masuda-Suzukake et al., 2013; Sacino et al.,
2014a; Paumier et al., 2015; Rey et al., 2016; Shimozawa et al., 2017; Duffy et al.,
2018). This model also develops neurotoxicity in dopaminergic and non-dopaminergic
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regions after the formation of pathology (Volpicelli-Daley et al., 2011; Luk et al., 2012b;
Brahmachari et al., 2016; Duffy et al., 2018; Luna et al., 2018; Yun et al., 2018).
Furthermore, intramuscular injection of PFFs can result in Lewy-like pathology mirroring
one of the suggested routes of Lewy Pathology spread early in disease (Sacino et al.,
2014b). The combination of all this evidence suggests that the PFF model of PD will
contribute to filling the knowledge gap left by neurotoxin and genetic models.

1.4 α-Synuclein mechanisms of spread and toxicity

1.4.1 Internalization and externalization of α-synuclein and the role of
conformational strains
Internalization of extracellular α-syn seeds is a key step in the propagation of αsyn pathology. The receptor, LAG3, has been shown to mediate α-syn PFF endocytosis,
but it has also been observed that α-syn has an affinity for heparan sulfate
proteoglycans on the neuronal cell surface similar to tau fibrils but with less specificity
(Holmes et al., 2013; Mao et al., 2016; Stopschinski et al., 2018). The expression of a
dynamin dominant negative mutant blocks clatherin mediated endocytosis and prevents
the intercellular transfer of pathology, further suggesting that α-syn pathology is
internalized by receptor mediated endocytosis (Desplats et al., 2009). However, these
data do not rule out other mechanisms of spread nor does it definitively show that
receptor mediated endocytosis is occurring in disease. It is also possible that α-syn
could enter recipient neurons via other mechanisms such as direct membrane
penetration, non-receptor mediated endocytosis, by internalization of a membrane
bound particle containing α-syn, or nanotubes (Summarized in figure 1.2). It is known
that many cell types (neuronal, non-neuronal, and immortalized) are capable of
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internalizing α-syn indicating that the mechanism of uptake is not specific to neurons and
is most likely a mechanism common to many cells (Luk et al., 2009; Chai et al., 2013;

Figure 1.2 Potential mechanisms of trans-cellular spread of pathological protein seeds.
(From Guo and Lee, 2014) Misfolded protein aggregates act as seeds by spreading from cell to
cell. The seeds form in the cytoplasm of the donor cell by recruiting soluble naïve monomer. a)
The seeds can be released as the protein alone or b) in membrane bound vesicles like
exosomes. The unbound free seeds can then either 1) disrupt the membrane and directly
penetrate the cell 2) enter the cell by bulk endocytosis non-specifically or 3) bind to a specific
receptor. 4) Exosomes would fuse with the target cell to release the seed and any cargo into the
target cell’s cytoplasm. 5) Seeds can also spread via a direct cytoplasmic connection like
nanotubes. Once inside the target cell, the seed would then initiate aggregation
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Kim et al., 2013; Bae et al., 2014; Kim et al., 2014; Reyes et al., 2014; Peelaerts et al.,
2015; Wang et al., 2015; Karpowicz et al., 2017; Loria et al., 2017). Nanotubes have
also been shown to be capable of transmitting PrP and α-syn in lysosomes between
cells further supporting the concept of transneuronal spread of pathological aggregates
(Gousset et al., 2009; Abounit et al., 2016). Although, this seems less likely due to
recent evidence suggesting that neurons that are functionally connected spread the
disease process more efficiently compared to neurons that are merely structurally
connected or adjacent to each other (Braak et al., 2004; Yau et al., 2018).
These data suggest that pathology spreads in an anatomically dependent
manner modulated by functional connectivity of the brain regions, and spread is unlikely
to be mediated by cell death because nearby regions are unaffected (Luk et al., 2012b;
Brettschneider et al., 2015; Ulusoy et al., 2015; Rey et al., 2018; Yau et al., 2018).
Pathology can be trafficked in both anterograde and retrograde directions in the neuron,
but it is currently unknown if α-syn seeds traffic via the same mechanism (Freundt et al.,
2012; Reyes et al., 2015; Brahic et al., 2016). Recently, it has been shown that human
α-syn spreads more quickly in a mouse α-syn null background (Helwig et al., 2016). This
could potentially mean that different forms of α-syn are spread by different mechanisms
or this effect could be due to the kinetics of aggregation where α-syn seeds are more
mobile when not converting endogenous naïve α-syn into a pathological conformation.
This remains to be determined.
It is still unknown how α-syn pathological seeds are externalized from neurons in
order to spread the pathological process. Free extracellular α-syn as well as α-syn in
exosomes have been isolated from Cerebrospinal fluid (CSF) and plasma (El-Agnaf et
al., 2003; Lee et al., 2005; Stuendl et al., 2016). It is possible that both extracellular and
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exosomal forms of α-syn are capable of spreading Lewy Pathology between neurons,
but this question remains an active area of investigation. Further explanation of this topic
is provided in Chapter 2.
Because α-syn adopts a fibrillar conformation when in pathological aggregates,
there has been considerable research into the heterogeneity that can exist among
pathological α-syn forms. Different strains of pathological α-syn that cause differing
phenotypes in vivo have been formed in vitro by varying the conditions under which they
fibrillize, by serially passaging them, or by deriving them from MSA or PD brains
(Bousset et al., 2013; Guo et al., 2013; Peelaerts et al., 2015; Peng et al., 2018).
Recently, it was discovered that fibrils carrying various artificial mutations in the α-syn
amino-acid sequence can lead to varying degrees of pathological formation in vivo and
cell models that do not correlate with the propensity at which the seeds fibrillize in vitro
(Luk et al., 2016a). This raises the interesting question of how does the cellular
environment interact with α-syn PFFs to form different strains with such wildly varied
properties. Furthermore, α-syn has been observed to modulate the aggregation
propensity and toxicity of other aggregation prone proteins like tau and Aβ suggesting
that in disease there is a complex interaction of the cellular environment and inter protein
interactions giving rise to the observed disease phenotype (Bachhuber et al., 2015;
Castillo-Carranza et al., 2018).
This phenomenon is utilized in chapter 3 to examine the effect of pathological
aggregation on neuronal viability. I used two strains of PFFs where one formed
pathology more efficiently than the other to examine if increased pathological formation
was in fact toxic. This experiment showed that strains that form pathology more
efficiently do cause increased toxicity of vulnerable neuronal populations. Even though
PFFs of differing strains enter cells at similar rates, their ability to convert naïve
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monomer into a fibrillar conformation determines pathogenicity (Luk et al., 2016a; Fares
et al., 2016; Karpowicz et al., 2017; Luna et al., 2018).

1.4.2 Lysosomal/autophagy and mitochondrial dysfunction
In the past several years PD pathogenesis has been linked to lysosomal
dysfunction. Many of the gene mutations that cause PD in a genetic manner cause
lysosomal dysfunction such as ATP13A2, VPS35, and GBA (Aharon-Peretz et al., 2004;
Ramirez et al., 2006; Zimprich et al., 2011). This is intimately linked to autophagy as the
autophagic system feeds into the lysosomal system for protein degradation. Multiple
lines of evidence from model systems also reveal that deficiencies in the
lysosomal/autophagy system lead to PD. α-Syn overexpression impairs trafficking of the
autophagy protein ATG9 and decreases the formation of autophagy precursors (Winslow
et al., 2010). α-Syn mutants can bind more tightly to the lysosomal protein Lamp2a
which can prevent its own degradation thus facilitating aggregation, and mutations in
VPS35 can impair trafficking of Lamp2a further promoting pathology formation (Cuervo
et al., 2004; Tang et al., 2015). Increased activity of GBA has been found to promote αsyn degradation and improve lysosomal function (Mazzulli et al., 2016). Mutations in
lysosomal genes, like TMEM175, have been found to increase the risk of PD and whose
deficiency can decrease lysosomal activity and increase pathology formation after PFF
treatment (Nalls et al., 2014; Jinn et al., 2017). Also, lysosomal dysfunction induced by
cathepsin D haploinsufficiency can promote α-syn spreading (Bae et al., 2015). PFF
treatment can also cause defective lysosomal maturation in primary neurons, and
lysosomal degradation of PFFs can limit pathology formation (Tanik et al., 2013; Sacino
et al., 2017). Furthermore, lysosomal impairment can increase pathology formation after
PFF treatment (Karpowicz et al., 2017).
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Mitochondrial ROS can cause DA oxidation which in turn can cause lysosomal
and GBA dysfunction providing a link between these multiple forms of toxicity known to
mediate neurodegeneration in PD (Burbulla et al., 2017). Primary dopaminergic neuronal
cultures treated with PFFs also exhibit increased oxidative stress (Dryanovski et al.,
2013). PD patient tissue has been shown to have increased antioxidant proteins and
decreased mitochondrial complex 1 further supporting that mitochondrial ROS is causing
neurotoxicity (Schapira, 2007; Bellinger et al., 2011). Mutations in Parkin, PINK1, and
DJ-1 all have a role in mitophagy where defective mitochondria are degraded further
linking mitochondrial ROS to lysosomal impairment (Kitada et al., 1998; Valente et al.,
2004a; Narendra et al., 2008). The selective deletion of mitochondrial transcription factor
A from DA neurons can cause DA neurodegeneration due to deficient oxidative
phosphorylation, and LRRK2 mutations can also cause mitochondrial impairment
(Ekstrand et al., 2007; Papkovskaia et al., 2012). α-Syn can localize with mitochondrial
associated ER and also to the mitochondrial protein TOM20 to prevent mitochondrial
import, suggesting α-syn may have a function in mitochondrial homeostasis and could
contribute to ER stress and mitochondrial dysfunction (Guardia-Laguarta et al., 2014; Di
Maio et al., 2016). In Drosophila, α-syn can mediate mitochondrial dysfunction through
interactions with actin and spectrin linking toxicity to defects in trafficking (Ordonez et al.,
2018).

1.4.3 The role of the innate and adaptive immune systems in PD
The immune system is split between the innate (IIS) and adaptive immune
systems (AIS) who function in complementary ways. The IIS reacts in the same way to
an insult each time it is presented whereas the AIS develops a more refined response
overtime to a particular antigen. The AIS also retains a memory of this antigen so that it
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can react more quickly should the antigen be encountered again. There has been
considerable debate as to the contribution of each of the arms of the immune system to
PD. The most prevalent cell of the IIS in the brain are microglia. Neuroinflammation in
the form of activated microglia has been noted in post mortem PD tissue and PD
models, including the PFF model, suggesting that microglia may play a role in PD
pathogenesis (McGeer et al., 1988; Watts et al., 2013; Sacino et al., 2014a; SanchezGuajardo et al., 2015; Duffy et al., 2018; Yun et al., 2018). Evidence from PFF treatment
suggests that microglia are actively inducing degeneration because microglia are
activated before the onset of degeneration and appear to mediate astrocyte induced
neurotoxicity in vivo through a glucagon like 1 receptor mediated mechanism (Duffy et
al., 2018; Yun et al., 2018). The exact factors that mediate this effect need to be
investigated as they may provide interesting drug targets to modulate PD pathogenesis.
Cytokines such as TNF-α and IL-1β are increased in PD patients relative to controls, and
the double knock-out of Interferon β and the Interferon receptor is sufficient to induce αsyn pathology, neurodegeneration, and a motor phenotype (Ejlerskov et al., 2015; Mogi
et al., 1994). It appears likely that various cytokines may be playing a role in mediating
the toxic effect microglia have in PD.
The AIS has also been suggested to play a role in PD pathogenesis through
several lines of evidence. There is an association of PD with certain HLA haplotypes
(Wissemann et al., 2013). T cells have been observed to infiltrate PD patient brains, and
catecholaminergic neurons are prone to upregulate MHCI (Brochard et al., 2009;
Cebrian et al., 2014). Recently, it was discovered that PD patients develop T-cells
capable of recognizing α-syn peptides suggesting that the AIS may play a role in the
induction or maintenance of the PD disease course (Sulzer et al., 2017). There also
appears to be an interaction between PD pathogenesis and the microbiome as it has
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been reported that microbiota are required for the motor symptoms observed in α-syn
overexpression and transgenic models of PD (Sampson et al., 2016). How this
interaction is occurring is unknown, but the AIS plays a significant role in maintaining the
microbiome and is likely modulating this effect (Kato et al., 2014).

1.5 The role of the current study in addressing potential neuronal
vulnerability/toxicity mechanisms associated with synucleinopathies

The overarching focus of this thesis is to identify the mechanism(s) underlying
cell type vulnerability and toxicity that occur as a result of α-syn aggregation. It is well
established that protein inclusions comprised of α-syn (i.e. Lewy Pathology) affect
specific neuronal populations in synucleinopathies, but the factors that predispose
particular neuronal sub regions to pathology formation and how aberrant α-syn
aggregation is linked to neurodegeneration in this group of disorders is still unknown.
Because no disease-course modifying agents or curative therapies exist for the
synucleinopathies, there is an impetus for studying the mechanisms of cell-type
vulnerability and toxicity which may reveal novel therapeutic targets.
In order to identify factors that modulate neuronal vulnerability and toxicity to
Lewy Pathology, I utilized a novel model of PD where α-syn inclusion formation
precedes neuronal loss allowing for the study of how α-syn aggregation is associated
with toxicity. I found that inclusion formation was in fact toxic in primary hippocampal
neurons. This observation implicates Lewy Pathology as detrimental to the viability of
neuronal subpopulations in disease and also allowed me to determine the mechanism of
neuronal subtype vulnerability. I took this further and found that the CA2-3 neurons of
the hippocampus were more vulnerable to pathology induced toxicity relative to neurons
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derived from the adjacent Dentate Gyrus because CA2-3 neurons contain increased αsyn expression. This cell type vulnerability in primary cultures also occurred in vivo and
had been previously noted in the PD literature (Hall et al., 2014; Armstrong et al., 2014).
Pathology induced toxicity could be ameliorated with an early knock-down of α-syn
levels again implicating α-syn expression in toxicity. Interestingly, when knock-down
occurred at later time points, pathology could still be reduced but viability was no longer
rescued. This suggests that vulnerable neurons have a toxic threshold to pathology that
once exceeded cell death occurs, but pathology is capable of forming beyond this point.
Even though viability could not be rescued at late time points by decreasing α-syn
expression, neuronal loss could be prevented by treatment with the antioxidant N-acetyl
cysteine, implicating oxidative stress as mediating α-syn aggregate induced toxicity.
Microglia and astrocytes were not necessary for CA2-3 neuronal vulnerability
demonstrating that Lewy Pathology induced toxicity in a cell-autonomous manner.
This thesis also explores possible non-cell autonomous mechanisms of neuronal
vulnerability by testing if the adaptive immune system is necessary for α-syn aggregation
and the subsequent toxicity of DA neurons in the SNpc in the same mouse model as
discussed above. I found that the adaptive immune system was not necessary for α-syn
aggregate initiation, formation, SNpc neuronal loss, or the associated motor phenotype.
These data suggest that modulating the adaptive immune system would have limited
benefits for synucleinopathy patients because pathology is already present and widely
distributed within the CNS by the time diagnosis is made. However, my results also
implicate the innate immune system as a key mediator of Lewy Pathology and toxicity
due to my observation that a mouse strain with alterations in the innate immune system
developed increased α-syn inclusions, neuronal loss, and a worse motor phenotype in
an age-dependent and α-syn-independent manner. These data suggest a potential non29

cell-autonomous mechanism of toxicity that is independent of both α-syn and the
adaptive immune system.
In summary the work presented in this thesis adds to the synucleinopathy
knowledge base in 4 significant ways by: 1) Defining a mechanism of neuronal
vulnerability to PD-like pathology in hippocampal neurons 2) Revealing additional
implications for the future treatment of PD should therapies to decrease α-syn levels
make it to clinic 3) Determining that the adaptive immune system does not mediate Lewy
Pathology formation and pathology induced toxicity and lastly 4) Identifying a mouse
strain with innate immune system dysfunction that develops more pathology, increased
neuronal loss, and potentiated motor deficits, thus implicating the innate immune system
in modulating α-syn aggregation induced phenotypes.
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Chapter 2: Bent out of shape: α-synuclein misfolding and the convergence
of pathogenic pathways in Parkinson’s disease1

________________________________
1

This chapter contains text and figures adapted from:

Luna E, Luk KC (2015) Bent out of shape: α-Synuclein misfolding and the
convergence of pathogenic pathways in Parkinson’s disease. FEBS Lett. 589(24P
Pt A):3749-59
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2.1 Abstract
Protein inclusions made up primarily of misfolded a-synuclein (a-Syn) are the hallmark of
a set of disorders known as synucleinopathies, most notably Parkinson’s disease (PD). It
is becoming increasingly appreciated that a-Syn misfolding can spread to anatomically
connected regions in a prion-like manner. The protein aggregates that ensue are
correlated with neurodegeneration in the various yet select neuronal populations that are
affected. Recent advances have begun to shed light on the spreading and toxicity
mechanisms that may be occurring in PD. Several key emerging themes are arising from
this work suggesting that a-Syn mediated neurodegeneration is due to a combination of
relative a-Syn expression level, connectivity to affected brain regions, and intrinsic
vulnerability to pathology.

2.2 Introduction
Parkinson’s disease (PD) is the most common motor disorder and second most
common neurodegenerative disorder after Alzheimer's disease, affecting an estimated 7
million people worldwide (Van Den Eeden et al., 2003; de Lau and Breteler, 2006). As age
is a significant risk factor, PD prevalence is expected to rise sharply as the average life
expectancy among the general population continues to increase (Reeve et al., 2014)
Despite its immense social and economic impact, our knowledge regarding the etiology of
this condition remains incomplete and no effective treatments which modify the course of
disease are presently available.
The most prominent feature in the brains of PD patients is the selective loss of
dopaminergic (DA) pigmented neurons within the substantia nigra (SN) and to a lesser
extent those residing in the ventral tegmental and retrorubral areas. Significant
degeneration is also observed in other nuclei and neurotransmitter systems including the
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dorsal raphe (serotonergic), locus coeruleus (noradrenergic), nucleus basalis of Meynert
(cholinergic) and the dorsal motor nucleus of the vagus nerve (Dauer and Przedborski,
2003). Degeneration in these areas likely contributes to both motor and non-motor
symptoms observed in PD, especially hallucinations, depression, and sleep disorders.
For over a century, it has been recognized that neurodegenerative diseases are
commonly associated with the accumulation of abnormally folded proteins within or in the
vicinity of cells of the central nervous system (CNS) (Goedert et al., 2013). PD is
characterized by the presence of eosinophilic inclusions in the soma of neurons termed
Lewy bodies (or Lewy neurites when present in the neurites). Lewy bodies (LBs) represent
a complex amalgamation of lipids, neuromelanin, and up to several hundred individual
proteins with a key component being alpha-synuclein (α-Syn), an 140 amino-acid protein
that is enriched in presynaptic vesicles of vertebrates (Maroteaux and Scheller, 1991;
Spillantini et al., 1997; Jellinger, 2003). A highly soluble lipid-binding protein normally
thought to regulate synaptic vesicle release through stabilization of SNARE (soluble Nethylmaleimide-sensitive factor attachment protein receptor) complexes, α-Syn in Lewy
Pathology occurs as highly ordered amyloid-type fibrils (Spillantini et al., 1997;
Wakabayashi et al., 1997; Hashimoto et al., 1999). In addition to abnormal conformations,
α-Syn in PD brains is also commonly post-translationally modified by cleavage,
hyperphosphorylation, ubiquitination, nitrosylation, and oxidation (Takeda et al., 1998;
Giasson et al., 2000; Fujiwara et al., 2002; Li et al., 2005; Anderson et al., 2006).
Several lines of evidence point to α-Syn playing a key, and possibly causal, role in
PD. For example, the genetic studies that led to the discovery of α-Syn as a major
component of LBs also revealed several point mutations which result in autosomal
dominant PD (Polymeropoulos et al., 1996; Kruger et al., 1998; Zarranz et al., 2004; AppelCresswell et al., 2013; Lesage et al., 2013). Duplication or triplication of the wildtype locus
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that lead to 1.5-2 fold overexpression also give rise to dominantly-inherited PD, while
several polymorphisms in the promoter region are reported to elevate the risk of
developing disease (Singleton et al., 2003; Chartier-Harlin et al., 2004; Maraganore et al.,
2006).
The significance of α-Syn is further supported by large-scale genome-wide
association studies that indicate a clear link between the SNCA locus and PD (SimonSanchez et al., 2009; Nalls et al., 2011). Intriguingly, several strong genetic risk factors
may have strong interactions with α-Syn. For example, mutations in glucocerebrosidase,
which causes the lysosomal storage disorder Gaucher’s disease, also elevates α-Syn
levels and increases the risk of PD by up to 30-fold in some populations (Sidransky et al.,
2009; Mazzulli et al., 2011). Moreover, Lewy Pathology has also been reported in multiple
forms of familial PD, such as those involving mutations in DJ-1, PINK1, and GBA, although
this is less certain for other genetic forms of PD (e.g., LRRK2, Parkin, ATP13A2)
(Bandopadhyay et al., 2004; Ramirez et al., 2006; Neumann et al., 2009; Samaranch et
al., 2010; Doherty et al., 2013; Kalia et al., 2015). Collectively, these data point to α-Syn
dysfunction as a key process in PD pathogenesis. Indeed, the observation that
cytoplasmic α-Syn inclusions are also characteristic of several other neurodegenerative
conditions, most notably multiple system atrophy (MSA) and dementia with Lewy bodies,
suggests that α-Syn accumulation is not merely a benign product of the degenerative
process (Spillantini et al., 1997; Gai et al., 1998; Braak et al., 2005; Goedert et al., 2013).
Despite the overwhelming evidence for a central role of α-Syn in PD and other
synucleinopathies and the explosion in our knowledge regarding this protein in both health
and disease, two fundamental questions still remain unanswered. Firstly, what instigates
the neurodegeneration that typifies PD? Secondly, why do selective cell populations
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undergo degeneration? This review discusses some of the recent advances that illustrate
the complex pathobiological relationships between α-Syn misfolding and PD.

2.3 Prion-like properties of pathologic α-Syn
The distribution of α-Syn inclusions observed in the CNS of patients with PD and
other synucleinopathies is highly non-uniform. On the contrary, Braak and colleagues
have previously demonstrated that α-Syn inclusions in PD form in a predictable manner
during disease progression, allowing categorization into at least six distinct
clinicopathological stages in the majority of PD patients. Lewy Pathology typically begins
in the olfactory bulb and deep brain stem nuclei (stages I and II). This pattern correlates
with several known prodromal symptoms of PD including olfactory impairment, autonomic
dysfunction, and REM sleep disturbances (Lee and Koh, 2015). Inclusion pathology is
then detectable in more rostral regions, most notably midbrain DA neurons in stages III
and IV. It is during these stages that the motor symptoms associated with PD become
evident. In the ultimate stages (V and VI) pathology begins to be observed in the neocortex
and has been correlated with the onset of dementia (Braak et al., 2003b). While this
stereotypic staging system appears to be valid in up to 80% in multiple patient
subpopulations, other studies point to a significant portion of patients (up to 50%) that do
not follow this classification (Halliday et al., 2008; Jellinger, 2008a; Kalaitzakis et al., 2008;
Dickson et al., 2010).Heterogeneity in the initial location where α-Syn aggregates are first
detected appears to be a source of this discrepancy resulting in modified or alternative
staging systems that attempt to encompass populations that do not fit the conventional
caudo-rostral pattern of spread, such as in dementia with LB (Beach et al., 2009).
Nonetheless, human studies clearly point to the gradual yet inevitable spread of α-Syn
pathology originating from select regions. In conjunction with this evidence, post-mortem
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examination of fetal mesencephalic neurons transplanted into PD patients show that they
develop Lewy Pathology in a time-dependent manner. As fetal neurons initially lack any
of the pathological processes and were unlikely to contain α-Syn inclusions at the time of
transplantation, the appearance of pathology several years in a neurodegenerative
environment argues that the initiation factor of pathology had been conferred and affected
healthy neurons (Kordower et al., 2008; Li et al., 2008).
In line with this histopathological evidence, more recent work in cell culture and
animal models has provided direct indication that α-Syn pathology is transmissible to
recipient cells. In particular, it is now clear that brain homogenates enriched in α-Syn
pathology can induce Lewy Pathology in the CNS of recipient animals. Importantly, the
source of this pathology, whether from transgenic mice exhibiting Lewy-like pathology or
from MSA or PD patient-derived extracts are capable of initiating pathological formation
(Mougenot et al., 2011; Luk et al., 2012a; Watts et al., 2013; Recasens et al., 2014).
Indeed, α-Syn itself can propagate pathology as recombinant α-Syn fibrils (or pre-formed
fibrils; PFFs) and induce Lewy-like pathology in cultured cells and neurons, as well as in
vivo following intracerebral introduction (Luk et al., 2009; Volpicelli-Daley et al., 2011; Luk
et al., 2012b; Masuda-Suzukake et al., 2013; Sacino et al., 2014a; Paumier et al., 2015).
Not only does α-Syn pathology form in these models, but aggregation develops at sites at
considerable distances from the injection site in vivo indicating propagation of the
misfolding process (Luk et al., 2012b; Masuda-Suzukake et al., 2013; Sacino et al.,
2014a).
Interestingly, intramuscular PFF injection also results in CNS pathology in
transgenic mice overexpressing α-Syn, suggesting that pathology can transmit via the
PNS, although the mechanism responsible remains unclear (Sacino et al., 2014b).
Analogous to this, the preponderance of Lewy Pathology in deep brain stem nuclei,
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especially the dorsal motor nucleus of the vagus, seen in early PD is consistent with a
spreading process originating in peripheral sites (Braak et al., 2003a). One location
commonly found to harbor α-Syn aggregates in PD patients are gastrointestinal tract
neurons, and a recent report suggests that long term risk of PD is significantly reduced
following full vagotomy, raising the interesting possibility of this system as potential route
of spread (Braak et al., 2006; Svensson et al., 2015).
The potential mechanisms by which misfolded α-Syn can initiate and propagate
intracellular inclusion formation that is reminiscent of human synucleinopathies have been
reviewed in detail elsewhere (Dunning et al., 2013; Goedert et al., 2013; Guo and Lee,
2014; Chu and Kordower, 2015) and appears to be predicated on three major
components: the generation of misfolded α-Syn species, internalization into a permissive
cellular environment/compartment, and engagement with the endogenously expressed αSyn pool.

2.3.1 Internalization of extracellular α-Syn
Among neurons, endocytosis appears to be a chief mechanism mediating
misfolded α-Syn entry into neurons, although the precise steps and whether other
internalization pathways play a role is an active area of research (Hansen et al., 2011;
Volpicelli-Daley et al., 2011). Blocking endocytosis with a dynamin dominant negative
mutant prevents cell to cell transfer of pathology (Desplats et al., 2009). It is not clear if
this is mediated by a selective uptake mechanism, e.g. a specific receptor that binds αSyn, although α-Syn aggregates appear to have an affinity for heparan sulfate
proteoglycans on neuronal cell surface like tau fibrils (Holmes et al., 2013). In line with
these properties, α-Syn internalization has also been described in multiple cell types, and
evidence suggests that microglia, astrocytes and oligodendrocytes are capable to
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internalizing α-Syn (Kim et al., 2013; Kim et al., 2014; Reyes et al., 2014; Peelaerts et al.,
2015; Wang et al., 2015). Several commonly used cell lines have also been shown to
internalize α-Syn (Luk et al., 2009; Chai et al., 2013; Bae et al., 2014). This provides
evidence as to how glia cytoplasmic inclusions (GCIs) could form in MSA, but it is unusual
that these inclusions would be able to form because neither cell type expresses much αSyn (Kim et al., 2013; Reyes et al., 2014). Another potential mechanism that could spread
pathology are nanotunnels between cells which have been shown to be capable of
spreading prion protein, but this has yet to be reported for α-Syn (Gousset et al., 2009).
The manner in which α-Syn is released from cells remains unknown as well. α-Syn
is found in vesicles released by exocytosis and in several body fluids, such as CSF and
plasma (El-Agnaf et al., 2003; Lee et al., 2005). α-Syn secretion continues when ER-Golgi
transport is blocked, ruling out conventional exocytosis as the primary mechanism of αSyn release (Lee et al., 2005; Jang et al., 2010). Other non-conventional forms of
exocytosis are being explored as the mediator of α-Syn spread including exosome release
and exophagy, an autophagosome mediated exocytosis (Webb et al., 2003;
Emmanouilidou et al., 2010; Hasegawa et al., 2011; Kunadt et al., 2015).

2.3.2 Multiple neuronal populations are permissive to pathological α-Syn
propagation
Mice, rats as well as non-human primates have been found to develop pathology
and nigrostriatal neurodegeneration after injection of PD patient brain lysate into the
striatum further illustrating that pathology and DA neuron toxicity are transmissible
(Recasens et al., 2014; Paumier et al., 2015). Targeting PFFs to separate CNS nuclei in
WT mice also gives rise to distinct spreading patterns for each injection site (MasudaSuzukake et al., 2014). Thus, it is clear that multiple cell populations in the CNS are
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permissive to seeding with exogenous misfolded α-Syn species. This data also indicates
that pathology spreads in an anatomically dependent manner. Furthermore, in vivo data
suggests that pathology spreads in a retrograde manner to synaptically connected brain
regions, and this is unlikely to be mediated by cell death (Luk et al., 2012b; Brettschneider
et al., 2015; Ulusoy et al., 2015). Pathology has also been observed to be trafficked in
vitro both towards and away from the soma (Freundt et al., 2012; Reyes et al., 2015). The
terminology of retrograde vs. anterograde should be used cautiously as pathology
propagation mechanisms are ill-defined and may not conform to traditionally defined
modes of axonal transport. Moreover, it is possible that different species of α-Syn (e.g.,
internalized misfolded vs. converted endogenous species) may undergo different modes
of trafficking/transport (i.e., propagation may be a separate but simultaneous event),
although pathology is capable of propagating both towards and away from the soma in
cultured neurons (Chu and Kordower, 2015).
The range of conformational species capable of inducing pathology remains a topic
of debate. Indeed, aggregates generated under different conditions or isolated from
different synucleinopathies have been reported to induce distinct phenotypes, leading to
the notion that multiple strains exist. When α-Syn is fibrilized in vitro under stringent
conditions, distinct α-Syn fibrils with different biochemical and biophysical properties can
be generated. These different fibril strains are able to cause different phenotypes in vivo
as well (Bousset et al., 2013; Peelaerts et al., 2015). In addition, α-Syn fibrils formed after
serial passaging have been found to gain novel properties and co-aggregate other
aggregation prone proteins such as tau, which is implicated in Alzheimer’s and other
disorders (Guo et al., 2013). This raises the possibility that PD and other
synucleinopathies may be caused by different strains of fibrilized α-Syn in humans,
although this is not yet definitive.
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2.4. Toxicity mediated by α-Syn misfolding
It is unclear if LB formation precedes cell loss, but the appearance of α-syn
aggregates within a neuronal population is highly correlated with the onset of neuronal
loss (Braak et al., 2003b; Mori et al., 2006; Dijkstra et al., 2014). In PD patients, cell loss
in the SNpc also highly correlated to worsening of symptoms, and disease progression is
associated with changes in network activity in several brain regions including the
subthalamic nucleus and globus pallidus (Greffard et al., 2006; Huang et al., 2007).
However, the degree to which these two variables correlate and their causality is still
contentious.
The sequence of events is somewhat clearer in experimental models and neurons
treated with α-Syn PFFs is that PFF-injected mice exhibit pathology formation before the
onset of cell loss suggesting that pathological species lead to neurodegeneration
(Volpicelli-Daley et al., 2011; Luk et al., 2012b; Mahul-Mellier et al., 2015). Nonetheless,
there is considerable debate as to whether inclusions such as LBs act as a protective sink
for toxic α-Syn intermediates or that they lead to sequestration of the physiological α-Syn
pool, resulting in the loss of normal α-Syn function. Thus, an important question is whether
neuroprotection or toxicity (or neither) is enhanced in cells that contain the pathological
aggregates. To address this issue, Unni and colleagues used multi-photon imaging to
monitor α-Syn pathology development and long term neuronal viability after intracerebral
α-Syn PFF injection in mice expressing an α-Syn-GFP fusion protein (Osterberg et al.,
2015). As predicted, these animals developed inclusions of α-Syn-GFP that matured and
condensed over time. By following the α-Syn-GFP aggregates within individual neurons
over time, the authors found that the aggregate-bearing neurons were selectively lost.
Their results also showed that while affected neurons were lost over a range of time after
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inclusion formation, neighboring neurons were consistently preserved, suggesting the lack
of a widespread toxic process involving other cells.
Collectively, these data provide several interesting clues into the toxicity of α-Syn
aggregation and the cause of neurodegeneration. First, they suggest that α-Syn inclusion
formation is necessary for toxicity and that cell death correlates with inclusion maturation.
Although it is clear that neurons containing pathology are the ones that are vulnerable,
this raises the question of whether fibrillar forms of α-Syn found in pathological aggregates
is necessary for neurodegeneration in the susceptible population. Moreover, synaptic and
trafficking impairments are detectable soon after pathological seeding when inclusions are
confined to axons (Volpicelli-Daley et al., 2014b). Lastly, they suggest that cell death
following inclusion formation is likely a primarily cell-autonomous process. α-Syn inclusion
induced cell death is also apparent in primary neuronal culture, where microglial
responses are limited (Volpicelli-Daley et al., 2011). Although, this does not preclude the
possibility of microglia activating after the onset of neurodegeneration further enhancing
cell death.

2.4.1 A protein of many (ascribed) functions: implications of loss of function
α-Syn is the most studied member of a three-member protein family comprised of
α, β, and γ synuclein (Maroteaux and Scheller, 1991; Bendor et al., 2013). α-Syn is an
140-amino acid protein comprised of three distinct domains. An amphipathic N-terminal
portion containing seven 11-amino acid repeats in thought to interact with membranes by
adopting an alpha helical structure when bound (Davidson et al., 1998). The function of
the acidic and proline-rich C-terminal region is unknown, but the presence of several
putative phosphorylation and post translational sites points to involvement in regulating αSyn activity and/or localization (Oueslati et al., 2010; Masuda-Suzukake et al., 2013).
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Biophysical studies also suggest that the C-terminus also interacts with the hydrophobic
region that forms the core of the α-Syn molecule, preventing its self-assembly into the
beta-sheet rich amyloid fibrils in LBs and GCIs (Bertoncini et al., 2005; Waxman et al.,
2009).
Although it is found in a number of tissues, α-Syn is most highly expressed in both
peripheral and central neurons (Iwai et al., 1995). At the intracellular level, the highest
levels of α-Syn are colocalized to pre-synaptic terminals, consistent with its purported
involvement in regulating synaptic vesicle cycling and endocytosis (Maroteaux et al., 1988;
Iwai et al., 1995; Chandra et al., 2005; Ben Gedalya et al., 2009). α-Syn has been shown
to facilitate and stabilize SNARE complex formation, and overexpression of WT α-syn in
cultured neurons leads to decreased exocytosis in both hippocampal and DA neurons
(Burre et al., 2010; Nemani et al., 2010). Interestingly, apart from modulation in DA release
and recycling pool homeostasis, mice lacking α-Syn show no noticeable phenotype,
possibly owing to redundancy of the other synucleins or other compensatory mechanisms
(Abeliovich et al., 2000; Yavich et al., 2004; Yavich et al., 2006; Scott and Roy, 2012).
Indeed, mice lacking α-, β-, and γ-syn show age-related neurodegeneration and
endocytosis abnormalities (Greten-Harrison et al., 2010; Vargas et al., 2014). Acute
knockdown of α-Syn by means of adeno-associated virus expressed RNAi also promotes
degeneration in SN neurons (Gorbatyuk et al., 2010).
In addition, α-Syn has been reported to be localized to the cytosol, nucleus, the
mitochondria associated membrane of the ER, and the inner membrane of mitochondria,
suggesting that it may be actively trafficked between different compartments (Nakamura
et al., 2011; Guardia-Laguarta et al., 2014). Additional studies have found that α-syn can
affect nuclear protein function (Goers et al., 2003; Specht et al., 2005; Kontopoulos et al.,
2006). α-Syn’s molecular weight is below the nuclear pore cut off allowing α-syn to diffuse
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from the general cytosolic population into the nucleus without a prototypical NLS. Other
putative functions for α-syn involve mitochondrial maintenance, consistent with reports
that α-Syn binds to mitochondria, and perturbation of α-syn levels can impair mitochondrial
function (Ellis et al., 2005; Martin et al., 2006; Li et al., 2007; Narendra et al., 2012).
Nonetheless, many of these functions ascribed to α-Syn remain too poorly defined, and
whether their loss contributes to toxicity remains to be elucidated.

2.4.2 Misfolded α-Syn as toxic species
In addition to the prototypical 12-15 nm wide amyloid fibrils found in LBs, multiple
molecular species of various sizes have been reported, including short fibril-like
intermediates (protofibrils) and spherical or annular oligomers ranging from ~25 to several
hundred α-Syn molecules (Conway et al., 2001; Norris et al., 2005). Toxic oligomers
contain a β-pleated sheet structure and are much smaller compared to aggregates and
are variable in size. Oligomers are believed to be on the pathway between α-Syn monomer
and fibrils, but off-pathway oligomers have been described to cause toxicity (Lorenzen et
al., 2014; Chen et al., 2015). It is also possible that as α-Syn becomes fibrillar and forms
inclusions, the concentration of intermediates (i.e. oligomers) may increase which could
increase toxicity (Cremades et al., 2012). Toxicity or mechanism thereof has been
controversial, although a common theme is the disruption of membranes. Winner et al.
showed that α-Syn mutants that preferentially formed oligomers resulted in enhanced DA
neuron loss when overexpressed in rat midbrain, and α-syn oligomers are capable of
forming pores in membranes and cause cell toxicity and death due to increased calcium
permeability (Conway et al., 2000a; Butterfield and Lashuel, 2010; Campioni et al., 2010;
Winner et al., 2011).
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The topic of oligomers as the toxic species is still contentious because membrane
permeabilization may not be specific to oligomers and may only be transient, which would
suggest that what is actually being observed is α-syn transiently binding to membranes
(van Rooijen et al., 2009; Roberts and Brown, 2015). Moreover, the unstable/transient
nature of oligomeric α-Syn has also precluded their isolation and in-depth characterization.
The recent work into oligomer and fibril toxicity suggests a gain of toxic function
mechanism, but this does not exclude the possibility of loss of α-syn function further
increasing toxicity. These two options need not be mutually exclusive, and this remains
an active area of debate.
The α-Syn aggregation and cell loss seen after seeding pathology with α-syn
PFFs is highly dependent upon the production of α-Syn within neurons. Importantly,
neither cell loss nor the induction of pathology occurs in α-Syn-/- mice or primary neurons
(Volpicelli-Daley et al., 2011; Luk et al., 2012b). We have also observed that as primary
neurons mature they develop pathology at a much faster rate compared to younger
neurons, which is most likely due to primary neurons producing more α-syn as they age
in culture (Volpicelli-Daley et al., 2011). Interestingly, it has been noted that the GABAergic
neurons are resistant to α-Syn aggregation in primary hippocampal cultures after PFF
addition, due to their lower levels of α-Syn expression compared to glutamatergic neurons
despite comparable capacity to internalize α-Syn (Taguchi et al., 2014). Similarly, M83
hemizygous mice expressing the A53T α-Syn mutant injected intracerebrally with PFFs
show delayed onset of symptoms compared to injected homozygous mice (Luk et al.,
2012a; Watts et al., 2013). It is worth noting that symptom-free survival in M83 hemizygous
mice was nearly double that of the homozygous counterparts, but their rate of decline was
similar suggesting that the increased α-syn expression in the M83 homozygous mice
increased the rate of nucleation and not neurodegeneration. Supporting this is the
44

observation that patients with α-Syn triplications develop disease at an earlier age
compared to patients with α-Syn duplications (Chartier-Harlin et al., 2004).

2.5 Origins of misfolded α-Syn
Despite the expanding literature on cell-to-cell transfer of α-Syn, much less is
known about how misfolded α-Syn species initially arise. The ubiquitous and robust
expression of α-Syn in neurons makes them the most probable location for this to occur.
Impairments in protein degradation and quality control machinery directly increase
intracellular α-Syn concentration, augmenting the rate of both cell autonomous α-Syn
aggregate formation and the risk of seeding by exogenous α-Syn.
However, the localization of α-Syn may be as important as its quantity. Most
groups report that α-Syn is mostly a natively unfolded monomer within the cell using both
denaturing and non-denaturing conditions and that α-Syn is only weakly associated with
synaptosomal and mitochondrial fractions (Kahle et al., 2000; Fortin et al., 2004; Fauvet
et al., 2012; Vargas et al., 2014). This contrasts with reports that α-Syn exists as a
membrane bound multimer and that stable tetramers can be isolated under nondenaturing conditions (Bartels et al., 2011; Wang et al., 2011; Dettmer et al., 2015). Given
the affinity of α-Syn for phospholipids and high curvature membranes, this discrepancy
could reflect interactions between α-Syn and membranes that are highly transient. Indeed,
cross-linking appears to stabilize a multimeric membrane bound pool and SNCA mutations
known to cause familial PD cluster within a small stretch of the N-terminal region,
suggesting that interactions with membranes is vital (Zhu and Fink, 2003; Middleton and
Rhoades, 2010; Bartels et al., 2011; Jensen et al., 2011; Wang et al., 2011; Dettmer et
al., 2015). These mutations, as well as directed mutations in the imperfect repeats
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preceding the core hydrophobic domain, reduce membrane binding through disruption of
α-Syn multimers (Westphal and Chandra, 2013; Burre et al., 2014).
Increased α-Syn dissociation is thought to result in the accumulation of unfolded
species in the cytoplasmic compartment shifting the α-Syn equilibrium towards the
formation of oligomeric and/or fibrillar species. Although several familial PD α-Syn mutants
show accelerated in vitro aggregation kinetics (e.g., E46K, H50Q, A53T), fibrillization in
others are reduced (A30P, G51D), indicating that both increased levels of unstructured αSyn and aggregation propensity factor in the generation of misfolded fibrillar species
(Conway et al., 2000b; Greenbaum et al., 2005; Khalaf et al., 2014; Rutherford et al.,
2014). In line with this, artificial α-Syn mutants with compromised membrane binding also
preferably segregate into the soluble unbound pool. Importantly, overexpression of these
mutants in vivo greatly enhances toxicity in SN DA neurons, although it remains to be
seen whether wildtype α-Syn also undergoes dissociation into a more aggregation-prone
state at levels that support misfolding (Burre et al., 2015).
Although modest accumulation is observed in the brains of transgenic animals
overexpressing α-Syn, the dramatic increase in pathological α-Syn following introduction
of either PD brain extracts or recombinant α-Syn fibrils suggests that normal α-Syn located
within membranes are vulnerable to conversion by pathologic species. This accelerated
conversion is also apparent in models of α-Syn seeding using non-transgenic rodents as
well as non-human primates indicating that fibrillar, and possibly oligomeric intermediates,
are capable of destabilizing native α-Syn (Volpicelli-Daley et al., 2011; Masuda-Suzukake
et al., 2013; Recasens et al., 2014; Paumier et al., 2015).
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2.6 Pathophysiology of α-Syn misfolding
Similar to the role α-Syn oligomers play in disease, considerable debate exists
regarding the cellular stressors arising from α-Syn misfolding that contribute to
neurodegeneration. Nonetheless, work from both genetic and fibril-injection based models
of synucleinopathies have provided fresh insights to the knowledge derived from more
traditional, mainly neurotoxin (e.g., MPTP, rotenone, and 6-OHDA) dependent models. A
particularly interesting observation is that α-Syn appears to modulate the toxicity in these
latter models. For example, mice lacking α-Syn expression show relative resistance to
MPTP induced degeneration of midbrain DA neurons, further highlighting a role for α-Syn
in degeneration and that these approaches may intersect at the stressor pathways they
activate (Dauer et al., 2002). Several different cell stressors have been implicated by both
neurotoxin based PD models and genetic models to cause neurodegeneration. Among
these are ER stress and the unfolded protein response (UPR), oxidative stress and
mitochondrial dysregulation, calcium homeostasis dysregulation, and neuroinflammation.

2.6.1 Endoplasmic reticulum stress
ER stress and activation of the unfolded protein response have been observed in
various cell culture and mouse models of PD where α-Syn aggregation is present,
including transgenic mice expressing human α-Syn with the A53T mutation (Colla et al.,
2012; Mercado et al., 2013). In both the MPTP and 6-OHDA models of PD upregulation
of markers such as CHOP and ATF4 also point to ER stress. Genetic deletion of CHOP
can prevent neurodegeneration in the 6-OHDA model, although this same effect did not
occur in the MPTP model (Silva et al., 2005). In addition, treatment with salubrinal, an
inhibitor of ER stress, can alleviate motor symptoms and cause neuroprotection (Colla et
al., 2012). A downstream consequence of ATF4 and CHOP activation is the increase of
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Trib3, and knockdown of this pro-apoptotic product reduces ER stress and attenuates
neuron loss in both neurotoxin and PFF based models (Aime et al., 2015).
In PD post mortem patient samples the presence of several key markers, including
phosphorylated PERK are also consistent with ER stress and UPR activation in the face
of increased misfolded α-Syn (Hoozemans et al., 2007). Several genetic mutations that
cause familial PD are known to affect protein degradation and trafficking. Chief among
these are the GBA, VPS35, ATP13A2, and LRRK2 mutations which affect either
lysosomal function or ER trafficking, and there is evidence that VPS35 may interact with
α-Syn (Aharon-Peretz et al., 2004; Zimprich et al., 2004; Ramirez et al., 2006; Zimprich et
al., 2011). ER-Golgi trafficking dysfunction has also been noted in the PFF model in
multiple cell types (Luk et al., 2009; Volpicelli-Daley et al., 2014b) while overexpression of
Rab1, a regulator of ER-Golgi trafficking in yeast, or its homologs leads to rescue from
cell death in PD models (Cooper et al., 2006). Induced pluripotent stem cells derived from
PD patients with genetic mutations also develop ER stress which is alleviated by the
ubiquitin ligase Nedd4, further implicating proteosomal/ER stress in PD, and enhanced
Nedd4 activity in attenuating this dysfunction (Chung et al., 2013; Tardiff et al., 2013). It is
unknown if ER stress and UPR activation are a cause or effect in PD pathogenesis,
although the evidence presented suggests both.

2.6.2. Oxidative Stress
As with ER stress, it is unclear if oxidative stress represents a cause and/or effect
in PD pathogenesis. Compared to controls, brain tissue from PD patients contain altered
levels of antioxidant proteins, such as GPX4 and glutathione, suggesting that this
mechanism may play a role in disease (Bellinger et al., 2011). In addition, mutations in
Parkin and PINK1, which maintain mitochondrial health, cause autosomal recessive forms
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of PD (Kitada et al., 1998; Valente et al., 2004b; Narendra et al., 2008). Even though
knockout of these genes in mice do not result in α-Syn aggregation, increased
mitochondrial stress has been observed in these mice indicating that they play a role in
maintaining neuronal health (Kim et al., 2005; Poole et al., 2008). Interestingly, α-Syn null
mice are also protected from DA neuron loss following treatment with the mitochondrial
complex I inhibitor MPTP suggesting that α-Syn mediates toxicity (Dauer et al., 2002).
Consistent with this, cultured DA neurons exposed to α-Syn fibrils show elevations in both
mitochondrial and cytoplasmic oxidative stress (Dryanovski et al., 2013). More recently,
α-Syn has been shown to be localized with mitochondrial associated ER, suggesting αSyn may have a function in mitochondrial homeostasis and disruption of this could
contribute to ER stress and mitochondrial dysfunction and providing a link to PD
pathogenesis and neurodegeneration of DA neurons (Guardia-Laguarta et al., 2014).

2.6.3 Calcium buffering and vulnerability within dopaminergic subpopulations
Calcium ions (Ca++) are used extensively for cell signaling but imbalances can also
be a potential source of toxicity (Surmeier et al., 2011). Furthermore, it is known that
multiple neuronal populations affected in PD show a combination of low Ca++ buffering
capacity and broad action potentials, leaving them vulnerable to increased cytoplasmic
Ca++ levels (Foehring et al., 2009; Mosharov et al., 2009). In particular, SN neurons utilize
Cav1.3 Ca++ channels for their rhythmic pacemaking activity, exposing them to higher
calcium conductance relative to neurons in the nearby ventral tegmental area (VTA) (Chan
et al., 2007). Blockers that prevent Cav1.3 mediated Ca++ entry protect from MPTP but
this is not clear for α-Syn PFF models (Kupsch et al., 1995; Kupsch et al., 1996). Curiously,
Ca++ toxicity in DA neurons also appears to be α-Syn-dependent (Mosharov et al., 2009).
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Because the ER represents a significant reservoir for intracellular Ca++, it is
possible that ER stress could be a source of Ca++ toxicity in PD. For example, disruptions
in calcium homeostasis has been shown in midbrain neurons derived from induced
pluripotent stem cells from patients bearing GBA mutations (Schondorf et al., 2014).
Higher Ca++ conductance has been linked to increased oxidative stress (Guzman et al.,
2010). It is possible that a vicious cycle involving a challenge of ER Ca++ storage capacity
and the reliance on voltage gated Cav1.3 channels leads to elevated Ca++ levels that
trigger the demise of SN, and possibly other, neurons.

2.6.4 Neuroinflammation
It has been suggested that neuroinflammation from activated microglia may
increase neuronal toxicity. It is known that microglia are activated in areas of
neurodegeneration in both post mortem PD tissue and in vivo mouse models of PD
(McGeer et al., 1988; Watts et al., 2013; Sacino et al., 2014a; Sanchez-Guajardo et al.,
2015). PD patients develop increased pro-inflammatory cytokines in their CSF, such as
TNF-α and IL-1β (Mogi et al., 1994; Dobbs et al., 1999). Oligomeric α-Syn has been shown
to bind TLR2, β1-integrin, and CD11b, which can activate microglia (Kim et al., 2013; Kim
et al., 2014; Wang et al., 2015). It is currently debated whether microglia in PD are actively
inducing neurodegeneration, have a more benign role of cleaning the cellular debris left
from dying cells, or possibly both. It has been shown that those neurons that develop
pathology eventually are lost where the surrounding neurons are spared in PFF models
suggesting that cell death is cell autonomous due to the pathological aggregate and not a
reactive extracellular milieu (Osterberg et al., 2015).
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2.7 Neuron-specific vulnerability
If α-Syn misfolding represents a driving pathogenic event, as suggested by clinical
and experimental evidence, then the selective pattern of degeneration that characterizes
PD would suggest that certain cell subpopulations possess an enhanced susceptibility to
acquire or develop α-Syn pathology along with elevated vulnerability to the induced toxicity
(Figure 1). SN DA neurons provide a prototypic example of how these factors might
converge in a susceptible population. Firstly, DA neurons carry enormous metabolic
demands due to their high-frequency autonomous firing resulting in greater production of
oxidative stress and increased calcium entry into the cell for the release of synaptic
vesicles (Guzman et al., 2010; Surmeier et al., 2011; Sulzer and Surmeier, 2013). Unlike
VTA neurons and other populations that express calcium binding proteins (e.g. calbindin),
SN neurons, particularly in the ventral tier, show a paucity of these buffers (Chan et al.,
2007). This, together with their susceptibility to elevated calcium levels due partly to a
dependence on Cav1.3 channels for their pacemaking activity furthers their exquisite
sensitivity to perturbations in oxidative respiration (e.g., complex 1 inhibition). In line with
the view that DA neurons are especially sensitive to mitochondrial impairment, mutations
in mitochondrial DNA or PINK1 and Parkin (two crucial components in mitophagy) are also
associated with PD. The bioenergetic demands of DA neurons are further pushed by the
need to maintain elaborate and high density of connections with target neurons. It is likely
that perturbations in the energy balance disrupt DA neuron arbors leading to the loss of
synapses, and in turn make it susceptible to loss of trophic support that likely helps sustain
the neurons (Matsuda et al., 2009; Bolam and Pissadaki, 2012).
Given the recent body of evidence suggesting pathological α-Syn transmission,
these neurons are at high risk of being exposed to seeding species due to their large
number of synapses and poorly myelinated axons. The high levels of α-Syn enriched in
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processes (especially synaptic terminals) further increases this risk. Consistent with this,
over 90% of PD α-Syn pathology is present as Lewy neurites, rather than LBs in the soma
(Kramer et al., 2008). Axons also represent the initial sites for the accumulation of
hyperphosphorylated α-Syn inclusions in cultured hippocampal neurons suggesting that
synaptic connections represent a general "hot spot" for pathology in other types of neurons
(Volpicelli-Daley et al., 2011).
It has also been argued that elevated Ca++ levels may also increase the rate of
endocytic and secretory events, major routes hypothesized for pathologic α-Syn entry and
exit, respectively, and making neurons prone to seeding aggregation. Possibly
exacerbating this is the observation that DA neurons exhibit robust α-Syn expression
which increases with age in the SN of both humans and non-human primates, a
phenomenon that is not observed in other DA neuronal populations that are relatively
spared in PD, such as the VTA (Chu and Kordower, 2007).
Intriguingly, many of these above properties also apply to a long list of neuron
subpopulations selectively affected in PD including those in the locus coeruleus, raphe
nucleus, dorsal motor nucleus of the vagus, pedunculopontine nucleus, nucleus basalis
of Meynert, and enteric neurons in the large intestine. Another commonality between
several of them is their monoaminergic neurotransmitter phenotype. In particular,
catecholamines are highly reactive and would predispose cells that contain high levels of
them to dysfunction or death due to oxidative stress (Chen et al., 2008; Sulzer and
Surmeier, 2013). Cells that contain catecholamine neurotransmitters also can contain
neuromelanin (NM) which is believed to be a protective mechanism preventing excess
oxidative stress due to catecholamine production (Sulzer et al., 2008). NM is a sign of
oxidative stress and can sequester metal ions like iron which can contribute to the Fenton
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reaction and lipid peroxidation (Sulzer et al., 2000). Supporting this is an age associated
increase in nigral NM content, and humans, the only species known to develop PD, tend

Figure 2.1. Spread and effect of α-syn pathology. Proposed sequence of pathological a-Syn
transmission. Pathology is initially transmitted between neurons and propagates primarily in a
retrograde manner. Resistant populations of neurons (top row) are either capable of degrading the
seeds without forming pathology or have increased capacity to survive and function with
pathological inclusions. Vulnerable populations (middle row) exhibit a-Syn aggregates that grow
and mature over time. These aggregates are capable of disrupting normal neuronal function
(yellow-green neurons) by oxidative stress, ER stress, or other potential stress mechanisms.
Diseased neurons containing inclusions may be capable of further pathological seeding. After a
certain level of cell stress is reached, the diseased neurons undergo cell death (yellow-green
neuron with dashed outline).

53

to develop much larger stores of NM compared to non-human primates (Fedorow et al.,
2005). More recently, it has been shown that catecholaminergic neurons are predisposed
to MHC I induction compared to other neuronal populations, and that cell death could
occur in the presence of the appropriate Cytotoxic T cells making this population prone to
neuronal loss (Cebrian et al., 2014).

2.8. Conclusion
The past several years have witnessed a dramatic expansion in our knowledge
regarding the role of α-Syn in the pathogenesis of PD and related proteinopathies. Recent
work clearly suggests that rather than a single dominant factor, the causes of α-Syn
pathology is multifaceted. Furthermore, these processes interact with inherent
vulnerabilities of certain neurons to give rise to the observed degeneration and symptoms.
These factors vary across neuron populations in the central and peripheral nervous
systems, and likely underlie some of the variability between the synucleinopathies.
Pathological α-Syn behaves as a prion-like agent, capable of templating the conversion of
intracellular α-Syn and providing a route for the propagation of the pathological process
into unaffected neurons. The rate of pathology induction is partially dependent on the total
amount of α-Syn, which can vary across neuronal populations. Following this is the onset
of neuronal dysfunction and then neurodegeneration of those neurons that contain
sufficiently large pathological aggregates (Figure 2.1). Understanding these areas and
how they interact will be key to developing disease modifying therapeutics to treat these
patients.
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Chapter 3: Differential α-synuclein expression contributes to selective
vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity1

_________________________
1

This Chapter is adapted from:

Luna E, Decker SC, Riddle DM, Caputo A, Zhang B, Cole T, Caswell C, Xie SX,
Lee VMY, Luk KC (2018) Differential α-synuclein expression contributes to
selective vulnerability of hippocampal neuron subpopulations to fibril-induced
toxicity. Acta Neuropathol. doi: 10.1007/s00401-018-1829-8.
Schaser AJ, Osterberg VR, Dent SE, Stackhouse T, Weston L, Wakeham C,
Anderson M, Owen N, Weissman TA, Luna E, Luk KC, Lloyd S, McCullough AK,
Cassidy P, Woltjer RL, Unni VK Alpha-synuclein is a DNA binding and repair
protein with implications for Parkinson’s Disease. In Preparation
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3.1 Abstract
The accumulation of misfolded α-synuclein (α-syn) and neuron loss define several
neurodegenerative disorders including Parkinson’s disease (PD) and dementia with
Lewy bodies (DLB). However, the precise relationship between pathology and
neurotoxicity and why these processes disproportionately affect certain neuron
subpopulations are poorly understood. We show here that Math2-expressing neurons in
the hippocampal Cornu ammonis (CA), a region significantly affected by α-syn pathology
in advanced PD and DLB, are highly susceptible to pathological seeding with pre-formed
fibrils (PFFs), in contrast to dentate gyrus neurons, which are relatively spared. Math2+
neurons also exhibited more rapid and severe cell loss in both in vitro and in vivo models
of synucleinopathy. Toxicity resulting from PFF exposure was dependent on
endogenous α-syn and could be attenuated by N-acetyl-cysteine through a glutathionedependent process. Moreover, α-syn expression levels strongly correlate with relative
vulnerability among hippocampal neuron subtypes of which Math2+ neurons contained
the highest amount. Consistent with this, antisense oligonucleotide (ASO) mediated
knockdown of α-syn reduced neuronal pathology in a time-dependent manner. However,
significant neuroprotection was observed only with early ASO intervention and a
substantial reduction α-syn pathology, indicating toxicity occurs after a critical threshold
of pathological burden is exceeded in vulnerable neurons. Together, our findings reveal
considerable heterogeneity in endogenous α-syn levels among hippocampal neurons
and suggest that this may contribute to the selective vulnerability observed in the context
of synucleinopathies.
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3.2 Introduction
The deposition of misfolded proteins in select cell populations is a feature shared
by many age-related neurodegenerative diseases (Jucker and Walker, 2013).
Intracellular inclusions containing α-synuclein (α-syn) define a group of neurological
conditions collectively known as α-synucleinopathies that includes Parkinson’s disease
(PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) (Lee and
Trojanowski, 2006). Underlying their significance in disease, α-syn inclusions in neuronal
cell bodies (Lewy bodies) and processes (Lewy neurites) are present in the vast majority
of both sporadic and familial PD patients (Poulopoulos et al., 2012), and mutations and
multiplication of the α-syn gene (SNCA) cause autosomal dominant PD (Reviewed in
Trinh and Farrer, 2013). Moreover, triplication of wildtype (wt) SNCA results in higher αsyn expression and earlier disease onset compared to PD resulting from gene
duplication, indicating that pathogenesis is also closely linked to α-syn expression levels
(Singleton et al., 2003; Chartier-Harlin et al., 2004; Farrer et al., 2004; Fuchs et al.,
2007).
The clinical progression of PD correlates closely with the appearance of α-syn
inclusions throughout the brain in a stereotypical pattern affecting a restricted number of
regions (Braak et al., 2003b; Dickson et al., 2009). Although the degeneration of
dopaminergic neurons in the substantia nigra pars compacta (SNpc) is a major
contributor to motor symptoms that define PD, populations belonging to glutamatergic,
serotonergic, noradrenergic, and cholinergic systems are also frequently impacted
(Fearnley and Lees, 1991; Kordower et al., 2013; Sulzer and Surmeier, 2013).
Furthermore, there is considerable heterogeneity in α-syn pathology burden and
degeneration between different CNS regions. Indeed, Lewy Pathology and cell loss
appear to be disconnected in some brain regions in PD. For example, the
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tuberomammilary nucleus of the hypothalamus develops Lewy bodies without
observable neuronal loss (Kremer and Bots, 1993). Conversely, neuronal loss with little
to no Lewy Pathology has been reported in the supraoptic nucleus (Ansorge et al.,
1997). Thus, the identities of vulnerable neurons and the relationship between
development of pathology and degeneration remain enigmatic (Surmeier et al., 2017).
A major obstacle to untangling these questions has been the lack of models that
concomitantly recapitulate the accumulation of pathological α-syn inclusions typical of
PD brains in both catecholaminergic and non-catecholaminergic neurons that precedes
progressive neurodegeneration in clinically-relevant neuronal subpopulations. For
example, commonly used neurotoxins induce α-syn-mediated catecholaminergic neuron
loss in nuclei such as the SNpc, but Lewy-like inclusions are observed only after chronic
exposure (Dauer et al., 2002; Fornai et al., 2005; Jenner, 2008). On the other hand,
viral-mediated or transgenic α-syn overexpression models recapitulate Lewy-like
pathology more reliably but involve ectopic overexpression or introduction of mutations
that may potentially distort the distribution of pathology and neuron loss (Visanji et al.,
2016). In both wt rodents and non-human primates, recombinant α-syn pre-formed fibrils
(PFFs) seed the conversion of endogenous α-syn into intracellular inclusions that exhibit
multiple morphological and biochemical properties that are characteristic of human Lewy
Pathology and elicit motor deficits (Volpicelli-Daley et al., 2011; Luk et al., 2012b; Luk et
al., 2012a; Masuda-Suzukake et al., 2013; Recasens et al., 2014; Paumier et al., 2015;
Abdelmotilib et al., 2017; Shimozawa et al., 2017). PFF-seeded neuritic and cell body
inclusions in cell-based systems are also linked to impaired neuronal activity and
trafficking, oxidative stress, and is followed by cell loss (Dryanovski et al., 2013;
Volpicelli-Daley et al., 2014b; Tapias et al., 2017). These features therefore allow for the
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examination of the relationship between α-syn aggregation and neurodegeneration in
cells and in vivo.
The fact that such models display both pathological spread and time-dependent
toxicity led us to hypothesize that neuronal toxicity is dependent on α-syn aggregation.
We provide here not only evidence supporting this hypothesis in non-dopaminergic
neurons but also demonstrate that glutamatergic neurons positive for the transcription
factor Math2 in the Cornu ammonis (CA), a known hotspot for α-syn pathology in PD
with dementia (PDD) and DLB, are particularly vulnerable compared to neurons from the
dentate gyrus (DG) (Armstrong et al., 2014; Hall et al., 2014). Surprisingly, toxicity
resulting from PFF-seeded α-syn pathology does not require the presence of astrocytes
or microglia in vitro. Furthermore, vulnerable Math2+ neurons contain higher α-syn
protein levels compared to other hippocampal subtypes, and antisense oligonucleotide
(ASO)-mediated knock-down of α-syn expression at various time points after PFF
treatment revealed that early and marked reduction of α-syn levels reduced pathology
most robustly and rescued toxicity. Neuroprotection and pathology reduction both
declined with delayed ASO treatment suggesting a cellular threshold for pathology
determined by endogenous levels of α-syn within an individual neuron and beyond which
toxicity is irreversible.

3.3 Methods
Animals
All animal procedures were approved by the University of Pennsylvania Institutional
Animal Care and Use Committee and conformed to the National Institute of Health
Guide for Care and Use of Laboratory Animals. Timed-pregnant CD1 mice (purchased
from Charles River Laboratories) or Snca-/- mice (Abeliovich et al., 2000) maintained on
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a C3H background were used to prepare primary neuronal cultures. Female
C57Bl6/C3H mice (purchased from Jackson Laboratories) were used for in vivo PFFinjection studies.

Reagents and Chemicals
Z-VAD-fmk (ZVAD; broad caspase inhibitor) was purchased from Enzo Life
Sciences. DPQ (PARP1/ Parthanatos inhibitor) was purchased from Santa Cruz
Biotechnology. Necrostatin-1 (Nec-1; RIPK1/ necroptosis inhibitor) and Ferrostatin-1
(Fer-1; Ferroptosis inhibitor) were purchased from Calbiochem. IU1 (USP14 inhibitor), Nacetyl cysteine (NAC; antioxidant), nicotinamide (NAM; NAD supplement), MK-801
(NMDA receptor antagonist), and Cytosine arabinofuranoside (Ara-C) were purchased
from Sigma-Aldrich. Antisense oligonucleotides (ASOs) targeting α-syn (5’TTTAATTACTTCCACCA-3’), which binds within intron 4 of the Snca gene, or control (5’CCTATAGGACTATCCAGGAA-3’) were generously provided by Tracy Cole and Hien
Zhao (Ionis Pharmaceuticals, Carlsbad CA). Complete ASO chemistry information is as
follows: α-syn ASO (Tes Teo Aks Ads Tds Ads mCds Tds mCds mCko Aeo mCes Ae)
and control ASO (mCes mCeo Teo Aeo Tes Ads Gds Ads mCds Tds Ads Tds mCds
Aeo Geo Aes Ae) where capital letters indicate base abbreviation, m=5-methylcytosine,
e=2’-O-methoxyethylribose (MOE), k= (S)-2’,4’-constrained 2’-O-ethyl (cEt),
d=deoxyribose, s=phosphorothioate, and o=phosphodiester (Seth et al., 2011;
Ostergaard et al., 2013).

Recombinant α-syn production, purification, and PFF fibrilization
Wildtype and chimeric α-syn protein production, purification, and fibrilization were
conducted as previously described (Luk et al., 2016a). Briefly, Huwt, Mswt, and HuS87N α60

syn constructs were expressed in E. coli BL21 (DE3) RIL cells and purified. PFF
assembly was achieved by diluting the purified α-syn to 5 mg/ml (360 µM) in sterile
Dulbecco’s PBS (pH 7.0; Mediatech) and then agitated constantly at 1000 rpm at 37oC
for 7 days.

Primary hippocampal neuron cultures and fibril transduction
Primary neuronal cultures were prepared from either CD1 or Snca-/- embryos on
E16-18, as previously described (Volpicelli-Daley et al., 2014a). Tissue culture plates
and coverslips were coated with Poly-D-lysine (Sigma) before addition of cells. Neurons
were plated either on glass coverslips (round 12 mm diameter; Carolina Biological
Supplies) in 24-well plates (50,000 cells/cm2), directly in 12-well plates for biochemical
studies (75,000/cm2), or in 96-well plates (60,000/cm2). Cultures were maintained in
Neurobasal medium supplemented with B27 (Invitrogen) unless otherwise indicated.
PFF treatment was performed at 7 days in vitro (DIV). α-syn PFFs were diluted in sterile
PBS without Ca2+/Mg2+ (Corning) and sonicated with a Biorupter bath sonicator
(Diagenode) for 10 cycles (highest power, 30s on, 30s off at 10oC) then diluted in
neuronal media before being added to cultures. PFF concentrations are expressed as
the total equivalent α-syn monomer content in the preparation. To control for different
cell plating densities in different formats, cultures were treated with ~25pg per cell
(equivalent to 200 nM in a 96 well plate or 350 nM in a 24 well plate) unless otherwise
indicated. At 7 days post transduction (DPT) 0.5 volume of the media in each well was
replaced with fresh media. Ara-C (1μM) was added to neuronal cultures (single
treatment at 4 DIV) to inhibit astrocyte growth for indicated experiments.

Stereotaxic PFF injection
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Injections were performed as previously described with minor modifications (Luk
et al., 2012b). Anesthetized mice received a single unilateral stereotactic injection of
sonicated PFFs (5 µg) into the anterior hippocampus (coordinates: -2.5 mm relative to
Bregma; 2 mm from midline; 2.4 mm beneath the dura). Animals were monitored
regularly after surgery and sacrificed at the indicated time points by overdose with
ketamine/xylazine. PFF injected mice were sacrificed at either 45- or 90 days postinjection (DPI), and PBS injected mice were sacrificed at 180 DPI. The brain and spinal
cord were removed after transcardial perfusion with heparinized PBS and fixed overnight
in 70% ethanol in 150mM NaCl (pH 7.4). Tissues were then embedded in paraffin for
sectioning.

Immunocytochemistry and antibodies
Cultured cells were fixed by replacing media with warm 4% paraformaldehyde (in
PBS/4% sucrose) for 15 min at room temperature (RT). Fixed neurons were washed 3
times with PBS and then blocked (3% BSA, 3% FBS in PBS) for 1 hour at RT or
overnight at 4oC. Cells were then incubated in primary antibodies diluted in blocking
buffer for 4 hours at RT or overnight at 4oC. Primary antibodies used in this study were:
p-S129 α-syn (pSyn; CNDR mouse monoclonal IgG2a 81A; 1:2000); NeuN (Millipore A60;
1:2000); Prox1 (Biolegend 925201; 1:500); CTIP2 (Abcam ab18465; 1:500); Math2
(Abcam ab85824; 1:500); GFAP (CNDR rat monoclonal 2.2B10; 1:500); Iba1 (Wako
019-19741; 1:250); α-syn (CNDR mouse monoclonal IgG2a 9027; 1:5k); Neurofilament L
(NFL; CNDR rabbit monoclonal; 1:2000); MAP2 (CNDR rabbit monoclonal 17028:
1:2000); GAD 65/67 (Chemicon AB1511; 1:1000); GAD 67 (Millipore MAB5406; 1:500).
This was followed by washing with PBS three times and incubating for 1 hour at RT or
overnight at 4oC in blocking buffer containing Alexa-Fluor conjugated isotype-specific
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secondary antibodies (Thermo Fisher). Coverslips were mounted on microscope slides
using Fluoromount G containing DAPI (eBioscience) and scanned on a Perkin Elmer
Lamina scanner or were captured on a Nikon Ds-Qi1Mc digital camera attached to a
Nikon Eclipse Ni microscope. Cells in 96-well plates were washed three times with PBS
and incubated 15 min at RT with DAPI (0.4 µg/ml in PBS) and then imaged using an
InCell 2200 (GE Healthcare Life Sciences). Quantification of cells grown on coverslips
was performed using HALO software (Indica Labs). 96-well plate quantification was
done using InCell Toolbox Analyzer software (GE Healthcare Life Sciences).

Protein extraction and immunoblot analysis of neuron lysates
Cells were scraped in SDS lysis buffer (2% SDS in 50mM Tris, 150mM NaCl, pH
7.6) containing phosphatase and protease inhibitor cocktail, sonicated, and centrifuged
at 100,000 x g for 30 min at 22oC. The supernatant from this step was resolved by SDSPAGE (10 or 15 μg total protein per lane), transferred to nitrocellulose membranes, and
blocked in 7.5% BSA in TBS for 1 hour at room temperature. For immunoblotting,
membranes were incubated overnight at 4oC with constant agitation in blocking buffer
containing the following primary antibodies: GAD 65/67 (Chemicon AB1511; 1:1,000); βIII tubulin (Invitrogen 32-2600; 1:5,000); α-syn (CNDR mouse monoclonal IgG2a
Syn9027; 1:20,000). Membranes were washed in TBS with 0.05% Tween20 three times
for 10 minutes each then incubated in diluted secondary antibodies (Li-Cor Biosciences;
1:20,000 in blocking buffer) for 1 hour at RT on an orbital shaker. Membranes were then
washed as before and imaged using a Li-Cor Odyssey infrared imaging system.

3.4 Results
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3.4.1 PFF-induced toxicity is dependent on the levels of pathological α-synuclein
We have previously shown that exposure to PFFs results in the aggregation of
endogenously expressed α-syn and subsequent neuronal toxicity in primary neuronal
cultures and non-transgenic mice (Luk et al., 2012b; Volpicelli-Daley et al., 2014a).
Since this experimental model reliably results in Lewy-like pathology and neuron death,
we first examined whether toxicity is proportional to the total pathology burden in primary
hippocampal neurons by inducing de novo pathology across a range of concentrations of
PFF seeds. We utilized PFFs assembled from recombinant human wt (Huwt) α-syn or a
chimeric mutant (HuS87N), which recruits endogenous α-syn into inclusions more
efficiently compared to PFFs containing Huwt and other α-syn sequences when
administered to hippocampal cultures or in vivo (Luk et al., 2016a). If toxicity is
proportional to α-syn pathology, HuS87N PFF treatment should result in increased neuron
loss compared to Huwt PFF treatment at each concentration, whereas similar neuron loss
would indicate that these processes are independent. Immunostaining for pathological αsyn phosphorylated at Ser129 (pSyn), a disease-specific post-translational modification
found in PD and in models of seeded synucleinopathy (Fujiwara et al., 2002; Luk et al.,
2012a), we observed that the amount of pathology increased in a dose- and timedependent manner in Huwt PFF-treated neurons. However, by 7 DPT, HuS87N PFF
treatment at all doses tested induced higher pathological burden than the highest Huwt
PFF concentration used, confirming that HuS87N PFFs are more pathogenic (Figure 3.1ac and Figure S3.1a).
Neuronal viability did not differ between PFF-treated and control cells at 7 and 9
DPT, but neurons loss was apparent by 12 DPT with the degree of toxicity being
proportional to the concentration of PFFs added (Figure 3.1d, e). Neurons treated with
Huwt PFFs showed markedly less toxicity compared to HuS87N treated neurons with only
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Figure 3.1 PFF-induced toxicity is dose-dependent and requires pathological α-syn
conversion. a, Primary hippocampal neurons treated with Huwt or HuS87N PFFs and
immunostained for NFL, NeuN, pSyn, and DAPI. b, c, pSyn staining area x intensity and pSyn
staining density relative to surviving NeuN+ neurons at 7 and 14 DPT. d, e, Neuronal viability
determined by the number of NeuN+ cells remaining per well relative to untreated wells. f, g, Total
NFL staining density measured relative to untreated wells. N= 14-18 wells from 3 biological
replicates for each group. Weighted least squares regression analysis after Box-Cox
transformation. All data are mean ± SEM. P-value significance determined after correcting for
multiple hypothesis testing. *p<0.05, **p<0.01, ***p<0.001. Scale bar, 100 µm.

the 1000 nM condition displaying any significant toxicity by 12 DPT (Figure 3.1d). Mouse
wt (Mswt) α-syn PFFs also reduced neuron survival in a dose dependent manner, but
toxicity was less than that of HuS87N PFFs at each dose (Figure S3.1b, c), in agreement
with Mswt PFFs inducing an intermediate level pathology between that of Huwt and HuS87N
PFFs, and further supporting that neuron toxicity is dependent on and proportional to αsyn pathology (Luk et al., 2016a). Both Huwt and HuS87N PFFs failed to induce α-syn
inclusions or neuron loss in Snca-/- neurons indicating toxicity requires the pathological
conversion of endogenous α-syn regardless of the type of PFFs used (Figure S3.2a)
(Volpicelli-Daley et al., 2011). Monomeric HuS87N α-syn, which lacks seeding activity, was
also unable to induce either pathology or toxicity (Figure S3.2b). Staining density of
neurofilament light chain (NFL), a structural protein expressed mainly in axons, closely
mirrored the dose dependent reduction in NeuN+ cell counts under each treatment
condition (Figure 3.1f, g), confirming that the observed NeuN loss in PFF-treated
cultures was due to neuron death rather than downregulation of NeuN.

66

3.4.2 α-syn pathology-induced toxicity affects specific neuronal subtypes
The largest decrease in neuronal viability occurred between 9-12 DPT and did
not appreciably decline afterwards even at the highest PFF doses, suggesting that a
significant subset of neurons continued to persist despite prolonged exposure to PFFs.
This observation prompted us to determine if differences in vulnerability between
neuronal subtypes present in this culture system were responsible for this effect.
Glutamatergic neurons derived from CA regions express the transcription factor Math2
while DG neurons contain Prox1. Another transcription factor, CTIP2, is found in both
CA1 and DG neurons (Bagri et al., 2002; Arlotta et al., 2005; Sugiyama et al., 2014).
Immunostaining showed that ~60% of NeuN+ neurons co-express Math2 indicating CA
origin; ~10% were co-positive for Prox1 (Figure S3.3a). Thus, the majority of neurons in
this culture system are glutamatergic with GABAergic neurons and other subtypes
representing ~30% of neurons.
All three major glutamatergic subpopulations declined significantly by 15 DPT
after HuS87N PFF treatment (Figure 3.2a). However, compared to Math2+ and CTIP2+
neurons (in which viability declined by 54% and 51%, respectively), the Prox1+
population declined by 32% relative to PBS controls (Figure 3.2b), indicating that these
neurons are relatively resistant to PFF-induced toxicity. To confirm this, we treated
primary cultures with 5-fold higher concentration of HuS87N PFFs, which reduced Math2+
neuron viability by >85% while approximately half of Prox1+ neurons still remained
(Figure 3.2c-e). Thus, Prox1+ neurons are more resistant to PFF-induced toxicity than
Math2+ neurons, although they are susceptible in the presence of a sufficiently high
pathological burden. Furthermore, we also found that the proportion of neurons that
contained cell body inclusions was significantly higher among Math2+ and CTIP2+
neurons compared with Prox1+ neurons (Figure 3.2f, g), consistent with the notion
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Figure 3.2 Math2+ neurons are vulnerable to α-syn pathology and toxicity relative to Prox1+
neurons. a, Neurons treated with 350 nM HuS87N PFFs were immunostained at 15 DPT for NeuN,
pSyn, DAPI, and indicated transcription factors (TF). b, Survival of neuronal subpopulations in
PFF-treated cultures relative to PBS treatment. N= 12-16 wells from 3-4 biological replicates per
group. One-way ANOVA with Tukey’s multiple comparison test. c, d, Neurons treated with 1.7 μM
HuS87N PFFs and co-labeled for Math2 or Prox1 and pSyn at DPT 15. e, Survival of neuronal
subpopulations in 1.7 μM HuS87N PFF-treated cultures relative to PBS treatment. N= 9 wells from
3 biological replicates. Unpaired two-tailed t-test with Welch’s correction. f, TF, pSyn, and DAPI
staining at 4 DPT. g, Percentage of cell body aggregates found in neuronal subpopulations.
Arrows point to cells that contain both cell body aggregates and are positive for the TF. N= 15-21
wells from 3 biological replicates per group. Kruskall-Wallis Test with Dunn’s Multiple Comparison
Test. All Data are mean ± SEM. *p<0.05, **p<0.01, ***p<0.001. Scale bar, 100µm.

68

that neuronal subpopulations that are most susceptible to developing pathology are also
more vulnerable to cell death.
It has been previously reported that glutamatergic neurons develop increased αsyn pathology compared to GABAergic neurons when treated with PFFs due to their
higher levels of α-syn expression (Taguchi et al., 2014). We did not detect cell body
inclusions in GABAergic neurons indicating that they are resistant to pathology formation
similar to Prox1+ neurons (Figure S3.3b). We did find that GABAergic neurons do
contain α-syn in this system suggesting that they may be capable of exhibiting PFFinduced toxicity (Figure S3.3c). We therefore measured GABAergic neuron viability by
immunostaining for GAD 65/67, an enzyme in the GABA synthesis pathway. At 15 DPT,
there was no statistical difference in GAD 65/67 staining (Figure S3.3d, e). This
contrasted with a ~25% reduction in overall neuronal viability measured by NeuN counts
during this same time period after HuS87N PFF treatment (Figure S3.3f). Normalized GAD
65/67 protein levels actually increased by ~50% at 14 DPT (Figure S3.3g, h), indicating
that GABAergic neurons make up a larger percentage of the surviving neuronal
subpopulations and thus are resistant to PFF-induced toxicity.

3.4.3 Math2 neurons are susceptible to PFF-induced pathology and toxicity in vivo
and in vitro
To further validate these findings, we next examined if hippocampal neurons in
vivo also display differential vulnerabilities to PFF-induced toxicity. Although less
pathogenic than HuS87N PFFs in vitro (Figure S3.1c), we have previously observed that
Mswt PFFs efficiently seed inclusion formation and result in SNpc neuron loss in vivo
(Luk et al., 2016b). Mice given a single unilateral injection of Mswt PFFs into the anterior
hippocampal hilum displayed pathology that was localized predominantly to the CA3
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Figure 3.3 α-syn PFFs induce toxicity in CA3 neurons in vivo. a, pSyn and NeuN staining of
ipsilateral and contralateral hippocampus. b, High magnification image of ipsilateral (left) and
contralateral (right) CA3 regions. Arrows indicate areas of NeuN + cell loss. c, Area of pSyn
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pathology in both ipsilateral and contralateral CA3. d, NeuN+ area of both ipsilateral and
contralateral CA3. PBS N=4 mice, 45 dpi N=4 mice, 90 dpi N=4 mice. NeuN and pSyn staining in
lateral entorhinal cortex (e) and substantia nigra (f). Arrows indicate pathological pSyn
aggregates. All data are mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, one-Way ANOVA with
Tukey’s multiple comparison test for each side. Scale bar, 100µm unless otherwise noted.

region of the ipsilateral hippocampus with CA1-2 regions showing moderate pSyn
staining by 45 DPI (Figure 3.3a). Pathology was also present in the corresponding
contralateral structures but to a lesser extent. In PBS-injected control mice, no pathology
or NeuN-positive cell loss was detectable between the ipsilateral and contralateral
hippocampal regions. In contrast, NeuN loss was observed as early as 45 DPI in the
ipsilateral CA3 region of PFF-injected mice and in the contralateral CA3 later at 90 DPI
(Figure 3.3b, arrows), consistent with our in vitro data showing that CA-derived neurons
are lost in a time- and pathology-dependent manner. Immunoreactivity for pSyn declined
significantly between 45 DPI and 90 DPI on the ipsilateral side. Interestingly, pSyn was
also increased at 45 DPI as well on the contralateral side and trended toward a
decrease by 90 DPI. (Figure 3.3c). The decrease in NeuN+ cells corresponded with the
decline in pathology similar to what was observed in the primary cultures that occurred
after cell loss (Figure 3.3d). Inclusions containing pSyn were also detectable in regions
synaptically connected to the hippocampal injection site and appeared on the ipsilateral
side including the lateral entorhinal cortex, but regions that are known to be permissive
to pathology but unconnected to the injection site such as the SNpc were spared (Figure
3.3e, f).
Given the increased susceptibility of Math2+ neurons to α-syn pathology in vitro,
we also quantified their number in wt mice after hippocampal PFF-injections. As
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Figure 3.4 Math2 neurons are susceptible to PFF induced toxicity and Math2 loss precedes
neurodegeneration. a, Math2 and DAPI staining of PBS-injected hippocampus. b, Math2 and
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DAPI staining of CA3 regions after PBS or PFF treatment. Arrowheads point to areas with
reduced Math2 staining. c, Math2+ cell counts in ipsilateral and contralateral CA3. PBS N=4 mice;
45 dpi N=4 mice; 90 dpi N=4 mice. One-Way ANOVA with Tukey’s multiple comparison test for
each side. d, WT hippocampal neurons treated with 350 nM HuS87N PFF immunostained for
Math2, NeuN, pSyn, and DAPI at indicated time points. e, Percentage of surviving Math2+ and
NeuN+ neurons in (d) relative to PBS (Normalized as 100% at each time point; red dashed line).
f, Ratio of Math2 to NeuN expressing cells in d. N=10-12 wells from 3 biological replicates. Twoway ANOVA with Bonferroni post-tests. All data are mean ± SEM. *p<0.05, **p<0.01, ***p<0.001.
Scale bar, 100 µm unless noted otherwise.

expected, Math2 was predominantly expressed in CA neurons in PBS-injected controls
(Figure 3.4a). However, Math2 staining in PFF-injected mice was markedly reduced in
the ipsilateral CA3 region at 45 dpi and remained lower at 90 dpi (Figure 3.4b, c),
confirming their vulnerability. Quantification revealed a decrease in the number of
contralateral Math2+ neurons although this did not reach statistical significance (Figure
3.4c).
Math2 has been reported to play a role in maintaining redox and mitochondrial
homeostasis (Uittenbogaard and Chiaramello, 2005; Uittenbogaard et al., 2010; Baxter
et al., 2012). Given that oxidative stress has been implicated as a mechanism for α-syn
toxicity in this model (Dryanovski et al., 2013; Tapias et al., 2017), we therefore asked
whether Math2 might be perturbed following the development of α-syn pathology. We
detected a reduction in Math2 shortly prior to NeuN loss and neurodegeneration in PFFtreated hippocampal cultures (Figure 3.4d). In fact, by 12 DPT Math2 levels were 50%
lower in HuS87N PFF treated cells and continued to decrease with time (Figure 3.4e). By
contrast, NeuN immunoreactivity decreased only slightly by (15% compared to PBS
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controls) at 12 DPT and was reduced by 46% at 16 DPT. Furthermore, the ratio of
Math2+ neurons to the total NeuN+ neuronal population decreased over time from ~65%
at 7 DPT, similar to PBS-treated controls, to 32% at 16 DPT (Figure 3.4f). Thus, Math2
loss precedes neurodegeneration.

3.4.4 Prox1+ neurons express low levels of α-syn and are resistant relative to
Math2+ subpopulations
Given their relative resistance to PFF-induced toxicity in vitro, we asked if Prox1+
DG neurons are spared while neighboring CA3 neurons degenerate after PFF-injection.
We observed neuritic α-syn pathology in the DG after injection with PFFs but not PBS,
and this pathology was predominantly restricted to the ipsilateral hemisphere (Figure
3.5a). Again, pathology was increased at 45 DPI which trended toward a decrease by 90
DPI (Figure 3.5b). NeuN staining area was decreased by 90 DPI in the DG showing that
neurons in the DG are susceptible to pathology induced toxicity similar to what we found
in vitro (Figure 3.5c). Interestingly, this loss was not evident until 90 DPI whereas NeuN
loss was observed as early as 45 DPI in the CA3 again suggesting that DG neurons
degenerate more slowly and are thus more resistant to pathology compared to CA3
Math2+ neurons.
Because pathology and toxicity are dependent on α-syn expression (Figure
S3.2a) we asked whether vulnerable neurons express higher α-syn protein levels
compared to resistant ones, thereby facilitating more rapid pathological conversion and
increasing pathology burden. To determine relative expression levels, cultures were costained for α-syn and the TFs that specify hippocampal glutamatergic neurons at 7-8
DIV, corresponding to the time at which PFFs were added in our toxicity studies and
when neuronal α-syn is mainly localized to the soma (Withers et al., 1997), allowing for
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accurate assignment to individual neurons. Neurons that stained most intensely for αsyn were overwhelmingly Math2+, while some Prox1+ cell bodies expressed lower or
undetectable levels of α-syn (Figure 3.5d, e). Staining intensities of CTIP2+ neurons
were generally between those of Math2+ and Prox1+ populations (Figure 3.5e).
Comparison of the means of the 3 groups also showed that Math2+ neurons expressed
the highest levels of α-syn (mean = 134 AU) followed by CTIP2 (mean = 109 AU) with
Prox1+ populations having the lowest relative α-syn expression (mean = 67 AU) (Figure
5f). Thus, the most resistant subpopulation in this model
expresses lower levels of α-syn compared to vulnerable Math2 and CTIP2 populations,
suggesting relative α-syn expression is a significant driver of vulnerability.

3.4.5 PFF-induced toxicity is dependent on α-syn expression levels, does not
require astrocytes or microglia in vitro, associated with DNA damage, and is
mediated by oxidative stress
Given that our data show that neuronal toxicity is dependent on pSyn pathology and that
neuronal susceptibility is strongly correlated with α-syn expression levels, we examined
whether decreasing α-syn expression could reduce pathology formation and rescue cell
viability. We used ASOs directed against α-syn mRNA to decrease α-syn expression
over an extended length of time. The ability of the ASO to reduce α-syn expression was
first confirmed by treating primary neuronal cultures at 8 DIV (equivalent to time of PFF
addition) and determining α-syn protein levels at 21 DIV (13 DPT). α-syn ASO treatment
significantly decreased α-syn levels in a dose-dependent manner at concentrations
ranging from 0.1 - 5.0 μM leading to 57 – 73% reductions in normal expression levels
after a single administration (Figure 3.6a).
We proceeded to apply ASOs to PFF-treated neuron cultures at various time
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Figure 3.5 Neuronal susceptibility to PFF-induced toxicity correlates with α-syn expression
levels. a, DG staining for NeuN and pSyn in ipsilateral and contralateral hippocampus of PFF- or
PBS-injected mice. b, Quantification of pSyn pathology area. c, Quantification of NeuN-
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immunoreactive area in ipsilateral and contralateral DG. One-way ANOVA with Tukey’s multiple
comparison test for each side. PBS N = 4 mice; 45 dpi N = 4 mice, 90 dpi N = 4 mice. d,
Immunocytochemistry of 8 DIV WT hippocampal neurons for α-syn, and either Math2, Prox1, or
CTIP2. Arrows and arrowheads point to the same cells expressing α-syn or not detected,
respectively. e, Histogram of binned relative α-syn-immunoreactivity of each neuronal
subpopulation (AU: arbitrary units). f, Comparison of α-syn intensity of Math2, Prox1, and CTIP2
populations. N = 8 coverslips per group from 3 experiments. Kruskall-Wallis Test with Dunn’s
Multiple Comparison Test. Data are mean ± SEM. *p<0.05, **p<0.01. Scale bar, 100 µm.

points after PFF treatment between 0 DPT (i.e., concurrent with PFFs) to 5 DPT (by
which time pSyn pathology can be detected) and examined the neurons at 14-15 DPT in
order to test if ASO treatment timing affected pathology formation and ultimately viability.
Pathology was reduced in a time-dependent manner after ASO treatment with
simultaneous application of α-syn ASO and PFFs showing the greatest effect (Figure
3.6b). Consistent with a direct relationship between α-syn pathology and neurotoxicity,
simultaneous co-treatment with ASO and PFF reduced pathology by ~95% compared to
untreated controls and almost completely preserved neuronal viability while the
protective effect of ASOs was reduced over time whereby no rescue was evident when
treatment was started at 5 DPT. Surprisingly, even when ASO treatment was started at 2
DPT and pathology levels decreased by ~75%, we observed only a mild rescue of
viability. Similarly, ASO treatment at DPT 5 reduced pathology by 47% but had no
protective effect (Figure 3.6c, d).
Because neurodegeneration in this model is driven by the aggregation of
endogenous α-syn which in turn correlates with α-syn expression levels in neuronal
subtypes, we also examined if toxicity is dependent on non-neuronal cell types. The
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Figure 3.6 Reduced α-syn expression with ASOs preserves neuronal viability. a,
Immunoblot showing α-syn expression in neurons after treatment with α-syn or control ASOs.
One-way ANOVA with Tukey’s Multiple Comparison Test, N = 9 wells from 3 biological replicates
per group. b, Immunostaining for pSyn, NeuN and NFL in neurons treated with 200 nM HuS87N
PFFs and 0.5 μM ASO. c, Neuronal viability measured by NeuN counts relative to PBS with same
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treatment and (d) normalized pSyn density relative to Control (Ctl) ASO treated with PFFs. N =
14-15 wells from 3 biological replicates. Data are mean ± SEM with one-way ANOVA with
Tukey’s multiple comparison test (c) or Kruskall-Wallis Test with Dunn’s Multiple Comparison
Test (d). *p<0.05, **p<0.01, ***p<0.001. Scale bar, 100µm .

primary hippocampal cultures used here contain a small proportion of non-neuronal cells
(mostly astrocytes), raising the possibility that glial cells mediate the neuron loss
observed after PFF treatment. In addition, α-syn PFFs have been shown to bind, enter,
and activate microglia via a variety of receptors (including CD11b, TLR-2 and -4
receptors) resulting in the release of neurotoxic factors (Fellner et al., 2013; Kim et al.,
2013; Doorn et al., 2014; Wang et al., 2015). Although they do not express appreciable
levels of α-syn, glial cells themselves might also be lost due to PFF exposure. To
mitigate these scenarios, we first determined whether astrocyte or microglia activation
occurs either following PFF treatment or at the onset of neurodegeneration by
monitoring GFAP and Iba1 levels. In all treatment conditions, GFAP signal increased
steadily over the duration of the experiment (Figure 3.7a), although GFAP staining was
comparable between PBS- and PFF-treated cultures at the time-points examined (2, 9,
and 14 DPT), even in the presence of decreased neuronal viability after HuS87N PFF
treatment (Figure 3.7b, c). Thus astrocytes in these cultures proliferate and/or activate
over the course of incubation but do so independently of PFFs and neuronal toxicity.
To further determine if astrocytes are necessary for toxicity, a subset of cultures
were pre-treated with Ara-C to minimize astrocyte proliferation. As expected, cultures
containing Ara-C showed a significant decrease in GFAP expression (Figure 3.7d).
Treatment with Ara-C alone was also accompanied by a moderate reduction in neuronal
viability, suggesting that astrocytes normally contribute to neuron health in this system or
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Figure 3.7 Astrocytes and microglia are unaffected by PFF induced pathology and toxicity.
a, Immunostaining of WT primary hippocampal neurons treated with 350nM HuS87N PFFs for
GFAP, pSyn, and NeuN. b, Average GFAP+ staining area normalized to PBS for each time point.
c, Neuronal viability was determined by the number of NeuN+ cells relative to the PBS for each
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time point. N = 11-12 wells from 3 biological replicates per group. Two-way ANOVA with
Bonferroni post-tests. d, e, f, Quantification of GFAP, neuron viability (NeuN), and pSyn
pathology at DPT 15. N = 9-13 wells from 3 biological replicates per group. Kruskall-Wallis Test
with Dunn’s Multiple Comparison Test. All data are mean ± SEM. *p<0.05, **p<0.01, ***p<0.001.
g, Immunostaining of 16 DPT primary hippocampal neurons for Iba1, pSyn, and NeuN. Scale
bars, 100 µm.

that Ara-C is intrinsically and mildly toxic to neurons. Nonetheless, PFF-induced toxicity
was still prominent in Ara-C treated neurons (Figure 3.7e). In line with the decreased
neuronal viability, pSyn immunoreactivity was also reduced after PFF administration in
Ara-C treated cells (Figure 3.7f). Microglia are rare in these cultures, as indicated by
Iba1 stain (<0.001% of the cells; Figure 3.7g), suggesting that toxicity in vitro is
independent of microglia activation.
We then addressed the mechanism that links α-syn aggregation toxicity by
treating neurons with a panel of pharmacological agents targeting pathways implicated
in α-syn models and in PD (Wong and Krainc, 2017). Compounds were administered
daily starting at 9-10 DPT, when α-syn pathology had already been established and
viability was assessed at 14-15 DPT. We were unable to detect rescue with inhibitors
against known execution pathways for cell-death including PARP, caspases, RIPK1,
NMDA excitotoxicity, wallerian degeneration, ferroptosis, and deubiquitinase activity
(Figure S3.4). Among the compounds tested, only treatment with 100 μM N-acetyl
cysteine (NAC), an antioxidant, significantly increased viability relative to PFF-exposed
neurons treated with vehicle. Other antioxidants such as Trolox and mitotempo did not
rescue toxicity at any concentration tested suggesting that NAC may be affecting viability
in a more specific manner. We hypothesized that NAC may be preventing toxicity
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through replenishing glutathione levels in the cells. To test this, we co-treated neurons
with 100 μM NAC and the glutathione depleting agent BSO and found that co-treatment
prevented NAC mediated rescue (Figure S3.4a, b). To corroborate if oxidative stress
could be mediating toxicity, we measured if DNA double strand breaks were occurring
associated with toxicity as these are commonly observed in oxidative stress dependent
toxicity (Ye et al., 2016). Indeed, we found that PFF treatment lead to an increase in
γH2AX+ DAPI foci by 12 DPT indicating double strand breaks were occurring.
Furthermore, neurons with cell body aggregates were γH2AX+ further supporting the
neurons that develop mature cell body pathology are the most at risk to degenerate
(Figure S3.5). Overall these data suggest that PFF induced toxicity is at least partially
mediated by glutathione depletion that develops to a critical point after pathology has
exceeded the cells ability to cope with the aggregates.

3.5 Discussion
Despite its central role in the pathogenesis of several major neurological
disorders, our understanding of how α-syn aggregation intersects with
neurodegeneration remains limited. Resolving why certain neurons are preferentially
susceptible to this process is critical towards elucidating the pathogenesis and
progression of synucleinopathies. The lack of disease models that reliably develop
intracellular α-syn inclusions and cell death in selectively vulnerable populations has
contributed to this knowledge gap. In this study, we utilized a model of seeded αsynucleinopathy that recapitulates these two key processes to address the relationship
between α-syn misfolding and cellular toxicity. While others have previously shown that
dopaminergic SNpc neurons are susceptible to toxicity in fibril-based models as is
observed in PD (Luk et al., 2012b; Masuda-Suzukake et al., 2013; Recasens et al.,
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2014; Paumier et al., 2015), this finding has not previously been examined in neocortical
and hippocampal regions, which are particularly affected in DLB and PDD (Camicioli et
al., 2003; Beach et al., 2009; Yang and Yu, 2017). This approach, which leverages the
natural heterogeneity that exists in the CNS, has yielded new insights into how Lewy-like
pathology may be linked to toxicity and a working hypothesis of differential vulnerability
between neuron subtypes.
Our data strongly support the notion that toxicity is closely linked to total α-syn
pathology burden in neurons. We further demonstrate that the kinetics of pathology
formation are largely determined by: 1) the availability of substrate (i.e., intraneuronal αsyn levels) and 2) the pathogenicity of the seeding agent (e.g., conformational strain).
Using both wt and human-mouse chimeric α-syn PFFs with distinct pathogenicities, we
observed that the degree of neuron loss is proportional to the initial seeding efficiency
and the resultant pathological load. Interestingly, although chimeric (HuS87N) PFFs clearly
increased pathology formation by as early as 7 DPT, toxicity was not evident until 12
DPT in all treatment conditions, a considerable period after the induction of inclusion
pathology and in stark contrast to the rapid cell loss typically observed following
excitotoxicity or axonal damage in cultured neurons (Peterson et al., 1989; Osterloh et
al., 2012). Consistent with its milder pathogenicity, Huwt PFFs at the highest dose tested
induced toxicity comparable to that seen with the lowest concentration of HuS87N PFFs,
while Mswt PFFs showed an intermediate level of potency, further supporting that α-syn
pathology correlates directly with toxicity in hippocampal neurons.
Given that lower concentrations of Huwt PFFs also induce α-syn inclusions, albeit
at a slower rate, we speculate that degeneration would ensue with extended incubation
periods that are beyond the period these neurons could be maintained under the
conditions used in this study. These data are also consistent with our previous finding
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that HuS87N PFFs accelerate pathology and toxicity in the SNpc after injection into the
dorsal striatum, while others have also reported time-dependent toxicity in vivo,
illustrating that toxicity eventually follows the accumulation of α-syn inclusions in multiple
CNS regions with known susceptibility in PD and DLB (Masuda-Suzukake et al., 2013;
Masuda-Suzukake et al., 2014; Osterberg et al., 2015; Luk et al., 2016a). Taken
together with the existing body of evidence from post-mortem studies supporting the
clinical correlation of PD symptoms with α-syn pathology spread, our data indicate that
α-syn aggregation directly contributes to neurotoxicity and is a marker of eventual
neurodegeneration (Braak et al., 2003b; Dickson et al., 2009).
Even after prolonged exposure to PFFs, degeneration does not occur uniformly
among neurons from a single neuroanatomical region such as the hippocampus. Indeed,
α-syn-mediated neurotoxicity appears to level off by 12-14 DPT after which, a
considerable proportion of neurons continue to survive. Given that primary neuronal
cultures are comprised of multiple neuronal subtypes as well as non-neuronal cells, this
would suggest differential vulnerabilities between subpopulations. Previous work
suggests that GABAergic neurons develop pathology less readily after PFF treatment
compared to their glutamatergic counterparts (Taguchi et al., 2014). We have further
established that glutamatergic subpopulations differ widely in their vulnerability to PFFinduced toxicity, a property that correlates closely with the rate at which they develop αsyn pathology. In particular, Math2 expressing neurons from the CA region are highly
vulnerable to PFF-induced toxicity compared to their DG-derived Prox1+ neighbors in
both in vitro and in vivo settings. Similarly, the majority of pathology that forms in vivo
following hippocampal PFF-injection occurs in CA2 and CA3 regions, where Math2+
neurons reside. This coincides with the prominent α-syn pathology found in these
regions in DLB and PDD brains whereas DG neurons are relatively spared (Armstrong et
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al., 2014; Hall et al., 2014). More recent work also shows that pathology and loss of CA1
neurons, another Math2+ subset which we identified as vulnerable from our in vitro data,
correlates strongly with cognitive decline in PDD (Adamowicz et al., 2017).
Since PFF-induced toxicity is intrinsically coupled to α-syn expression, high
intracellular levels of α-syn should render neurons more permissive to seeding by
increasing the rate of pathological conversion (Volpicelli-Daley et al., 2011; Luk et al.,
2012b). Indeed, relative α-syn expression levels of the three major glutamatergic
subpopulations in our primary cultures correlate with their vulnerability to PFF treatment
with the most vulnerable Math2+ neurons containing the highest levels and resistant
Prox1+ neurons having the least. CTIP2+ neurons, which generally express levels
between that of the two former subpopulations, display an intermediate degree of
vulnerability. The differences in expression levels we observed by immunostaining is
further supported by RNA-seq data showing that α-syn mRNA levels are highest in CA3,
relative to DG and CA1 and -2 regions where Prox1+ and CTIP2+ neurons are found
(Figure S3.6a, b and Cembrowski et al., 2016). Consistent with this pattern, CA3
neurons also exhibited the highest pathology burden and neuron loss compared to the
DG and other CA regions in PFF-injected mice. Thus, heterogeneity in α-syn protein
levels provides a likely explanation for the selective vulnerability of CA neurons in both
our model and disease, although we cannot exclude additional subpopulation-specific
properties, such as susceptibility to high intracellular calcium levels and metabolic
demands, as contributors to vulnerability (Pacelli et al., 2015).
Microgliosis and astrocytosis are commonly observed in PD brains suggesting a
role for inflammation in synucleinopathies (McGeer et al., 1988; Forno et al., 1992;
Iannaccone et al., 2013). Moreover, these non-neuronal cells are readily activated by
misfolded α-syn internalized via CD11b and TLR-2/4 receptors (Fellner et al., 2013; Kim
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et al., 2013; Doorn et al., 2014; Wang et al., 2015), and thus may be potential mediators
of α-syn toxicity. Our data show that although GFAP staining increases over time in
culture, astrocytes are not required in PFF-mediated neurotoxicity. The minute fraction of
microglia present also suggests a limited role for them in vitro although studies using
PFF-injection in rats suggest a role for microglia in vivo (Harms et al., 2017; Thakur et
al., 2017). Additional investigation will be required to address their role, especially in the
hippocampus.
At the cellular level, Math2 loss precedes overt neurodegeneration since other
neuronal markers (e.g., NeuN) and structural proteins such as NFL decrease later
indicating that overt degeneration is occurring and not solely phenotype switching.
Math2 is a master transcription factor responsible for a number of processes, including
mitochondrial homeostasis and regulation of apoptosis, raising the possibility that
transcriptional dysregulation represents an early step of the degeneration cascade
(Uittenbogaard and Chiaramello, 2005; Baxter et al., 2012). Impairment of axonal and
organelle transport by the accumulation of misfolded α-syn may also play a concurrent
role in toxicity (Cooper et al., 2006; Volpicelli-Daley et al., 2014b). Interestingly,
transcriptomic analysis of post-mortem brains from Alzheimer’s disease patients, in
which α-syn co-pathology is common (Toledo et al., 2016), indicate a reduction in Math2
in the hippocampus relative to healthy controls (Hokama et al., 2014; Satoh et al., 2014),
and genetic analysis has linked certain Math2 polymorphisms to late onset AD (Barral et
al., 2015; Fowler et al., 2015; Li et al., 2015). Collectively, these data suggest that Math2
identifies a subset of hippocampal neurons that are vulnerable in multiple
neurodegenerative settings, although it remains unclear whether α-syn toxicity is directly
related to Math2 expression and function.
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For example, Math2 is reported to increase cellular tolerance for oxidative stress
by inducing scavenging enzymes such as Gpx1 and SOD2 (Uittenbogaard et al., 2010).
Consistent with this and previous work showing elevated oxidative stress in
dopaminergic neurons containing α-syn inclusions (Dryanovski et al., 2013; Tapias et al.,
2017), only an antioxidant that replenishes glutathione levels (NAC) effectively reduced
toxicity. However, Math2 is detected in only a few neuronal subpopulations outside of
the hippocampus, including in the isocortex, cortical subplate, and a small subset of
striatal neurons (Lein et al., 2007). Moreover, Math2 is not present in other vulnerable
populations in PD such as SNpc neurons, which further decouples Math2 expression
from intrinsic vulnerability.
Surprisingly, inhibitors of several established cell death pathway’s executors
(e.g., caspases and PARP1) did not alter PFF-induced toxicity, suggesting that cell loss
occurs outside of caspase-dependent apoptosis and parthanatos, which have been
reported in mice administered with the neurotoxin MPTP or in post mortem PD patient
samples (Cosi et al., 1996; Hartmann et al., 2000; Bilsland et al., 2002; Lee et al., 2013).
The lack of protection provided by NMDA receptor antagonist and NAD supplement also
argues against a major role for excitotoxicity and Wallerian degeneration, respectively, in
this α-syn seeding model. This diverges somewhat from previous reports implicating
caspase 3, -8 and -9 activation in PFF-triggered toxicity both in cell-lines, primary
hippocampal cultures and organotypic slices (Desplats et al., 2009; Mahul-Mellier et al.,
2015). However, we note that neuron death in our experimental system requires severalfold lower concentrations of α-syn seeds compared to those used in other studies,
although we cannot exclude activation of different mechanisms of toxicity following acute
vs. chronic α-syn exposure and/or aggregation. While unlikely, the cell death pathways
triggered by the same stressor may also differ between neuron subpopulations.
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A number of soluble oligomeric entities ranging from misfolded monomers to
protofibrils have been reported to be associated with cellular or neuronal toxicity, and it
has also been suggested that exogenous fibrillar α-syn can seed misfolding along the
plasma membrane leading to its disruption (Volles and Lansbury, 2002; Cremades et al.,
2012; Mahul-Mellier et al., 2015). Although amyloid forms of α-syn represent the
predominant species applied to neurons and in vivo, our data cannot discern if they are
solely responsible for toxicity or if additional or transient α-syn species such as oligomers
also accumulate over time and contribute to cellular demise. Nonetheless, the
observation that α-syn knock out provides neurons with immunity to extended exposure
to high concentrations of Mswt and HuS87N α-syn PFFs indicates that intracellular Lewylike α-syn pathology is necessary for toxicity (Volpicelli-Daley et al., 2011; Luk et al.,
2012b). Determining whether a similar sequence of events is responsible for
neurodegeneration in synucleinopathy patients, where multiple strains likely exist, will be
crucial.
Finally, these findings prompted us to test whether PFF-induced toxicity can be
attenuated by knocking down α-syn expression with a targeted ASO that significantly
suppressed α-syn expression over several days after a single administration. Cotreatment with α-syn ASO dramatically reduces PFF-induced Lewy-like pathology and
subsequent toxicity, further supporting that toxicity is directly downstream of α-syn
pathology. Intriguingly, delayed ASO treatment after PFF-seeding can still significantly
reduce pathology, yet is largely ineffective in restoring neuron viability. This requirement
for early knock down suggests that neurons have an intrinsic but finite tolerance for αsyn pathology (or a pathological intermediate species) but toxicity is irreversible after this
threshold is exceeded.
In summary, this work provides new insight into determinants that predict
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Figure 3.8 Proposed model of relation between α-syn pathology formation and
neurotoxicity. a, Upon exposure to misfolded species neurons develop α-syn pathology in a
time-dependent manner after a lag period, starting as neuritic inclusions that coalesce into larger
inclusions in the cell body. Pathology formation occurs more rapidly in vulnerable neurons
(Math2+ cells in the hippocampus), and leads to more rapid cell death. Formation and
accumulation of α-syn pathology in resistant Prox1+ neurons is comparably slower, partially due
to lower α-syn expression levels. b, In susceptible Math2+ neurons, degenerative mechanisms
are triggered when the critical threshold of α-syn aggregation is reached. In the case of Math2+
neurons, cell death is preceded by the loss of this key transcription factor. Math2+ neurons reach
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this threshold faster than neighboring Prox1+ neurons due to their higher endogenous α-syn
protein levels, which facilitates faster propagation of pathological α-syn. c, Early knockdown of αsyn reduces neurodegeneration in vulnerable neurons by preventing α-syn pathology from
reaching critical levels, but knockdown at later stages is not sufficient for rescuing neurons
despite reducing overall pathology burden.

neuronal subtype vulnerability to α-syn pathology-related toxicity by leveraging the ability
to modulate pathology in permissive neuronal populations and CNS regions. Our
findings support a model (summarized in Figure 3.8) where increased levels of α-syn
expression enhance the vulnerability of different neuronal subtypes to forming Lewy
Pathology and consequent toxicity. Subpopulations that express lower α-syn levels are
likely protected as this pathological process is delayed. Similarly, early intervention in
decreasing α-syn prevents toxicity by suppressing pathology burden below the critical
threshold for toxicity, whereas delayed intervention only partially inhibits pathology but
has a limited effect in preventing toxicity. Elucidation of the cellular processes involved in
α-syn pathological aggregation will help optimize the therapeutic window for strategies
targeting α-syn.
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Chapter 4: The adaptive immune system is not necessary for α-synuclein
pathology formation or dopaminergic neuron loss after pre-formed fibril injection

________________________________
Luna E, Boesteanu AC, Liang Y, Zhang B, Johnson LA, Gill SI, Luk KC The
adaptive immune system is not necessary for α-synuclein pathology formation
nor dopaminergic neuron loss after pre-formed fibril injection. In preparation
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4.1 Abstract
Genetic and pathological evidence points to the α-synuclein (α-syn) misfolding as being
central in Parkinson’s disease (PD) pathogenesis along with the adaptive (AIS) and
innate (IIS) immune systems. To examine the potential interactions between α-syn
aggregation and these functionally distinct systems, we administered α-syn pre-formed
fibrils (PFFs) to mice either with an intact AIS (C57BL/6), lacking an AIS (Rag2-/-; Il2rγ-/mice on a C57BL/6 background; RDKO), or with deficiencies in both AIS and the IIS
(SCID; Il2rγ-/- mice on a Non-Obese Diabetic background; NSG). Each mouse received
unilateral injections of α-syn PFFs or PBS in the ventral and dorsal striatum along with
the overlying cortex and incubated for up to 6 months post-injection (mpi). We found no
differences between the C57BL/6 and RDKO mice at 3 or 6 mpi in α-syn pathology
burden as measured by the phosphorylation at S129 (pSyn), dopaminergic (DA) cell loss
in the substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA), motor
behavior (weight, rotarod, forelimb grip strength, and vertical pole tests), or in the
expression of several key PD-related genes (e.g. α-syn, Parkin, PINK1, DJ-1, GBA).
However, NSG mice showed significantly increased pSyn pathology at 6 mpi in both the
SNpc and VTA compared to both C57BL/6 and RDKO mice, but no differences were
observed at 1 mpi or 3 mpi. NSG mice also exhibited higher DA neuron loss in the SNpc
at 3 and 6 mpi and in the VTA at 6 mpi. Furthermore, NSG mice showed weight loss by
6 mpi relative to other strains, which was accompanied by a worse motor phenotype. No
differences in PFF degradation at the injection site were observed in NSG mice
compared to C57BL/6 mice. Among the PD genes tested, Parkin was increased in NSG
mice relative to both C57BL/6 and RDKO mice. These data show that AIS function is not
a prerequisite for either the initiation or propagation of α-syn pathology and does not
exacerbate downstream toxicity in DA neurons and motor phenotype in the PFF-injection
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model. In contrast, NSG mice have a potentiated phenotype in terms of pathological αsyn formation, DA cell loss, and motor behaviors in an age dependent manner.
Pathology initiation was unchanged in NSG mice, and the increased pathology seen at
later time points was unaccounted for by increased α-syn levels nor PFF uptake,
suggesting an α-syn independent mechanism. This suggests that the IIS, but not the
AIS, may play a role in α-syn pathology progression and neurotoxicity. The NSG mouse
line thus provides a new model for studying the effects of the IIS on pathological α-syn
accumulation.

4.2 Introduction
The signature motor symptoms of PD (i.e., bradykinesia, resting tremor, and
rigidity) are caused by the loss of dopaminergic neurons of the substantia nigra pars
compacta (SNpc). PD is the second most common age-related neurodegenerative
disease, and, as of yet, there are no therapies to stop the loss of SNpc neurons and
prevent the onset and progressive worsening of the motor symptoms. α-Synuclein (αsyn) is the main component of Lewy pathology (LP) which characterizes the disease,
and genetic studies have linked mutations, duplications, and triplications in α-syn to
autosomal dominant PD (Polymeropoulos et al., 1996; Chartier-Harlin et al., 2004;
Singleton et al., 2003; Spillantini et al., 1997). How α-syn aggregation contributes to PD
remains unknown, but there is increasing evidence that neuroinflammation plays a
pivotal pathogenic role. For example, increased inflammatory cytokines (IL-1β, IL-6, and
TNFα) are found in CSF and plasma from PD patients compared to controls, and
cytokines like IFNγ correlate with clinical severity (Mogi et al., 1994; Blum-Degen et al.,
1995; Eidson et al., 2017; Gelders et al., 2018). Also, reactive microgliosis is observed in
the degenerating SNpc of PD patients (McGeer et al., 1988). In experimental models,
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reactive astrocytes and microglia have been reported to mediate neurotoxicity in
response to α-syn aggregation (Yun et al., 2018). In addition, treatment of rats with αsyn preformed fibrils (PFFs) reveals that microgliosis and upregulation of MHCII, a
molecule involved in antigen presentation from the IIS to the AIS, occurs following
pathology formation but precedes neurodegeneration of dopaminergic (DA) neurons in
the SNpc, a sequence which suggests that microglia play a role in mediating neuronal
loss (Duffy et al., 2018). Although these data point to a role for neuroinflammation,
particularly the innate immune system (IIS), in PD pathogenesis, the role of the adaptive
immune system (AIS) is more enigmatic.
The AIS, of which B- and T-lymphocytes are primary components, is functionally
distinct from the IIS in that these cellular players are capable of refining their response
over time to specific antigens and develop immunological memory. Several lines of
evidence suggest that the AIS may also mediate PD pathogenesis. For example, single
nucleotide polymorphisms in MHCII have been associated with increased risk of
developing PD (Hamza et al., 2010; Guo et al., 2011; Ahmed et al., 2012; Sun et al.,
2012) while knockout of MHCII reduces SNpc neurodegeneration after viral
overexpression of α-syn (Harms et al., 2013). Mice lacking B- and T-cells exhibit
reduced neurotoxicity to the neurotoxin MPTP which selectively causes SNpc neuronal
loss, and T cells have been observed to infiltrate the PD brain (Brochard et al., 2009).
Furthermore, T cells recognizing α-syn specific peptides are enriched in PD blood, thus
linking PD to the MHCII haplotypes that increase the risk of disease (Sulzer et al., 2017).
In this present study we determined whether α-syn pathology formation and
subsequent dopaminergic neurodegeneration following intracerebral PFF injection is
mediated by either the AIS or IIS. This disease model induces LP formation in the SNpc
by 1-month post injection (mpi), with loss of tyrosine hydroxylase positive (TH+) neurons
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in the SNpc and accompanying motor deficits by 6 mpi (Luk et al., 2012b; MasudaSuzukake et al., 2013; Sacino et al., 2014a). We treated mice from wildtype (wt)
C57BL/6, Rag2-/-; Il2rγ-/- on the C57BL/6 background (RDKO), and SCID; Il2rγ-/- on the
Non Obese Diabetic (NOD) background (NSG) with intracerebral PFF injection. Both
RDKO and NSG mice lack both mature B and T cells, but NSG mice possess several
additional well characterized deficits in the IIS such as defective macrophage maturation
and function, limited natural killer cell activity, and no C5a component of hemolytic
complement (Baxter and Cooke, 1993; Serreze et al., 1993; Ogasawara et al., 2003).
Based on the inflammatory profile associated with PD in humans, we hypothesized that
RDKO and NSG mice would therefore exhibit less pathology formation and
neurodegeneration due to the lack of a mature AIS. Contrary to this prediction, we report
that the AIS is not required for pathological α-syn initiation, formation, TH neuronal loss,
or any measured motor phenotype. Interestingly, we also found that the NSG mouse line
developed increased pathology, more severe neuronal loss in the SNpc and ventral
tegmental area (VTA), and a potentiated behavioral phenotype that was not due to
increased α-syn levels in the NOD strain, altogether suggesting that the IIS modulates
PD pathogenesis in an age-dependent manner.

4.3 Materials and Methods
Animals
The University of Pennsylvania Institutional Animal Care and Use Committee approved
all animal procedures, and all procedures followed the National Institute of Health Guide
for Care and Use of Laboratory Animals. C57BL/6 and SCID; Il2rγ-/- on a Non-Obese
Diabetic (NOD) background (NSG) mice were purchased from Jackson Laboratories;
Rag2-/-; Il2rγ-/- on a C57BL/6 background (Rag double knock out; RDKO) were
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purchased from Taconic Biosciences. Female mice were used for all experiments
described.

Recombinant aSyn production, purification, and PFF fibrilization
Wildtype mouse (Mswt) α-syn protein expression, purification, and fibrilization were
conducted as previously described (Volpicelli-Daley et al., 2014a; Luna et al., 2018).
Briefly, the Mswt α-syn was expressed in E. coli BL21 (DE3) RIL cells and purified. PFFs
were produced by diluting the purified α-syn to 5 mg/ml (360 µM) in sterile Dulbecco’s
PBS (pH 7.0; Mediatech). Diluted α-syn was then agitated constantly at 1000 rpm for 7
days at 37oC to yield PFFs.

Stereotaxic PFF injection
Injections of PFFs were performed as previously described with modifications (Luk et al.,
2012b; Ugras et al., 2018). Mice were anesthetized with ketamine/xylazine; Each mouse
received a single unilateral stereotactic injection of PFFs (5 µg; 2.5ul per site) sonicated
with a Biorupter bath sonicator (Diagenode) for 10 cycles (highest power, 30s on, 30s off
at 10oC) into the ventral striatum (coordinates: 0.2 mm relative to Bregma; 2 mm from
midline; 4.2 mm beneath the dura), dorsal striatum (coordinates: 0.2 mm relative to
Bregma; 2 mm from midline; 3.2 mm beneath the dura), and overlying cortex
(coordinates: 0.2 mm relative to Bregma; 2 mm from midline; 1.4 mm beneath the dura).
Animals were monitored regularly after surgery. Before sacrifice, the mice were
anesthetized with isofluorane. The brain was then extracted after transcardial perfusion
with heparinized PBS and fixed overnight in 70% ethanol in 150mM NaCl (pH 7.4).
Tissues were then embedded in paraffin for sectioning.
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Immunohistochemistry and TH cell counting
Immunohistochemistry for phosphorylated Ser129 α-syn (pSyn) and TH were
implemented on 6 μm-thick coronal sections as previously described (Luk et al., 2012b).
Images for quantification were acquired with either a Perkin Elmer Lamina Scanner at
20x magnification or an Olympus DP71 digital camera connected to a Nikon Eclipse 50i
microscope. DA neurons belonging to the SNpc and the VTA were counted from THimmunostained sections and pSyn area was quantified from pSyn-immunostained
section spanning the entire extent of the midbrain (every 9th section). Only intact
neurons with visible nuclei and TH positive staining were included in the counting based
on established criteria (Fu et al., 2012). Counting and area analysis were done using
HALO software (Indica Labs). Staining for injected PFFs was accomplished using a
conformation-specific antibody Syn506 (Waxman et al., 2008). Antibodies against GFAP
(CNDR Rat monoclonal; 1:10,000) and TMEM119 (Abcam ab209064; 1:250) were used
to stain for activated astrocytes and microglia. 15 month old 5x Familial Alzheimer’s
disease (5xFAD) mouse sections that express 5 familial mutations for Alzheimer’s
disease were graciously provided by Dr. Zhuohao He as a positive control for activated
microglial staining (Boza-Serrano et al., 2018).

Protein extraction and immunoblotting
12-14 week old non-injected mice were anesthetized using isofluorane and transcardially
perfused with heparinized PBS. Whole brains were extracted and cut into hemispheres.
One hemisphere was dissolved and protein extracted in SDS lysis buffer (2% SDS in
50mM Tris, 150mM NaCl, pH 7.6) containing phosphatase and protease inhibitor
cocktail, then sonicated and centrifuged at 100,000 x g for 30 min at 22oC. The
supernatant was used for immunoblot analysis (20 μg total protein per lane). The
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following primary antibodies were used: α-syn (CNDR mouse monoclonal IgG2a
Syn9027; 1:20,000) (Covell et al., 2017); GBA1 (Abcam ab55080; 1:200); Parkin
(CNDR/Covance mouse monoclonal Parkin 8; 1:500) (Pawlyk et al., 2003); PINK1 (UC
Davis 75-060; 1:500); DJ-1 (Abcam ab18257; 1:2000); GAPDH (Advanced
Immunochemical 2-RGM2; 1:10000). Primary antibodies were detected with appropriate
secondary antibodies (Li-Cor Biosciences; 1:20,000). Membranes were imaged using a
Li-Cor Odyssey infrared imaging system.

Behavior testing
Rotarod
Each mouse was weighed prior to behavior testing. Mice were then placed on the
Rotarod apparatus (MED-Associates). Each mouse was given four training sessions five
minutes apart. The test period was 1 h later, and each mouse placed on the rotarod with
increasing speed, from 4 rpm to 40 rpm in 300 sec. Total test duration was 600 seconds.
The latency to fall off the rotarod within this time period was recorded. Each mouse
received two consecutive trials and the mean latency to fall was used in the analysis.

Grip Strength
Forelimb grip strength was measured using a Grip Strength Meter (IITC Life Science
Inc., Woodland Hills, CA). Mice were initially trained on holding the instrument. Animals
were held by the tail, and allowed to grab a steel grip gauge with forelimbs only. After the
mice retained a grip of the steel grip gauge, they were steadily pulled away until they
released the grip. The recorded grip strength was the force measured at the moment of
grip release. Mice were trained for 5 consecutive sessions with a one-minute break
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Figure 4.1 NSG mice develop increased α-syn pathology in the SNpc and VTA by 6 mpi. A,
B, Accumulation of α-syn inclusions in ipsilateral and contralateral SNpc and VTA at 3 mpi (A) or
6 mpi (B) of PFF injected mice. Graphs show total pSyn-immunoreactive area in SNpc and VTA.
N= 7-10 mice. One-Way Anova with Tukey’s Multiple Comparison Test. All data are mean ±
SEM. *p<0.05, ***p<0.001.
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between training sessions. Testing occurred 1 h after training which consisted of 5
consecutive trials. The average of the highest 3 recorded forces were used for analysis.

Vertical pole test
The pole was constructed from a 60 cm long plastic rod (1 cm diameter) wrapped with
labeling tape (Fisher Scientific). Mice were placed near the top of the pole (5 cm) facing
upwards. The total time required to reach the base was recorded. Mice were trained for
two consecutive days. Each training session consisted of five trials with a one-minute
break in between trials. On the test day, mice were evaluated in five sessions and the
total time was recorded. A maximum cutoff time of 60 seconds was used, and this was
also recorded if the mouse couldn’t grip on and fell.

4.4 Results
We began by testing whether PFF-seeded α-syn pathology is affected by the AIS
by unilaterally injecting Mswt PFFs or PBS into the ventral and dorsal striatum and the
overlying cortex. We injected three strains of mice to test whether the AIS and/or IIS
might play a role in mediating PFF-induced pathology. RDKO mice, which lack the B and
T cells of the AIS, were injected alongside background matched C57BL/6 mice which
have an intact IIS. In addition, we injected NSG mice which lack B and T cells like the
RDKO mice but are on the NOD background which harbors several known innate
immune deficiencies that would allow us to glean information regarding the contribution
of the IIS after PFF injection (Baxter and Cooke, 1993; Serreze et al., 1993; Ogasawara
et al., 2003). NOD mice spontaneously develop autoimmune diabetes which would
complicate any findings after PFF injection as hyperglycemia has CNS effects (McCall,
1992; Sharma et al., 2010; Kachapati et al., 2012; Mazaika et al., 2016). Given this we
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Figure 4.2 Dopaminergic cell loss is exacerbated in NSG mouse SNpc and VTA. A and B,
TH staining of the ventral midbrain (SNpc and VTA) of PFF- and PBS injected mice from
C57BL/6, RDKO, and NSG lines. Total TH cell counts from SNpc and VTA on the hemisphere
ipsilateral and contralateral to injection. N= 3 (PBS) or 7-10 (PFF) mice per group. All data are
mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, two-way Anova with Tukey’s multiple comparison
test. Scale bar, 500μm.
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chose instead to examine the NSG line, which allows us to forego those effects and
study the IIS after pathology formation.
We examined the extent of α-syn pathology in PFF-seeded animals by
immunostaining for phosphorylated S129 (pSyn), an established marker of LP, in the
SNpc and VTA (Fujiwara et al., 2002). pSyn developed on the ipsilateral SNpc of all
three strains of mice. Thus, the AIS is not required for the initiation nor the formation of
α-syn inclusions after PFF treatment. The ipsilateral VTA also showed a trend toward
increased pathology on the ipsilateral side in all 3 strains of mice, but this did not reach
statistical significance (Figure 4.1A). Pathology formation in the VTA most likely arises
from connections from the ventral striatum, but this also suggests that the VTA is less
permissive to α-syn pathology formation. This is consistent with data showing that the
SNpc degenerates in PD and not the VTA (Braak et al., 2003b; Chu and Kordower,
2007).
At 6 mpi, pSyn inclusions were still detectable in the ipsilateral SNpc in all of the
groups. However, the ipsilateral SNpc of NSG mice showed significantly higher
pathology compared to either the C57BL/6 or the RDKO groups. Neither the C57BL/6
nor the RDKO groups exhibited increased pathology in the ipsilateral SNpc compared to
their respective contralateral sides at this time point. pSyn area decreased in the SNpc
between 3 mpi and 6 mpi in the C57BL/6 and RDKO groups. The VTA in NSG mice also
showed increased pathology compared to both the contralateral side and to the other
mouse strains (Figure 4.1B).
PFF injection into the dorsal striatum causes TH+ neuron loss in the SNpc by 6
mpi in WT C57BL/6 mice (Luk et al., 2012b; Masuda-Suzukake et al., 2013). Neuron
loss is restricted to the ipsilateral SNpc as mice lack extensive cross-hemispheric
nigrostriatal projections. Thus, we assessed if neuronal loss was also occurring in DA
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Figure 4.3 Motor deficits are potentiated in PFF injected NSG mice relative to C57BL/6 and
RDKO mice. A, B, Mouse weight. C, D, Forelimb grip strength. E, Rotarod assessment of motor
ability. F, Time to turn and descend vertical pole. A-E, Data presented at PFF injected group
relative to PBS for all three mouse strains. 100% set to average of C57BL/6 group. PBS: N= 3
mice PFF: N=7-10 mice. One-Way Anova with Tukey’s Multiple Comparison Test. All data are
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mean ± SEM. *p<0.05, **p<0.01, ***p<0.001

neurons of the SNpc and VTA following α-syn pathology formation in wt and
immunodeficient mice. Only NSG mice showed a significant decrease in TH+ neurons in
the SNpc at 3 mpi relative to the contralateral side. This was not observed in the WT or
RDKO strains (Figure 4.2A). At 6 mpi, all 3 groups of mice showed significantly
decreased TH+ neuron counts in the SNpc, but NSG mice showed the greatest reduction
with ipsilateral SNpc TH+ neurons decreasing by >50% relative to the contralateral side
and the PBS injected control group. In addition, only NSG mice showed decreased TH+
cell counts in the ipsilateral VTA after PFF injection, suggesting that NSG mice not only
form more pathology in an age-dependent manner, but that α-syn pathology is more
widely distributed across neuronal populations, including those that are not affected in
WT and RDKO mice (Figure 4.2B).
Given the observed increase in α-syn pathology in the SNpc and VTA in NSG
mice, along with lower TH neuronal viability, we hypothesized that this may also
manifest in a more severe behavioral and physical phenotype in the NSG group. There
were no differences in body weight between PBS- and PFF injected mice in any of the
groups at 3 mpi (Figure 4.3A). However, at 6 mpi NSG mice injected with PFFs showed
lower body weights compared PBS-injected counterparts, a phenotype that was not
seen in either C57BL/6 or RDKO mice (Figure 4.3B).
At 6 mpi, PFF-injected NSG mice also had lower grip strength compared to PBS
controls and the other strains (Figure 4.3D). This trend toward lower forelimb grip
strength in NSG PFF-injected mice relative to PBS and RDKO was also present at 3 mpi
but did not reach statistical significance (Figure 4.3C). When assessed by rotarod, only
the NSG PFF-treated group had a reduced latency to fall at 6 mpi (Figure 4.3E). Lastly,
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we tested these mice by the vertical pole test, and found no difference in latency to
descend the pole between PFF and PBS of any of the groups of mice (Figure 4.3F).
Together these data illustrate that NSG mice have a more severe phenotype compared
to C57BL/6 and RDKO mice by 6 mpi. The lack of differences observed between
C57BL/6 and RDKO mice are consistent with the finding that the AIS alone does not
modulate α-syn aggregation.
Because NSG mice showed TH cell loss by 3 mpi and that any reduction in
pathology could also be a sign of neuronal loss, we next determined whether pathology
levels were higher in NSG mice at an earlier time point prior to neurodegeneration
occurring (Luna et al., 2018). We therefore compared total pSyn immunoreactivity at 1
mpi between C57BL/6 mice and NSG mice. No differences were observed between
these lines, indicating that pathology initiation at earlier time points does not appear to
be mediated by genetic differences between these strains (Figure 4.4A). Also, we found
that comparable amounts of residual PFFs remained at the injection site at 1 mpi,
suggesting that both groups received similar amounts of the injected material and have
similar rates of degradation (Figure 4.4B).
We also examined if there was differential astrocytosis and microgliosis between
the mouse strains at 3 mpi. We chose this time point because others have found that
microgliosis occurs after at least 2 mpi and before neurodegeneration occurs in the rat
(Duffy et al., 2018). However, we found no astrocytosis nor microgliosis in the SNpc or
VTA relative to control groups by 3 mpi (Figure S4.1).
Lastly, we also examined if levels of α-syn and several other key PD-related
genes were differentially expressed between un-injected C57BL/6, RDKO, and NSG
mice, which may account for the phenotypic divergence observed. We found no
difference in α-syn, GBA, PINK1, or DJ-1 levels. Interestingly, NSG mice show a ~50%
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Figure 4.4 pSyn burden, PFF uptake, and α-syn expression is unchanged between NSG but
Parkin is upregulated. A, Ipsilateral SNpc pSyn staining at 1 mpi of C57BL/6 and NSG mice. N
= 6 mice/ group. Student t-test. B, LB506 staining for PFF injected material at 1 mpi in the
striatum. A, B, Scale bars as indicated. C, Immunoblot showing protein expression of PD genes
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in NSG, C57BL/6, and RDKO mouse brain. N= 4 mice. One-Way Anova with Tukey’s Multiple
Comparison Test. All data are mean ± SEM. *p<0.05.

increase in Parkin levels compared to both C57BL/6 and RDKO groups (Figure 4.4C).
This data shows that NSG mice have increased pathology formation in an age
dependent manner that is independent of α-syn levels.

4.5 Discussion
The origins of neuron loss in PD remains enigmatic. Although recent evidence
indicates that both the AIS and IIS may mediate neurotoxicity (Sulzer et al., 2017; Yun et
al., 2018), the exact pathways for these effects are not known. In this study, we aimed to
explore the role of the AIS and IIS following the accumulation of α-syn inclusions in vivo.
The data presented here show no differences after PFF-injection with regards to
pathology formation, midbrain DA cell loss, or behavioral phenotype between wt
C57BL/6 and RDKO mice, which lack a functional AIS. This indicates that AIS activity is
not necessary for either the formation of LP as a result of exogenous α-syn seeding nor
subsequent neuron loss that follows this process. This is consistent with the fact that Band T-cells are quite rare in the CNS in the absence of infection or autoimmune reaction
(Waisman et al., 2015). It also suggests that any effects of α-syn pathology proceed
largely independent of the AIS once established in the SNpc or VTA, although this does
not rule out the AIS playing a role in more upstream (i.e., disease-initiation) or
downstream (e.g., neuroinflammation) events in the disease.
It is currently hypothesized that α-syn pathology and the PD disease process
initiates in the gut and from there spreads to the brain stem and in the CNS (Braak et al.,
2003b; Braak et al., 2003a). In line with this, a large majority of PD patients develop
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constipation or have constipation as a prodromal symptom (Kaye et al., 2006; MartinezMartin et al., 2007; Savica et al., 2009). The gut has a large AIS presence, and the AIS
is actively involved in immune surveillance in the gut (Kato et al., 2014). α-Syn pathology
has been found in the colon of both PD and normal patients as well as Meissner’s and
Auerbach’s plexus that innervate the gut (Braak et al., 2006; Shannon et al., 2012; Hilton
et al., 2014; Chandra et al., 2017). Also, colonic inflammation may increase α-syn levels
thus leaving the gastrointestinal system more prone to developing α-syn pathology, and
intestinal flora have been shown to be required for α-syn pathology and motor deficits in
a transgenic PD model (Devos et al., 2013; Kelly et al., 2014; Sampson et al., 2016).
These data all suggest that the colon is a likely area for the AIS to modulate α-syn
pathology initiation and PD pathogenesis. Our data is consistent with this interpretation,
and once pathology reaches the CNS, the aggregation and toxicity are independent of
the AIS.
We initially hypothesized that NSG mice might express higher levels of α-syn
which would enhance aggregation, as we have previously found that neuronal
populations with increased α-syn are more vulnerable to seeding by exogenous α-syn
(Volpicelli-Daley et al., 2011; Luk et al., 2012b; Luk et al., 2012a; Luna et al., 2018).
Contrary to this hypothesis, no difference in pathology was observed at 1 mpi, and α-syn
expression was the same in all mouse strains. Furthermore, PFF injected material was
taken up at equivalent levels at 1 mpi between NSG and C57BL/6 mice suggesting an
age dependent and α-syn independent mechanism is causing the heightened phenotype
in NSG mice. This does not rule out the possibility that α-syn expression might be
increased at a later time (e.g., 6 mpi) compared to C57BL/6 and RDKO mice causing
NSG mice to develop increased pathology and neurotoxicity. Furthermore, we only
measured total brain levels of α-syn, and may have failed to detect more local, cell
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subtype-specific, changes. GBA, PINK1, and DJ-1 were also expressed at equivalent
levels between the groups.
Surprisingly, we found that NSG mice had higher Parkin levels compared to
C57BL/6 and RDKO mice. This is counterintuitive as higher Parkin levels should be
beneficial, and it is loss of function mutations that cause PD (Kitada et al., 1998; Wang
et al., 2005b; Wang et al., 2005a; Matsuda et al., 2006). We hypothesize that increased
Parkin is compensatory as these mice also have known lysosomal deficits relative to
C57BL/6 mice which predispose the NOD line to autoimmune diseases (Monteith et al.,
2016). Furthermore, the increased Parkin levels could be preventing further
neuroinflammation as recent studies suggest that Parkin mediated mitophagy prevents
activation of the IIS by mitochondrial DNA (Sliter et al., 2018). The exact mechanism of
NSG vulnerability remains to be determined, and NSG mice provide a valuable tool to
study role of the IIS in PD neurodegeneration.
Interestingly, we found here that NSG mice, which also lack key components of
the IIS compared to the RDKO line, develop an exacerbated phenotype after PFF
injection. This effect is most likely modulated by the NOD background of these mice
suggesting that the IIS is functionally different in NSG mice compared to C57BL/6 mice
and that the IIS is playing a role in PD pathogenesis in the CNS. A possible culprit is
microglia because CNS-infiltrating monocytes have been reported to be required for TH
cell loss after PFF injection in rats and the fact that microgliosis occurs before the onset
of neurodegeneration (Harms et al., 2017; Duffy et al., 2018). Interestingly,
macrophages derived from NOD mice have deficits in antigen presentation and the
phagocytosis of apoptotic bodies (Piganelli et al., 1998; O'Brien et al., 2002), which may
help reconcile these findings with our observations. Additional experiments using the
NSG model should help clarify how the IIS interacts with Lewy Pathology.
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Although our data challenges several hypotheses regarding the role of the
immune system, particularly the AIS, in α-syn pathogenesis, this present study also has
several limitations. Although the study design allowed us to examine the role of the AIS
and is suggestive of the role of the IIS, it provides only restricted information regarding
which particular IIS deficits are mediating this effect. There are also many genetic
differences between NOD and C57BL/6 mice. To this end, this study provides an initial
examination of what could be leading NSG mice to be more vulnerable to α-syn
pathology. We did try to examine astrocytes and microglia to determine if there was
differential activation but did not find this. This does not rule out any differences in
astrocyte and microglial activity between the mouse strains. Studies regarding microglial
migration and phagocytosis would be very informative. Microglial differences between
NSG and C57BL/6 mice are not well characterized and would provide additional insight
into the role of the IIS in PD pathogenesis. Associated with this limitation, this study was
designed to examine α-syn inclusions and neuronal loss by histology. It would be very
informative to study cytokines and neuroinflammatory markers, but this is best done via
biochemical methods requiring another round of injected mice. We are attempting to
determine any neuroinflammatory differences at 1 mpi using microarray. These results
are forthcoming. Lastly, the increased Parkin levels in NSG mice is difficult to interpret
given the phenotype. Further studies using Parkin KO or Parkin knock down may be
helpful in determining if Parkin is playing a role in NSG mice and in PFF injection in
general.
There are several lines of evidence that demonstrate that inflammation is
mediating PD pathogenesis like media derived from PFF activated microglial can induce
astrocyte activation and consequently neuronal loss after PFF treatment, and a deficient
AIS can protect against MPTP treatment (Brochard et al., 2009; Yun et al., 2018). With
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the data we present here, we propose that the AIS is not necessary for PD pathology
progression, but the IIS is modulating α-syn aggregation.
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Chapter 5 Discussion
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The work presented in this thesis focuses on defining the factors that determine
the neuronal subtype vulnerability and toxicity in α-synuclein (α-syn) aggregation. I used
a model where α-syn aggregation of endogenously-expressed WT α-syn can be initiated
though the addition of recombinant α-syn that is misfolded in vitro into a fibrillar
conformation as opposed to its natively unstructured conformation. These pre-formed
fibrils (PFFs) of α-syn are able to instigate pathology by converting naïve endogenous αsyn monomer into a toxic conformation that resembles Lewy Pathology (LP) supporting
the hypothesis that α-synucleinopathies such as Parkinson’s disease (PD) may be prionlike disorders. Additionally, this model allows for studying the connection between α-syn
aggregation and toxicity because it exhibits both phenotypes in PD relevant neuronal
populations (Luk et al., 2009; Volpicelli-Daley et al., 2011; Luk et al., 2012b; Luk et al.,
2012a; Masuda-Suzukake et al., 2013; Sacino et al., 2014a; Paumier et al., 2015; Rey et
al., 2016; Shimozawa et al., 2017; Duffy et al., 2018).
I began this thesis work by reviewing in Chapter 2 the role of α-syn in PD, the
knowledge base that suggests α-syn pathology spreads in predictable and stereotypical
brain regions and neuronal subsets, and the potential neurotoxic mechanisms
associated with α-syn aggregation. In Chapter 3, I describe my original work that
identified Cornu Ammonis (CA) 2-3 neuron vulnerability to α-syn pathology is largely due
to increased expression of this protein relative to nearby neurons, a finding which had
not been previously appreciated. I also determined that reducing α-syn expression early
on in the inclusion formation process was sufficient to rescue this intrinsically vulnerable
population. Finally, in Chapter 4, I studied the effect of the adaptive immune system
(AIS) on α-syn aggregation in dopaminergic neurons after PFF injection.
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5.1 Untangling the complexities of intrinsic neuronal vulnerability
The CA2-3 region of the hippocampus has been noted to be a hot spot of LP in
advanced PD (Armstrong et al., 2014; Hall et al., 2014). The cause of this had been
unknown. In fact, why specific neuronal populations develop α-syn pathology in general
has been a large overarching question in the PD field for some time. This question
becomes more complicated when trying to correlate LP with neuronal loss. Pathology is
highly correlated in many regions like the substantia nigra pars compacta (SNpc) and
the locus coeruleus, but regions have been observed to have LP without any
appreciable neuron loss like the tuberomammilary nucleus of the hypothalamus or vice
versa like the supraoptic nucleus where neuron loss occurs in the absence of detectable
pathology (Kremer and Bots, 1993; Ansorge et al., 1997; Zarow et al., 2003; Dickson et
al., 2009; Surmeier et al., 2017). Because toxicity does not correlate perfectly with
pathology and is difficult to establish definitively in cross-sectional post-mortem studies,
it has been debated whether pathology is toxic or protective (Tompkins and Hill, 1997).
In the original description of the PFF model, primary hippocampal neurons first
develop pathology in axonal processes that then coalesce and “mature” into cell body
inclusions reminiscent of LP and then neuronal toxicity would ensue (Volpicelli-Daley et
al., 2011; Osterberg et al., 2015). This shows that α-syn aggregates directly correlate in
toxicity. In the study described in Chapter 3, we took this observation further by first
asking whether increased pathology caused heightened toxicity in order to determine if
pathology levels correlated with degeneration. We did this using two strains of α-syn that
we have previously established cause α-syn aggregation at varying rates (Luk et al.,
2016a). In this experiment we did indeed find that even at the same PFF concentration,
the PFF strain that forms pathology most efficiently caused the most cell death in a dose
dependent manner confirming that pathology correlates with toxicity. This does not
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speak to the species of α-syn that is causing toxicity although several studies suggest
that α-syn oligomers are responsible for the toxic effects of α-syn aggregation.
Determining this would be an important future direction that this research now makes
possible.
Interestingly, we were unable to achieve complete neuronal loss in this
experimental paradigm, and there was consistently a floor effect where no more neurons
would degenerate despite increasing the concentration of PFFs. From this, we
hypothesized that there may be neurons with varying degrees of vulnerability within
primary hippocampal cultures. We examined the effect the PFF treatment had on the
neuronal subtypes in the cultures and found that neurons derived from the CA region
were more sensitive to α-syn aggregation induced toxicity relative to neurons derived
from the Dentate Gyus (DG) region. We then injected mice into the hippocampus to
determine if this same effect is true in vivo as there could be other factors that mediate
vulnerability in vivo like inflammation or the fact that the majority of the DG matures
postnatally thus limiting what we could visualize in the embryonic cultures that were
used (Altman and Bayer, 1990). We found this same effect in vivo where the CA2-3
region was more vulnerable relative to the DG region. Furthermore, we found that the
CA2-3 region formed pathology faster compared to the DG region. This finding confirms
the validity of the PFF model as we have found that the CA2-3 neurons preferentially
form pathology over other neurons in the surrounding area and undergoes degeneration
similar to what is observed in PD.
Based on this finding, we next explored what might be causing this vulnerability.
We examined α-syn protein levels and found that CA neurons had higher α-syn
expression compared to DG neurons. This was confirmed by existing mRNAseq data
showing that the CA2-3 region expresses higher levels of the α-syn transcript compared
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to the DG (Cembrowski et al., 2016). We next tried to rescue viability by decreasing αsyn expression using ASO treatment. Indeed, we found that reducing α-syn expression
early did rescue neurons as we expected. We established that more pathology led to
more toxicity and it follows that less pathology would cause less toxicity. Interestingly,
when we modulated the time at which we reduced α-syn expression, we could find time
points where we could still achieve a decrement in α-syn aggregation, but there was no
discernable effect on viability. This led us to hypothesize that the vulnerable neuronal
populations can tolerate pathology up to a threshold where toxicity would ensue, but
pathology can continue to form beyond this threshold before degeneration has occurred.
Furthermore, this points towards a degeneration pathway that may take days to reach its
full resolution.
We also observed that the transcription factor Math2 that marks the vulnerable
population is down regulated up to 2 days before degeneration in vitro. These data are
also interesting because it suggests that transcriptional dysregulation accompanies cell
loss. We also found that astrocytes and microglia do not appear to be playing a role in
this form of cell death because the absence of either did not affect toxicity. Lastly, we
found that of the various cell death inhibitors tested only the antioxidant NAC could
partially rescue viability which was blocked using a glutathione depletion agent (BSO)
showing that glutathione is mediating toxicity and possibly vulnerability.
There are several future directions that this research makes possible. We have
established a PD relevant model to determine the cause of neuronal vulnerability to αsyn aggregation in a non-dopaminergic population. We have determined that at least
one factor that determines vulnerability is α-syn expression, but this is only part of the
story as we still have intermediate amounts of neuronal loss within neurons of the CA2-3
region in our model. Therefore, other factors are likely to modulate neuronal
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vulnerability. Nonetheless, this model lends itself to single cell analyses (e.g. RNA-seq)
to try and determine these cell-autonomous factors. Since we now have markers for
defining both vulnerable and resistant populations, this facilitates identification of their
differences. Another possibility is to look at the differences in these populations before
and after toxicity to determine the factors that differentiate the surviving population from
the vulnerable because we found that even some of the resistant DG neurons still
degenerate along with the Math2 population. We also have data suggesting that
transcriptional dysregulation is occurring along with toxicity. Learning what pathways are
affected during degeneration could help in identifying what mechanisms are contributing
to cell death and potentially could suggest therapeutic targets.
These data also show that reducing α-syn expression is a viable option for
rescuing neuronal toxicity from α-syn inclusion induced degeneration. However, the
implications of our work is that treatment must occur early and be sufficient for a >70%
knock-down in α-syn expression to achieve the goal of complete rescue. Although we
only tested this scenario in hippocampal neurons, the same approach is expected to
work in dopaminergic populations among others but remains to be tested. This is very
exciting because a similar drug, Nusinersen (SpinrazaTM), using the same ASO
technology to treat Spinal Muscular Atrophy (SMA) was recently FDA approved (Claborn
et al., 2018). Although, these data also suggest that for α-syn ASO treatment to be
effective treatment would have to occur before toxicity is irreversible. Because patients
can have up to 70% of dopaminergic neuron loss before motor symptoms present
themselves, and thus when diagnosis is made, biomarkers for detecting early stages of
the disease are needed to realize the potential of these approaches (Fearnley and Lees,
1991). At the very least, this treatment may prevent further neuronal loss after diagnosis
and alleviate the progression to symptoms like dementia in late stage PD.
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It is currently unknown what properties affect pathological spread in either
dopaminergic and non-dopaminergic populations. This model that we have optimized
can also be harnessed to further study the features that modulate α-syn pathology
propagation between neuronal populations both in vivo and in primary cultures. We
found that the DG still develops pathology but at a later time than the CA2-3 region even
though they were both exposed to PFFs. Furthermore, we found the connected regions
like the entorhinal cortex, a non-dopaminergic neuronal region, develops pathology after
PFF injection and not the SNpc. Because both the CA2-3 and DG regions develop
pathology and are adjacent to each other, we have created an opportunity to modulate
them, e.g., using viral mechanisms to overexpress or knockdown specific proteins like
synaptic proteins, to see how pathology spread to connected non-dopaminergic areas is
affected. A similar experiment could be done using an optogenetic approach to alter the
firing properties of these neurons to see if pathology spread to connected regions is
altered. Concurrently with the in vivo experiments, we could use the information we have
discovered here to sort these neurons before plating and then plate them in a chamber
system where a given population would be in a respective chamber but synapticallyconnected. This would allow further manipulations to be possible on selectively
vulnerable or resistant populations to determine the factors that modulate α-syn
aggregation and the spread of pathology in the future.

5.2 Role of the adaptive immune system in Lewy Pathology formation and induced
neurotoxicity
In Chapter 4, we studied if the AIS modulated pathological α-syn inclusion
formation, toxicity of dopaminergic neuronal populations, and any resultant motor
phenotype. Addressing this issue is critical to PD treatment because several effective
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medications exist that modulate the AIS and more have been proposed or are already in
the PD drug development pipeline. Two examples are, Tacrolimus, a FK506 inhibitor
that prevents IL-2 expression which prevents the proliferation of T cells, and Rituximab,
a CD20 monoclonal antibody that depletes B cells (Tocci et al., 1989; Townsend et al.,
2010). Being able to repurpose these already FDA approved treatments would be highly
beneficial because it would expedite the time to get these treatments to patients, and
these treatments already have known safety and side-effect profiles. There is growing
evidence that the AIS is playing a role in PD because small nucleotide polymorphisms
(SNPs) in MHCII loci associate with PD, there is an increase in MHCII+ microglia in PD
and after PFF injection in rats, and α-syn antigenic peptides can be recognized by Tcells in PD patients (McGeer et al., 1988; Hamza et al., 2010; Guo et al., 2011; Ahmed
et al., 2012; Sun et al., 2012; Sulzer et al., 2017; Duffy et al., 2018). These data suggest
a link between PD and the AIS, and understanding this link could provide novel
therapeutic options.
We began by intracerebrally injecting wild-type (WT) C57BL/6 mice similar to
what we and others have done along with two other strains that lack a mature AIS,
Rag2-/-; Il2rγ-/- mice on a C57BL/6 background (RDKO) and SCID; Il2rγ-/- mice on a Nonobese diabetic (NOD) background (NSG) (Volpicelli-Daley et al., 2011; Luk et al., 2012b;
Masuda-Suzukake et al., 2013; Sacino et al., 2014a; Rey et al., 2016). We expected that
if the AIS modulated α-syn aggregation then both the RDKO and NSG mice would show
similar phenotypes. The NSG line was chosen to examine the role of the innate immune
system (IIS) because the NOD background on which the NSG line is on has welldocumented IIS defects (Baxter and Cooke, 1993; Serreze et al., 1993; Ogasawara et
al., 2003). Using NOD mice carries the complication that the line itself spontaneously
develops autoimmune diabetes. This condition is T-cell dependent in NOD mice and is
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thus abrogated in the NSG line which lack mature T-cells. Very little work has been done
on NSG mice regarding the CNS although peripheral macrophages develop several
defects (Piganelli et al., 1998; O'Brien et al., 2002). Because microglia are also derived
from the embryonic yolk-sac precursor cells that become macrophages in other tissues,
we surmise that microglia will have similar deficits (Ginhoux et al., 2010; Prinz et al.,
2017). By injecting these three strains we hoped to determine if either arm of the
immune system mediated α-syn aggregation and subsequent effects like toxicity that the
PFF model now allows us to study.
We initially hypothesized that both the RDKO and NSG mice would show
diminished α-syn aggregation and neurotoxicity because mice lacking an AIS exhibit
reduced neuronal loss following MPTP treatment (Brochard et al., 2009). Surprisingly,
we found that RDKO mice had the same phenotype as the C57BL/6 mice showing that
the AIS is not necessary for α-syn aggregation initiation, formation, spreading, neuronal
vulnerability, subsequent dopaminergic neurotoxicity, or any motor phenotype. This
suggests that immunomodulatory treatments that affect the AIS, like tacrolimus or
rituximab, will not affect PD pathology once the disease presents and is diagnosed.
An interesting finding from this study though is that NSG mice develop a
potentiated phenotype in an age dependent manner compared to the other two strains.
Not only was this observed in the SNpc, a known vulnerable region in PD, but we also
detected increased pathology compared to the control strains in the VTA by 6 months
post injection (Braak et al., 2004; Chu and Kordower, 2007). These data indicate that the
NOD background potentiates either or a combination of pathology formation,
neurotoxicity, neuronal vulnerability, and the motor deficits after PFF injection.
We wanted to determine if pathology initiation was affected and thus checked for
α-syn aggregation and degradation of the injected PFFs at an early time point before
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neuronal loss. We also looked at α-syn levels because we have previously shown that αsyn levels affect aggregation and neurotoxicity (Volpicelli-Daley et al., 2011; Luk et al.,
2012b; Luk et al., 2012a; Luna et al., 2018). We observed no difference in either of these
phenotypes in NSG mice compared to C57BL/6 mice and found no difference in α-syn
expression levels. These data suggest that the IIS may be modulating α-syn aggregation
and neurotoxicity in the SNpc and the VTA in an age dependent and α-syn independent
manner.
Further research needs to be done to identify the specific elements of the IIS that
modulate α-syn aggregation. An exciting avenue to study this would be to determine the
cytokine and neuroinflammatory differences between the NSG and C57BL/6 mice after
PFF injection. PFF treatment has been shown to increase several cytokines in isolated
microglia such as TNFα, IL-6, and IL-1β (Yun et al., 2018). This could be done through
an RNA-seq experiment or a more direct approach such as cytokine profiling of CSF or
even possibly plasma. This would be very informative to begin understanding the role of
neuroinflammation in PD. Furthermore, studying if microglia have altered phenotypes in
NSG mice compared to C57BL/6 mice in areas such as cytokine release to LPS, or
motility to a chemotactic reagent, or uptake of apoptotic debris would be very
informative.
Another possible explanation for the exacerbated phenotype observed in NSG
mice is that they have additional genetic differences that are unrelated to the IIS. We
therefore also examined other PD related genes to determine if their expression was
altered between C57BL/6, RDKO, and NSG mice. We expected that if any levels were
altered, the gene expression would be lower in NSG mice because it is loss of function
mutations in these genes that cause PD. We found no difference between any of the
three strains in α-syn, GBA1, PINK1, or DJ-1 by western blot. Interestingly, we found
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that Parkin levels were upregulated, which is opposite to our hypothesis. Parkin
upregulation would be expected to be beneficial because of the increased ubiquitin
ligase activity promotes increased protein degradation.
These data that we uncovered led me to look into whether or not there could be
mutations in these genes that account for the increased pathology we see. It could be
that there is increased Parkin expression, but if it is non-functional, then we would still
have the exacerbated phenotype that we observed. Examining for mutations in α-syn,
Parkin, PINK1, DJ-1, GBA1, and VPS35 revealed no genetic differences (Keane et al.,
2011). Interestingly, there are seven missense mutations in the ATP13A2 gene (Table
5.1). ATP13A2 is a lysosomal ATPase implicated in loss of lysosomal activity that
causes early onset autosomal recessive PD (Ramirez et al., 2006; Dehay et al., 2012).
There is also evidence pointing to the lysosomal abnormalities as a potential cause of
the autoimmune phenotype in NOD mice (Monteith et al., 2016). There is an intriguing
possibility that the differences that are observed in the NSG mice are due to lysosomal
abnormalities. Further research needs to be done to explore this possibility. For

Observed
C/G
A/G
A/G
A/G
C/T
A/C
C/T

Mutation (amino
acid: position)
VL:112
GS:186
IV:440
TA:485
CR:539
AE:695
SF:809

C57BL/6J Nucleotide
G
G
A
A
T
C
C

NOD/ShiLtJ Nucleotide
C
A
G
G
C
A
T

Table 5.1 Chart of missense mutations in ATP13A2 gene between C57BL/6J and NOD/ShiLtJ
mice. This chart shows that there are seven missense mutations between the control C57BL/6J
and NOD/ShiLtJ mice in the ATP13A2 gene as various locations throughout the gene. These are
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V112L, G186S, I440V, T485A, C539R, A695E, S809F. (Keane et al., 2011;
https://phenome.jax.org/)

example, primary neuronal cultures could be taken from these mice and compared to
C57BL/6 primary cultures to determine if there is increased α-syn pathology formation
and toxicity following PFF exposure. These data also suggest that ATP13A2 KO mice
would develop a potentiated phenotype if they were injected with PFFs. Parkin has a
well-known role in regulating the clearance of damaged mitochondria (Pickrell and
Youle, 2015). Interestingly, recently it was published that Parkin induces mitophagy to
prevent an increase in cytosolic and circulating mitochondrial DNA, which otherwise
activates a component of the IIS, STING, a mediator of the type 1 interferon response to
cytosolic DNA (Sliter et al., 2018). It is possible that the higher Parkin levels in the brain
of NSG mice are a compensatory response that dampens IIS activation, but the
ATP13A2 mutations in these mice could cause a lysosomal deficit which in turn could
prevent proper degradation of mitochondria and consequently activate the IIS even
further. Thus, crossing NSG mice to Parkin KO mice or knocking down Parkin may
cause increased α-syn aggregation, TH cell loss, and worse behavioral outcomes at an
even earlier time point, although it is equally possible that the observed increase in
Parkin is unrelated to the potentiated pathology formation and neurodegeneration in
NSG mice.
It is important to stress that even though we found that the AIS does not mediate
α-syn aggregation in the SNpc, this does not necessarily mean that the AIS does not
have a role in PD. It is currently thought that the PD disease process begins in the gut
because 1) early stages of Braak staging show pathology in the dorsal motor nucleus of
the vagus nerve (DMV), a nucleus that innervates much of the gut, 2) pathology can be
123

found in the colon and the enteric nervous system, and 3) constipation is a frequent and
prominent prodromal symptom of PD (Braak et al., 2006; Kaye et al., 2006; MartinezMartin et al., 2007; Savica et al., 2009; Shannon et al., 2012; Hilton et al., 2014;
Chandra et al., 2017). The gut is also an interface between the body and the outside that
is a site of heighted immune surveillance and is likely an area for the AIS to interact with
α-syn pathology. Consistent with this, the microbiome composition has been suggested
to affect PD pathogenesis (Sampson et al., 2016). I hypothesize that the AIS may
actually be mediating PD pathogenesis in the colon/enteric system. It would be
informative to inject PFF treated mice in the colon after PFF treatment with an agent to
induce colitis such as Dextran Sulfate Sodium (DSS) to determine if pathology is
enhanced and/or spreads from the colon to the CNS and if this rate differs from nonDSS treated mice. Attempting this experiment in RDKO mice might allow us to
determine if the AIS plays a role in pathology formation and spread from the gut.
Further supporting the role of the enteric system-immune axis in modulating αsyn pathology formation and increased neuronal toxicity in these mice is that NOD mice
are known to develop colitis soon after weaning indicating intestinal/immune dysfunction
(Alam et al., 2010). These data suggest that the inflammatory profile of the NSG mice or
the intestinal flora composition could be mediating the effects we observed. We also
observed in this experiment that several of the NSG mice, both PBS and PFF injected,
had colonic distension when they were perfused, but unfortunately, we did not harvest
the colons for further study. Examining the differences in the microbiota over time and
examining the colons for inflammation, α-syn levels, and other brain-gut axis mediators
like the short chain fatty acids produced by the intestinal flora in NSG mice and C57BL/6
mice after PBS or PFF injection would be an interesting additional future direction that
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could yield new information on how the gut interacts with PD pathology (Carabotti et al.,
2015).

5.3 Concluding remarks
The only treatments for PD affect the motor symptoms, and there still are not any
curative or disease-modifying therapies. This is partially because we still woefully
misunderstand how α-syn aggregation begins, how it spreads, why it spreads to where it
does, and how it leads to neurodegeneration. This thesis has shed light on some these
aspects using the PFF model of PD that allows us to link α-syn inclusion formation
reminiscent to what we see in PD to neurodegeneration. First, we identified that neurons
derived from the CA2-3 region of the hippocampus are vulnerable to PFF induced
toxicity because they form pathology faster compared to the nearby relatively resistant
neuronal population derived from the DG. We took this further and established that this
vulnerability to pathology formation was cell-autonomous in nature due to increased αsyn protein levels, and reduction of α-syn expression can rescue these neurons from
both pathology formation and toxicity. This decrement had to occur early to be
neuroprotective because a >50% reduction in pathology formation and a >70% decrease
in α-syn expression was required. We looked at what linked α-syn aggregation to toxicity
and found that the observed toxicity was glutathione-dependent, implicating oxidative
stress in mediating neurodegeneration to α-syn pathology. In agreement with this,
treatment with antioxidants not known to replete glutathione levels (i.e., Trolox and
Mitotempo) did not rescue toxicity. Glutathione is a recycling antioxidant system within
the cell, and we hypothesize that its longer lasting action compared to other antioxidants
underlies its ability to prevent toxicity, especially in our model of neurodegeneration due
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to the long time course and delay in the development of toxicity which takes weeks to
occur.
Lastly, we examined if the AIS was involved in PD pathogenesis and found that
the AIS did not mediate α-syn aggregate initiation, formation, neurodegeneration of DA
producing SNpc neurons, or the motor behavioral phenotype. This is important because
it helps inform what therapies would (or would not) work once pathology has reached the
SNpc. We also discovered a mouse strain with characterized IIS deficits that developed
a potentiated phenotype. Up until now, there are no reports of a mouse strain that
deviates from the pathology development seen in commonly used WT strains. Studying
the NSG strain may therefore provide further clues into PD pathogenesis.
When these data are taken together with our results on PFF-induced toxicity of
hippocampal neurons, it becomes clear that different neuronal populations have differing
vulnerability to α-syn pathology formation and subsequent pathology-induced
degeneration. Neuronal vulnerability is partially dictated by the expression of α-syn and
we showed that decreasing α-syn expression rescues CA2-3 neurons of the
hippocampus, a finding that complements previous work demonstrating that α-syn-/- mice
do not develop α-syn inclusions nor neurodegeneration in the SNpc after PFF injection
(Luna et al., 2018; Luk et al., 2012). Furthermore, we found the same cell type
vulnerability in vivo and in primary hippocampal cultures suggesting that the neither the
IIS or AIS predispose the CA 2-3 region to pathology induced toxicity, but the potentiated
phenotype observed in NSG mice suggests that the IIS is mediating toxicity in the SNpc
and VTA. It would not be surprising if the various neuronal populations affected by PD
pathology do not share the same mechanisms of vulnerability. Heterogeneous
vulnerability mechanisms provides an explanation as to why pathology has been
observed to form in spatially separated nuclei in the early Stage 1 of the Braak staging
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scheme, namely the olfactory system as well as brain stem nuclei, and may explain why
particular brain regions exhibit neuronal loss with little pathology like the supraoptic
nucleus, or the opposite where neurons contain pathology but there is no measurable
neuronal loss, as in the tuberomammillary nucleus of the hypothalamus (Kremer and
Bots, 1993; Ansorge et al., 1997; Braak et al., 2004). Further study into neuronal
subtype vulnerability and the factors that mediate pathology formation is required to
better explain this phenomenon.
PD is but one of several disorders typified by pathological α-syn accumulation.
Dementia with Lewy bodies (DLB) and multiple system atrophy (MSA) also share this
characteristic and are even less understood than PD (Spillantini et al., 1997). DLB and
MSA are highly complex because, to date, no genetic mutations have been linked to
DLB or MSA, but these studies are limited by the number of participants due to smaller
patient population sizes relative to PD. Studying α-syn aggregation provides insights into
these synucleinopathies as a whole. For instance, the CA2-3 region is also a known
area of LP development in DLB similar to PD and what we observe in the PFF model
(Dickson et al., 1991; Adamowicz et al., 2017). All of this suggests that the phenomenon
that we observed is the cause of CA2-3 vulnerability in both of these diseases and
exemplifies the validity of the α-syn PFF model. Also, the α-syn aggregates found in
oligodendrocytes in MSA, Glial Cytoplasmic Inclusions (GCIs), are capable of forming
neuronal α-syn inclusions albeit with a much higher potency compared to LP derived
pathological α-syn (Woerman et al., 2015; Peng et al., 2018). These data suggest that
the synucleinopathies have similar mechanisms of pathogenesis. The data in this thesis
regarding hippocampal neuronal subtype vulnerability and the role of the AIS in
neurodegeneration provides both biological and therapeutic insights into these other
disorders. A prime example is utilizing ASO treatment not only for PD but for the other
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synucleinopathies. Given that α-Syn aggregation is likely causative in both DLB and
MSA, decreasing α-syn expression may also ameliorate symptom progression in these
conditions. The exact mechanism of α-syn regulation remains to be determined in
neurons and the mechanism of regulation is even less defined in oligodendrocytes, but
ASO treatment remains a promising therapeutic avenue.
At the outset of this thesis, I set out to learn how to develop testable hypotheses
and translate my scientific inquiries into medically relevant topics. Neurodegenerative
disorders lie at the intersection between neurobiology and the many diseases that are
quickly reaching epidemic proportions like PD which is why I focused on this group of
disorders for my graduate studies. My graduate career has taught me several valuable
scientific lessons regarding asking relevant questions based on previous literature as
well as optimizing assays in my own hands before progressing further. Additionally, I
have learned other lessons that will help me beyond my scientific career, such as project
and team management. These skills were crucial in the taking my projects to completion
and will certainly be useful as I move forward in my medical and scientific career in
neurology.

128

APPENDIX I: Supplemental Figures Chapter 3

Figure S3.1 Pathology development is dose, time, and conformation dependent. a,
WT primary hippocampal neurons treated with Huwt or HuS87N PFFs immunostained for
NFL, NeuN, pSyn, and DAPI. b, c, pSyn and neuronal viability (NeuN) or primary
cultures fixed at 15 DPT after Mswt or HuS87N PFF treatment. N = 18 wells from 3
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biological replicates per group. Data mean ± SEM with Kruskall-Wallis Test with Dunn’s
Multiple Comparison Test. *p<0.05, **p<0.01, ***p<0.001. Scale bar, 100μm

Figure S3.2 Endogenous α-syn and PFF fibrillar conformations are required to
induce pathology and toxicity with mutant HuS87N PFFs. a, SNCA-/- primary
hippocampal neurons treated with 350nM HuS87N PFFs and immunostained for NeuN,
pSyn, and DAPI at DPT 16. N= 10-11 wells from 3 biological replicates per group.
Unpaired student t-test. b, WT primary hippocampal neurons treated with 350nM HuS87N
PFFs or HuS87N monomer. Coverslips immunostained for NeuN, pSyn, and MAP2.
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Viability Determined by number of NeuN+ cells relative to PBS after treatment. Two-way
ANOVA with Bonferroni post-tests. N= 6-7 wells from 2 biological replicates per group.
Data are mean ± SEM. * p<0.05, **p<0.01. Scale bar, 100μm.
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Figure S3.3 Mixed neuronal-glia cultures are predominantly comprised of
glutamatergic neurons and GABAergic neurons are resistant to PFF induced
toxicity. a, 14 DIV WT primary hippocampal neurons immunostained for NeuN, DAPI,
and either Math2, Prox1, or CTIP2 transcription factors (TFs). Ratio as a percentage of
each TF to NeuN is shown. Note that CTIP2+ neurons also co-express either Math2 or
Prox1. N = 11-12 wells from 3 biological replicates per group. Data are mean ± SEM. b,
Immunostaining for GAD 67 and pSyn at 14 DPT. Arrows indicate GABAergic neurons
without cell body aggregates. Arrowheads point to neurons that contain cell body
aggregates. c, Immunostaining for GAD 67 and α-syn at 8 DIV. d, Immunostaining of
WT primary hippocampal neurons for GAD 65/67, NeuN, pSyn, and DAPI treated with
350 nM HuS87N PFFS and incubated until 15 DPT. e, GAD 65/67+ area normalized to
PBS wells. N= 8-9 wells from 3 biological replicates per group. f, Neuronal viability
determined by total NeuN counts of PFF relative to PBS. N= 4-6 wells from 2 biological
replicates per group. g, Lysates of wt primary hippocampal neurons treated with 350 nM
HuS87N PFFs and incubated until 14 DPT immunoblotted for GAD 65/67. h, Expression
levels of GAD 65/67 to PBS treated group. N- 9 wells from 3 biological replicates per
group. All data are mean ± SEM. Unpaired student t-test. *p<0.05, ***p<0.001. Scale
bar, 100μm.
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Fig S3.4 PFF induced toxicity is partially dependent on oxidative stress. a, Neurons
treated with either PBS or 200 nM HuS87N PFFs and subsequently treated with vehicle or
133

indicated treatment daily from 9-10 DPT to 13-14 DPT and fixed at 14-15 DPT. Neuronal
viability determined by NeuN counts of PFF group relative to PBS of treatment group
and presented as percentage relative to PFF treatment + vehicle. Data are mean ± SEM.
N= 8-15 wells from 3 biological replicates. One-way ANOVA with Dunnett’s post-test
comparing all groups to NAC only treatment. **p<0.01. b, Immunostaining of NeuN,
pSyn, and DAPI of PBS and PFF treated neurons at 15 DPT after daily treatment from 914 DPT with either vehicle, 100 µM NAC or 100 µM NAC + 5 µM BSO. Scale bar, 100
µM.

Figure S3.5 Lewy Pathology is associated with increased DSBs in mouse
hippocampal neurons in culture. 12 DPT Cultured mouse hippocampal neurons
treated with HuS87N PFFs or PBS show a large increase in nuclear γH2AX staining in the
PFF-treated group that forms Lewy Pathology. N= 3000-4000 cells from 4 replicates per
group. All data are mean ± SEM. Unpaired student t-test. *p<0.05. White squares
represent areas shown at higher magnification in middle and right images. Scale bar
100µm. (Modified from Schaser et al., In preparation)
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Fig S3.6. Differential expression of α-syn mRNA in mouse hippocampal neurons.
a, In Situ hybridization of α-syn, Math2, CTIP2, and Prox1 mRNA showing relative
expression levels in adult hippocampus (http://brain-map.org) (Lein et al., 2007). b,
Mean α-syn mRNA levels from RNA-seq of hippocampal neurons showing differential
expression between CA and DG subpopulations (http://hipposeq.janelia.org)
(Cembrowski et al., 2016).
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APPENDIX II: Supplemental Figure Chapter 4

Fig S4.1 Neither astrocytosis nor microgliosis occurred after PFF treatment in any
mouse strain. Ipsilateral midbrain sections at 3 mpi after Mswt PFF injection of C57BL/6,
RDKO, and NSG mice. Aged 15 months 5x Familial Alzheimer’s Disease (5xFAD) mice
stained as positive control for microgliosis in the hippocampus using TMEM119. Scale
bars as indicated
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